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I. OBJECTIVES OF THE THESIS 
 
The objective of this thesis is to evaluate the potential use of cyclodextrins as replacement for 
polysorbates in the field of freeze-drying for pharmaceutical relevant proteins. Stable freeze-
dried formulations of therapeutic proteins shall be developed and the mechanism by which 
cyclodextrins stabilize proteins will be elucidated. The focus of this study clearly lies on the 
hydroxypropylated derivative HPβCD, because of its toxicological safety and interfacial 
activity. Furthermore, the use of cyclodextrins in spray-drying will be investigated. State-of-the-
art analytics will be performed to investigate protein stability immediately after the drying 
process and after storage stability studies.  
Furthermore, a second focus of this thesis is to evaluate the impact of controlled nucleation in 
pharmaceutical freeze-drying. Although knowledge of the impact of ice nucleation temperature 
on the freeze-drying process is available, controlled nucleation has been hyped recently with 
the development of commercially available methods. In this thesis, we developed and applied 
an own, new method to study ice nucleation effects on pharmaceutically relevant formulations 
as well as on highly-concentrated protein formulations. 
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II. CYCLODEXTRINS IN FREEZE-DRYING AND SPRAY-DRYING 
OF PROTEINS 
II.1 INTRODUCTION1 
II.1.1 GENERAL MECHANISMS OF STABILIZATION BY EXCIPIENTS DURING 
FREEZING, DRYING AND IN THE DRIED STATE 
Excellent reviews have been published summarizing the stabilization of proteins during drying 
and in the dried state [1-4]. Commonly used excipients which can counteract the 
aforementioned stresses and their mechanisms of stabilization are presented briefly in the 
following section.  
To prevent unfolding of proteins at high and low temperature stresses, disaccharides like 
sucrose or trehalose or polyols like sorbitol or mannitol are commonly employed, acting via the 
preferential hydration / exclusion mechanism [5]. In the field of freeze-drying, those excipients 
are employed to stabilize the protein drug during the freezing step and are referred to as 
cryoprotectants.  Polymers, like dextran, polyvinylpyrrolidone and polyethylenglycol (PEG) are 
commonly used as cryoprotectants as well [4].  
Unfolding of proteins at interfaces can be prevented by surfactants. Surfactants, primarily the 
non-ionic polysorbate 20 and 80 are frequently added to the bulk solution to inhibit unfolding 
of proteins at interfaces, for example at the air-liquid interface present during spray-drying and 
at the ice-water interface, occurring during the freezing step in freeze-drying [6-8]. As 
mentioned in a preceding paragraph, surfactants are known to compete with proteins for the 
adsorption to interfaces and hence reduce unfolding and subsequent aggregation at the 
interface [9, 10]. 
To preserve the activity of proteins during dehydration, two commonly accepted hypotheses 
are discussed: the water replacement [11-14] and the vitrification [15-19] hypotheses. 
Excipients stabilizing the protein during the drying stage and in the dried state are referred to 
as lyoprotectants [1].  
                                               
1
 The section II.1 is part of the publication Serno, T., R. Geidobler, and G. Winter, Protein 
stabilization by cyclodextrins in the liquid and dried state. Advanced Drug Delivery Reviews, 
2011. 63(13): p. 1086-1106. The text present in the thesis is the same as in the publication 
and was written by R. Geidobler and corrected for publication by G. Winter.  
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During dehydration, the hydration shell surrounding the protein is lost, and the loss of hydrogen 
bonds can be compensated by excipients able to interact with the protein by hydrogen-
bonding, thus serving as a water substitute. Disaccharides like sucrose and trehalose and 
polyols like sorbitol are commonly used lyoprotectants. By acting as a water substitute, the 
native protein structure is preserved and the protein is thermodynamically stabilized with an 
increase in free energy of the unfolded state [3, 20]. Usually, direct interaction of the stabilizer 
and the protein and defined minimum ratios of stabilizer to protein are needed [21, 22].  
The vitrification (or glassy dynamics) hypotheses refers to a kinetic mechanism of stabilization 
in the dried state. A steady increase in viscosity of the amorphous phase, during the freezing 
and dehydration steps in freeze-drying or during the evaporation stage in spray-drying leads 
to the formation of an amorphous glass [23]. An adequate glass forming excipient needs to be 
present. Commonly used excipients are disaccharides and polymers like dextran and PEG 
[23]. In the rigid environment below the glass transition temperature, featuring a high viscosity, 
the protein is immobilized and hence kinetically stabilized. In contrast to the water replacement 
hypothesis, not a molar ratio of stabilizer to protein but a certain volume of stabilizer is required 
for dilution of the protein into the amorphous matrix [20].   
II.1.2 POSSIBLE MECHANISMS OF STABILIZATION PROVIDED BY CYCLODEXTRINS  
Due to their particular structural properties, cyclodextrins are valuable excipients for drying of 
protein pharmaceuticals. A CD-derivative frequently used as stabilizer in freeze-drying and 
spray-drying of formulations is the substituted derivative hydroxylpropyl-beta-cyclodextrin 
(HPßCD), which in contrast to the parent α-, β- and γ-cyclodextrin shows interfacial activity at 
concentrations of 0.1 % (w/v). [24]. This amphiphilic quality of HPβCD may stabilize proteins 
during the cooling and freezing step and upon rehydration of lyophilizates as well as during the 
atomization step in spray drying, possibly inhibiting protein unfolding and aggregation at 
interfaces, as discussed above. 
Due to their carbohydrate nature all CDs are in principle able to interact with proteins by 
hydrogen bonding fulfilling the needs for water replacement during dehydration. However, it is 
known that especially the parent cyclodextrins form an intramolecular hydrogen bond ring [25]. 
Therefore, parent cyclodextrins should be less able to provide intermolecular hydrogen bonds 
to proteins and this mechanism of stabilization must be expected to be operative mainly for the 
substituted derivatives, especially hydroxypropylated derivatives. 
In literature, the nomenclature and the assignment to an assumed stabilizing mechanism of 
cyclodextrins is not consistent. CDs are referred to as surfactants [26, 27], polymers [28] or 
sugars [29, 30], indicating that the stabilization mechanism is not yet fully understood. 
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II.1.3 TABULAR OVERVIEW OF CYCLODEXTRINS USED AS EXCIPIENTS FOR 
DRYING OF PROTEINS 
There are several reports on the use of cyclodextrins with different drying techniques. An 
overview of these studies is presented in Table 5 and Table 6. In the nineteen-nineties, several 
studies were performed using enzymes as model proteins assessing the stabilizing potential 
of CDs by determining their enzymatic activity after drying and reconstitution [26, 30-34]. 
Besides those model proteins, also reports on drying on therapeutic proteins, such as a mouse 
IgG antibody [35], IL-2 and tumor necrosis factor (TNF) [36] in the presence of CD derivatives 
were published. Cyclodextrins were investigated in a wide range of concentrations, ranging 
from 0.0001 % (w/v) up to 10 % (w/v) [30, 37]. From these numbers it can already be deducted 
that CDs presumably fulfilled very different roles in these formulations. The following chapter 
gives an overview on the available studies and elucidates the different molecular mechanisms 
by which CDs can provide stabilization during the drying of proteins as well as during storage 
of dried protein formulations. 
Table II-1: Overview of studies using CD-derivatives as excipients in freeze-drying (FD) of protein formulations. 
*: abbr. for (3-[(3-Cholamidopropyl)-dimethylammonio]-1-propanesulfonate) 
Protein(s) CDs Further excipients 
used 
Analytical 
methods used for 
characterization 
of protein stability 
Key results Proposed 
protein 
stabilizing 
mechanism by 
cyclodextrins 
Reference 
Invertase 
(0.064 mg/ml) 
β-CD 
(10% w/v),  
β-CD-Alginate 
(10%),  
β-CD + 
Trehalose (1:1, 
10%) 
Alginate, 
Dextran, 
Trehalose 
Invertase assay 
with sucrose 
β-CD and β-CD-A 
inferior to trehalose 
during FD, β-CD + 
trehalose showed 
best  results during 
storage over 25 h at 
43% controlled 
humidity; inhibition 
of trehalose 
crystallization 
complexation 
of hydrophobic 
residues for β-
CD and β-CD-
A 
Santagapita 
et al [28] 
CYP3A4 
(0.4 µM) 
MβCD, HPβCD 
(different molar 
ratios  
(50:1 – 600:1 
(~0.003 - 
~0.034 % w/v)) 
2 Crown ethers, 
Sucrose, 
Trehalose, 
Mannitol 
CYP3A4-
Activity with 
testosterone 
CDs inferior to 
sugars, slight effect 
at very low 
concentrations 
water 
replacement  
Chefson et al 
[29] 
LDH  
(0.25 mg/ml) 
HPβCD 
(0.005 %, 
0.02 %, 0.1 %) 
Sucrose, 
Trehalose, 
Glucose, 
Dextran, PEG, 
Ficoll, 
Polysorbate 80, 
Brij 35 
LDH assay, 
PAGE 
CDs inferior to 
sugars but better 
than no excipient 
and polysorbate 80 
surface activity Anchordoquy 
et al [27] 
LDH  
(2 µg/ml) 
HPβCD, MβCD, 
α-CD, β-CD, γ-
CD (0.005 mM 
– 100 mM)  
PEG 3350, 
CHAPS*, 
Sucrose fatty 
acid monoester, 
Polidocanol, 
SDS, Glucose, 
Trehalose, 
Sodium 
glutamate 
LDH assay HPβCD and MβCD 
preserved 
enzymatic activity 
during FD at 
concentrations of 
0.1 mM to 10 mM, 
no effect of parent 
CDs; HPβCD 
stabilization 
independent of 
phosphate-buffer 
concentration 
surface 
activity, 
interaction 
with 
hydrophobic 
residues 
Izutsu et al 
[33] 
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Protein(s) CDs Further excipients 
used 
Analytical 
methods used for 
characterization 
of protein stability 
Key results Proposed 
protein 
stabilizing 
mechanism by 
cyclodextrins 
Reference 
LDH  
(12.8 µg/ml) 
α-CD, HPαCD, 
β-CD, HPβCD, 
SBEβCD, 
MβCD, γ-CD, 
HPγCD (1% 
w/w) and 
0.0001% to 1 % 
(w/w) for 
HPβCD 
Glucose, 
Maltose, 
Trehalose, 
Sucrose, 
Raffinose  
(1% w/w) 
LDH assay HPαCD, HPβCD, 
MβCD, and HPγCD 
superior to 
trehalose; other 
derivatives provide 
stability similar to 
trehalose and 
sucrose; 
Increasing degree 
of substitution (DS) 
correlated with 
increase in relative 
activity 
No clear 
statement: 
water 
replacement / 
amorphous 
glass forming / 
complexation 
Iwai et al [37] 
TNF 
(0.25 mg/ml) 
HPβCD  
(0.5% w/v) + 
Mannitol 1.5 % 
PEG 6000, 
Dextran, 
Sucrose, 
Trehalose 
TNF assay (cell 
killing), SDS-
Page 
HPβCD + Mannitol 
resulted in less 
dimer formation 
than lyophilization 
without excipient; 
bioactivity was 
preserved 
Amorphous 
glass forming 
Hora et al 
[36] 
Mouse IgG2a 
mAb  
(1.0 mg/ml) 
HPβCD  
(5% w/v) 
Sucrose, 
Dextran 
SDS-Page, SE-
HPLC, ELISA, 
IEF 
HPβCD comparable 
to sucrose and 
dextran after 
lyophilization but 
superior during 
storage at 56 °C; 
HPβCD inhibited 
aggregate 
formation at 4 °C 
for 32 days. 
Amorphous 
glass with high 
Tg, 
complexation 
Ressing et al 
[35] 
BSA (0.1%), 
Trypsin (0.1%) 
α-CD 
(9.9% w/w) 
Lactose, 
Sucrose, 
Mannitol, 
Dextrin, 
Tween 80, 
some others 
Trypsin assay, 
SEM, DSC, 
ESCA (Electron 
spectroscopy 
for chemical 
analysis) 
α-CD showed 
highest Trypsin 
acitivities and low 
Trypsin surface 
coverage but high 
BSA surface 
coverage after 
annealing; no 
correlation of 
surface coverage 
and activity 
no clear 
statement; 
carbohydrate-
like behaviour 
(water 
replacement, 
amorphous 
glass forming) 
Millqvist-
Fureby et al 
[30] 
β-
Galactosidase 
(0.1 mg/ml) 
HPβCD, 
MβCD, α-CD, 
β-CD, γ-CD 
(0.01 mM – 
10 mM) 
Glucose, 
Trehalose, 
Proline, 
Polidocanol, 
SDS, CHAPS*, 
sucrose fatty 
acid monoester, 
PEG 400, 3350 
β-
Galactosidase 
assay with 
Galactopyranos
ide-derivative, 
SE-HPLC, 
SDS-Page,  
HPβCD and MβCD 
showed stabilizing 
effects at 
concentrations 
above 0.1 mM,  
α-CD,  β-CD  and 
γ-CD not; 
HPβCD and DM-β-
CD showed positive 
effect  in 
reconstitution 
medium 
surface activity Izutsu et al 
[32] 
IL-2  
(0.8 mg/ml) 
β-CD  
(5 mg / ml) 
Mannitol, 
Sucrose, 
Trehalose, 
Raffinose, 
Stachyose 
FTIR, Turbidity, 
activity assay, 
SE-HPLC, 
SDS-Page 
Stabilization by  
β-CD 
high Tg of 
dried product 
and water 
replacement 
Prestrelski et 
al [38] 
LDH  
(2 µg/ml) 
HPβCD 
0.01 mg/ml – 
10 mg/ml  
(+ Mannitol 
400 mM / 
Sucrose 
200 mM) 
CHAPS, PEG 
400, 3000, 
20000, 
Polidocanol, 
Triton X-100, 
Brij 58, sodium 
cholate, 
sucrose 
monolaurate 
LDH Assay HPβCD showed 
best stabilizing 
effect  used alone 
and intermediate 
effects when used 
in combination with 
mannitol and 
sucrose 
surface 
activity, 
formation of 
an amorphous 
glass 
Izutsu et al 
[26] 
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Protein(s) CDs Further excipients 
used 
Analytical 
methods used for 
characterization 
of protein stability 
Key results Proposed 
protein 
stabilizing 
mechanism by 
cyclodextrins 
Reference 
IL-2 
(1 mg/ml) 
HPβCD 
(0- 25 % w/v) 
and 0.2 % - 2 % 
in combination 
with sucrose 
(1% - 2 %, all 
w/w); β-CD 
(concentration 
not stated) 
- Visual 
inspection, 
Turbidity, 
Western blot, 
centrifugation, 
4D UV, 
Bioactivity  
(HT-2 cell 
proliferation 
assay) 
HPβCD reduced 
turbidity in 
concentrations of  
> 0.5 % in 
combination with 
sucrose (1 %) 
during storage, no 
turbidity was 
observed with 
HPβCD but with  
β-CD, both in 
combination with 
sucrose (1-2 %) 
complexation Brewster et 
al [39] 
IL-2  
(1 mg / ml) 
HPβCD (0.5 %) 
in combination 
with sucrose 
(2 %) 
Polysorbate 80, 
HSA, Arginine, 
Carnitine, 
Betaine 
SE-HPLC, RP-
HPLC, Western 
blot, 
Fluorimetric 
light scattering, 
bioactivity  
(HT-2 cell 
proliferation 
assay), ELISA 
Fully bioactive IL-2, 
negligible dimer 
formation but 
significant amount 
of oxidized IL-2 
detected during 
storage 
unclear: 
hydrophobic / 
hydrophilic 
character of 
HPβCD 
Hora [40] 
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Table II-2: Overview of studies using cyclodextrins as excipients for spray-drying (SD) or supercritical fluid drying (SCFD) of 
protein formulations. 
Protein(s) used CD(s) used Other excipients 
used 
Analytical 
methods used for 
characterization 
of protein stability 
Outcome of test Proposed protein 
stabilizing 
mechanism of 
cyclodextrins 
References 
β-
Galactosidase 
(4% w/v) 
HPβCD  
(1% w/v) 
alone and in 
combination 
with  Sucrose 
1% 
Sucrose µDSC,  
SE-HPLC,  
SDS-Page, 
Galactosidase 
assay. 
HPβCD superior 
to sucrose  
inhibition of 
denaturation at 
liquid/air 
interface 
Branchu et 
al [34] 
Trypsin 
(0.02 %, 0.1 %, 
0.5 % w/w) 
α-CD (9.5 % - 
9.98 % w/w) 
Lactose, 
Sucrose, 
Mannitol, 
Dextrin,  
Tween 80 
ESCA, DSC, 
Surface 
tension, Trypsin 
assay 
α-CD showed 
good results in 
residual activity 
and was best 
excipient in FD  
no clear 
statement; 
carbohydrate-
like behaviour 
(water 
replacement, 
amorphous 
glass forming) 
Millqvist-
Fureby et 
al [31] 
rhGH  
(2 mg/ml) 
MβCD (10, 
100, 1000:1 
Molar ratio, 
0.12 %, 1.2 % 
and 12 % 
w/v), 100:1 
MβCD also in 
combination 
with 
Polysorbate 
20 (0.01%), 
Zinc (2:1 
molar ratio) 
and lactose  
(4 mg / ml) 
Polysorbate 
20, Lactose, 
Zinc 
SE-HPLC MβCD stabilizes 
in molar ratio of 
1000:1 and 
100:1 (SE-
HPLC) and in 
combination 
with Zinc, 
Lactose and 
Polysorbate 20 
at 100:1 molar 
ratio 
surface activity Jalalipour 
et al [41] 
IgG 
monoclonal 
antibody  
(20 mg / ml) 
HPβCD 
(80 mg / ml) 
Trehalose 
(80 mg / ml) 
FTIR, CD, 
Fluorescence, 
UV 
spectroscopy, 
SE-HPLC, 
SDS-PAGE 
HPβCD as 
efficient as 
trehalose 
no clear 
statement; use 
of HPβCD as a 
sugar 
Jovanovic 
et al [42] 
 
II.1.4 PROTEIN STABILIZATION BY CYCLODEXTRINS AT LOW CD-
CONCENTRATIONS – NON-IONIC SURFACTANT-LIKE BEHAVIOUR 
Evidence for surfactant-like effects of cyclodextrins was found for freeze-dried LDH at a 
concentration of 0.25 mg/ml in the presence of HPβCD at different concentrations (0.005 %, 
0.02 % and 0.1 %) [27]. HPβCD showed a slightly positive effect on remaining enzyme activity 
after reconstitution of lyophilizates and in freeze-thawing experiments at concentrations of 
0.1 %, and it was found to be superior to polysorbate 80. However, enzymatic activity was 
much better preserved by employing glucose, trehalose or sucrose. Slightly different results 
were observed in another study with freeze-dried LDH at much lower concentrations (2 µg /ml 
protein) [33]. HPβCD and MβCD turned out to be effective in preserving enzymatic activity. 
The protective effect of HPβCD, as measured by LDH activity, was most pronounced at 
concentrations above 1 mM (approx. 0.14 % w/v). MβCD showed best stabilization at 0.2 mM 
(approx. 0.026 % w/v), while the parent cyclodextrins as well as sucrose and trehalose showed 
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almost no remaining LDH activity after lyophilization and reconstitution. A third study using 
LDH as model protein achieves similar results. A wide concentration range of HPβCD from 
0.0001 % to 1 % (w/w) was investigated and could clearly show that HPβCD was able to 
preserve the enzymatic activity already at very low concentrations (0.01 %) with a maximum 
stabilization between 0.1 % and 1 % [37].  
In addition to the concentration-dependent stabilization by HPβCD, the degree of substitution 
(DS) of the CD-derivatives was also found to have a significant influence on recovery of LDH 
activity. The higher the degree of substitution, the better was the recovery of activity of LDH. It 
is known that an increase in the degree of substitution of the CD correlates with a decrease in 
surface tension of water – therefore the surfactant-like effects of CDs must be expected to 
become more pronounced with increasing DS [24, 43].  
HPβCD was also studied by Izutsu et al with the same model protein, LDH, in a concentration 
of 2 µg/mL as single excipient and in combination with 200 mM sucrose and 400 mM mannitol 
[26]. At concentrations of around 0.01 % (w/v) and 0.1 % (w/v), HPβCD showed best results 
when used alone and comparable results were obtained in combination with sucrose whereas 
the combination with mannitol resulted in slightly lower activity at the same concentrations. 
The authors state that the amphiphilic character of HPβCD and its ability to remain amorphous 
is protecting LDH during freeze-drying, which is in agreement with results obtained on another 
enzyme, β-galactosidase [32]. Parent cyclodextrins formed an amorphous glass, but failed to 
stabilize β-galactosidase during freeze-drying whereas MβCD and HPβCD were effective at 
maintaining the enzymatic activity at concentrations of 0.014 % (w/v), indicating surfactant-like 
behavior of the CD-derivatives.  
Further evidence for interfacial stabilization by CDs is given by a study on spray-dried β-
galactosidase at a concentration of 40 mg / ml [34]. The enzyme was spray-dried along with 
1 % (w/v) HPβCD, a mixture of 1 % (w/v) HPβCD and 1 % (w/v) sucrose and sucrose alone. 
HPβCD as single excipient yields almost 100 % remaining activity whereas sucrose alone even 
had a negative impact on the relative activity of the enzyme. The combination of HPβCD and 
sucrose was inferior to HPβCD alone. No alterations of the enzyme as compared to before 
drying were detected by DSC, SE-HPLC, SDS-PAGE and IEF patterns in all formulations. The 
authors speculate that the mechanism of protein degradation consisted of subtle changes in 
protein structure at the air-water interface and  they concluded that HPβCD successfully 
protected β-galactosidase from surface denaturation. This was also observed for MβCD, which 
protected rh-GH during spray-drying at concentrations above 1.2 % (w/v) [41]. The addition of 
polysorbate 20, lactose and zink further reduced aggregate levels, as determined by SE-
HPLC. The authors conclude that surfactant-like behaviour of MβCD is protecting rh-GH from 
denaturation at the air-water interface. 
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However, there are also reports on amphiphilic cyclodextrin derivatives failing to stabilize 
proteins at low excipient concentrations. For instance, MβCD and HPβCD failed to stabilize 
the enzyme CYP3A4 [29]. Both derivatives showed no significant increase in activity recovery 
of CYP3A4 at very low protein concentrations and a 50:1 molar ratio excess of the CDs 
(approximately 0.003 % (w/v)). Disaccharides like sucrose or trehalose performed better than 
both cyclodextrin derivatives; however, they were used at much higher molar ratios up to 
30000:1. This indicates that dehydration could have been the predominant stress for CYP3A4 
and disaccharides are able to compensate for the loss of the hydration shell. The 
concentrations for the cyclodextrins employed in this study are probably too low to serve as 
sufficient lyoprotectants whereas their quality as surfactant-like excipients did not alter protein 
stability in this case. 
II.1.5 PROTEIN STABILIZATION BY CYCLODEXTRINS USED AT HIGH 
CONCENTRATIONS – WATER REPLACEMENT AND VITRIFICATION 
Besides their effect on stabilization at the air-water, ice-water and solid-void interface, 
cyclodextrins are also reported to stabilize by both water-replacement and vitrification. 
However, the clear attribution of the mechanism of stabilization to one particular effect might 
be difficult, since several modes of action often contribute to the protein stabilization observed. 
For the purpose of employing CDs as lyoprotectants, much higher weight ratios are needed 
compared to the use as surfactant like excipients; typical weight ratios of sugar to protein range 
from at least 1:1 to approx. 5:1 [2]. However, these ratios are greatly dependent on the type of 
protein. Concentrations of bulking agents prior to freeze-drying are typically in a range between 
1 % and 10 % (w/v) [1]. Cyclodextrins usually yield amorphous glasses.  
As discussed above, parent cyclodextrins, which are known to form intramolecular hydrogen 
bonds, hindering them to form hydrogen bonds with other molecules, are likely to exhibit little 
degree of water-replacement but should still be able to form amorphous glasses and stabilize 
according to the vitrification hypothesis. Proof for this can be found in a study on LDH, in which 
various cyclodextrins, including parent-CDs and derivatives (HPαCD, HPβCD, SBEβCD, 
MβCD, HPγCD) as well as disaccharides were investigated, all in concentrations of 1 % (w/w) 
[37]. All hydroxypropylated derivatives as well as MβCD yielded higher relative activities than 
the parent cyclodextrins and SBEβCD. The relative activity of LDH freeze-dried with the parent 
cyclodextrins was on the same level as LDH freeze-dried with trehalose and sucrose. The 
authors found that a concentration of 1 % is too low for water replacement by disaccharides 
and that the increased activity observed for hydroxypropylated CD derivatives is due to their 
additional hydroxyl moieties, possibly contributing to hydrogen-bonding. There are numerous 
further reports of failure or at least of inferiority of parent cyclodextrins as compared to 
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hydroxypropylated derivatives with regard to protein stabilization, but in turn this could also be 
attributed to their lack of surface activity [28, 32, 33, 39]. 
In contrast, in cases in which the formation of amorphous glasses was shown to be sufficient 
to preserve protein stability, parent cyclodextrins can well fulfill this task, as demonstrated in a 
study on spray- and freeze-drying of trypsin and BSA [31]. Relative activity for spray-dried 
trypsin in the presence of amorphous α-CD was 95 % and 92 % for freeze-dried trypsin, 
respectively. The authors stated that the mechanism of stabilization is unclear, but glass 
forming excipients seemed to have a higher ability to preserve the enzyme’s activity, compared 
to partly crystalline sucrose and mannitol.  
II.1.6 PROTEIN STABILIZATION BY CYCLODEXTRINS DURING STORAGE OF 
LYOPHILIZATES 
Besides the aforementioned protein-stabilizing mechanisms during freezing and drying, there 
are some additional factors influencing storage stability of lyophilizates. These are for example 
high glass transition temperatures (Tg) of the lyophilized cake [44, 45] and an optimal residual 
water content (usually < 1 % w/w) [46]. Furthermore, crystallization of initially amorphous 
excipients might be harmful to the dried protein [47]. Little is known about glass transition 
temperatures of freeze-dried cyclodextrins with only some published values available. Due to 
its high molecular weight, parent β-CD possesses a rather high glass transition temperature, 
Reported Tg-values of freeze-dried β-CD are 55 °C at a water content of 2.5 % (w/w) in 
combination with invertase and 108 °C at a water content of 2.5 % – 3.5 % (w/w) in combination 
with IL-2 [28, 38]. 
There are some hints available in literature that storage stability of CD-containing lyophilizates 
can be attributed to the high glass transition temperatures of cyclodextrins. In an early study 
on an antibody, HPβCD at a concentration of 5 % (w/v) was employed to freeze-dry an IgG 
monoclonal mouse antibody [35]. Recovery of the antibody immediately after lyophilization as 
measured by ELISA was above 80 % even without any excipients and was not improved by 
the addition of HPβCD, sucrose or dextran. However, during subsequent storage for 18 days 
at 56°C, the HPβCD-containing formulation yielded higher levels of antigen binding than the 
sucrose- and dextran-formulation. Residual moisture levels of the freeze-dried cakes were 1-
2 % (w/w), probably resulting in storage close to or above the Tg of sucrose but most likely 
below the Tg of HPβCD and dextran [38, 48].  
The high glass transition temperature of β-CD was probably also beneficial in a study on 
freeze-dried formulations of the cytokine IL-2. During storage at 45 °C for 36 weeks, β-CD 
prevented protein aggregation more effectively than sucrose and dextran but slightly less than 
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trehalose. In addition to their high Tg-values, cyclodextrins, remaining amorphous can inhibit 
crystallization of other excipients during storage of lyophilizates. This was the case with β-CD 
at a concentration of 10 % (w/v) in combination with trehalose [28]. In another study, HPβCD 
was used at a concentration of 0.5 % in combination with mannitol (1.5 %) for freeze-drying of 
TNF [36]. After storage for one month at 37° C, HPβCD-containing formulations showed 
intermediate levels of non-reducible dimers and well preserved bioactivity. The stabilizing 
effect of HPβCD during storage of the lyophilizates was attributed to vitrification. 
II.1.7 CONCLUSIONS 
Summarizing the different studies on the use of CDs in lyophilized protein formulations, it can 
be stated that cyclodextrins, especially the substituted derivatives, are valuable excipients. 
Different mechanisms of stabilization seem to be exerted simultaneously. From the fact that 
protein stabilization can already be achieved at low concentrations of cyclodextrins and that 
surface active cyclodextrins (hydroxypropylated and methylated derivatives) seem to be most 
effective at inhibiting aggregation it can be deducted that surfactant-like effects of CDs seem 
to play an important role in the mechanism of stabilization. In addition there is evidence that 
sugar-like effects, most importantly water replacement, play an important role. The formation 
of an amorphous glass alone (vitrification), as provided by parent CDs, can be insufficient to 
ensure adequate protein stability. However, the high glass transition temperatures observed 
in protein formulations containing cyclodextrins can contribute to the physical stability of 
freeze-dried products, for example by preventing crystallization of amorphous stabilizers. 
II.1.8 RATIONAL USE OF CYCLODEXTRINS IN PARENTERAL PROTEIN 
FORMULATIONS 
We gave an overview on studies investigating cyclodextrins as excipients in dried protein 
formulations. Based on these studies some practical guidance on how to rationally apply 
cyclodextrins for the design of dried protein formulations is given in the following: First, it has 
to be determined which purpose the cyclodextrin-derivative should serve in the formulation. 
The purpose will determine the choice of derivatives as well as the concentration range to be 
tested. If a surfactant-like effect is desired, the choice will be on surface active-derivatives at 
comparably low concentrations; if CDs are supposed to serve as lyoprotectants, higher 
concentrations of amorphous, hydrogen-bond forming derivatives shall be selected. 
Another aspect takes into account the acceptance of CDs as excipients in parenteral products.  
If only CD-derivatives should be selected that are already used in approved parenteral 
products, HPβCD is without doubt the excipient of choice. Because of its surfactant-like and 
amorphous carbohydrate-like properties and toxicological safety, it perfectly meets the 
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requirements to stabilize proteins during all process steps in freeze- and spray-drying as 
discussed in section II.1.2. Figure II-1 shows a decision chart on how to select the proper 
cyclodextrin derivative. 
 
Figure II-1: Guidance to cyclodextrin type and concentration selection for dried protein formulations. 
The most prominent characteristic of HPβCD is its interfacial activity, which renders it a 
valuable replacement for surfactants, such as polysorbates. The concentration of CD needed 
for adequate stabilization of proteins during freeze-drying is rather low when surfactant-like 
effects are desired. From section II.1.4 it can be deduced that for HPβCD concentrations of 
approximately 0.1 % (w/v) up to 1 % (w/v) of HPβCD were most effective and further increase 
does not provide further stabilization against interfacially-induced stress conditions.  
If cyclodextrins are supposed to act as lyoprotectants, higher concentrations (larger than 1 % 
(w/v)) should be applied. However, the positive effects of CDs in this function are not as clear 
from the current literature as their impact on the suppression of interfacially-induced 
degradation pathways. In some cases it might be beneficial to add CDs to protein formulations, 
because high glass transition temperatures can be achieved allowing for good physical stability 
of the lyophilized cakes at elevated temperatures. The possibility to increase Tg’ in liquid 
formulations allows for a higher storage temperature of bulk solutions. 
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II.1.9 AIM OF THE STUDY 
The aim of this study was to evaluate the potential use of cyclodextrins as replacement for 
surfactants, mainly polysorbates in the field of freeze-drying of pharmaceutical relevant 
proteins. The focus clearly lies on the hydroxypropylated derivative HPβCD, because of its 
safety and interfacial activity. If stable formulations can be achieved, they will be analysed with 
state-of-the-art analytics and storage stability of the lyophilizates will be evaluated. If possible, 
the stabilization mechanism of HPβCD will be evaluated.  
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II.2 MATERIAL AND METHODS 
II.2.1 MATERIALS 
A monoclonal antibody MabR1 was used as a model protein because it is sensitive to freezing- 
and drying associated stresses. The antibody was formulated in a 10.5 mM sodium-phosphate 
buffer at pH = 6.4. Human growth hormone (hGH) was formulated in a 10 mM sodium-
phosphate buffer at pH = 7.00. Granulocyte-colony stimulating factor (GCSF) was formulated 
at pH = 4.00 in a 10 mM citrate buffer. Both proteins are known to be sensitive to interfacial 
stresses [49, 50]. Sodium phosphate monobasic and dibasic were bought from Merck, 
Darmstadt, Germany or Applichem, Darmstadt, Germany; Sodium chloride and Trehalose was 
purchased from BDH Prolabo, (VWR, Ismaning, Germany) or Merck (Darmstadt, Germany). 
Sucrose was kindly provided from Suedzucker (Plattling, Germany). Polysorbate 80 was 
obtained from Sigma Aldrich Chemicals. Hydroxypropyl-beta-cyclodextrin (Cavasol HP 
Pharma)  and methyl-beta-cyclodextrin (Cavasol M Pharma) were kindly provided by Wacker 
Chemie AG, München. Germany. All chemicals were of analytical grade.  
II.2.2 PREPARATION OF FORMULATIONS 
Formulations were prepared by mixing concentrated stock solutions of excipients and protein 
and final dilution with buffer. For Sucrose, Trehalose, HPβCD and MβCD, usually 10 % or 20 % 
(w/v) solutions were prepared and for polysorbate 80, a 1 % (w/v) solution was used. The final 
solutions were filtered through 0.22 µm PVDF filters (Pall Acrodisc or Millipore Millex) which 
were pre-rinsed with at least 5 ml of buffer to remove extractables, particularly surfactant 
residuals. 2.3 ml of filtered solutions were pipetted into DIN 6R vials which were semi-
stoppered and transferred to the freeze-dryer.  
II.2.3 LYOPHILIZATION PROCESSES 
II.2.3.1 CONVENTIONAL FREEZE-DRYING PROCESS 
Lyophilization of the samples in a conventional process was performed using a Martin Christ 
Epsilon 2-6D freeze-dryer (Martin Christ, Osterode, Germany) equipped with a pirani pressure 
sensor. The samples were equilibrated at -3 °C for 1 hour and subsequently frozen to -50 °C 
using a ramp of 0.3 °C/min. After a 2 h isothermal hold, the pressure in the chamber was 
reduced to 0.09 mbar and the shelf temperature was increased to -20 °C with 0.5 °C/min. 
Primary drying with these settings was carried out for 35 h. After primary drying, the shelf 
temperature was increased to 5 °C with 0.1 °C/min and to 25 °C with 0.2 °C/min. Secondary 
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drying was carried out for 7 h at 25 °C. The samples were stoppered at approximately 800 
mbar with dry nitrogen gas and crimped after unloading. 
II.2.3.2 CONTROLLED NUCLEATION FREEZE-DRYING PROCESS 
To decrease specific surface area compared to the conventional freeze-drying process, 
controlled ice nucleation was performed with our published method [51]. Ice nucleation of the 
samples was induced at a product temperature of approximately -5 °C by lowering the 
pressure to approximately 3.7 mbar followed by re-pressurization of the chamber via the cold 
condenser. The shelf temperature was held at -8 °C for 2 h post-nucleation to allow for slow 
ice crystal growth and Ostwald ripening. Complete solidification was obtained by lowering the 
shelf temperature to -50 °C with 1 °C/min. Primary drying and secondary drying ramps were 
the same as with the conventional freeze-drying process with a final shelf temperature of 25 °C 
(1% Sucrose) or 35 °C (5% Sucrose) which was held for 7 h. The samples were stoppered at 
approximately 800 mbar with dry nitrogen gas and crimped after unloading. 
II.2.3.3 COLLAPSE FREEZE-DRYING PROCESS 
Collapse lyophilization, which is freeze-drying above Tc, was performed to intentionally reduce 
specific surface area. Freezing of samples was performed using the same protocol as with 
conventional freeze-drying cycle. After freezing, the chamber pressure was reduced to 1.03 or 
2.56 mbar and the shelf temperature was increased to 45 °C with 0.5 °C/min and held for 24 h. 
The samples were stoppered at approximately 800 mbar with dry nitrogen gas and crimped 
after unloading. 
II.2.4 SAMPLE PREPARATION FOR FREEZE-THAW STUDIES 
Samples which were subjected to the freeze-thawing stress were placed in the lyophilizer and 
frozen in the same way as the samples which were freeze-dried. After equilibration at the final 
freeze-temperature of -50 °C, samples were unloaded and stored at -80 °C until further 
analysis. Thawing of samples was performed in a 25 °C water bath. 
II.2.5 SPRAY-DRYING PROCESS 
Spray drying was performed using a B-290 spray dryer (Büchi Labortechnik AG, Flawil, 
Switzerland) equipped with the two-fluid nozzle which was water-cooled throughout the 
process. The liquid was atomized with nitrogen at fluid flow rate of approximately 4.4 ml / min 
and atomizing gas flow rate of 667 l / h. Inlet temperature was set to 160 °C and the aspirator 
was set to 100 % or approximately 38 m³/h, resulting in an outlet temperature of 76 °C ± 3. A 
LT Mini dehumidifier (Deltatherm, Much, Germany) was used to lower relative humidity of inlet 
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air. A high efficiency cyclone with grounding was used to collect the spray-dried powder in a 
50 ml falcon tube. Samples were then weighed and aliquoted into DIN 6R vials in a glove box 
with a humidity of less than 10 % r.h. 
II.2.6 PREPARATION OF ATOMIZATION-CONTROL SAMPLES 
The same hardware setup as for spray drying was used. To check for interfacial stress exerted 
on MabR1 by atomization and baseline particle concetrations, the protein solution as well as 
placebos were pumped through the two-fluid nozzle and atomization was performed as in the 
spray drying process. The liquid was collected using a 50 ml falcon tube directly placed under 
the nozzle. 
II.2.7 RECONSTITUTION OF DRIED PRODUCTS 
Reconstitution of dried samples was performed by adding the amount of water which was 
removed by the corresponding drying process. The density of the solutions prepared was 
determined in a pycnometer. The mass of protein and excipients was subtracted and the result 
is the mass of water which needs to be added for rehydration. Reconstitution times were 
determined and the time until a clear solution was obtained was recorded as reconstitution 
time.  
II.2.8 TURBIDITY 
The turbidity of samples was measured using a Hach Lange Nephla nephelometer (Hach 
Lange GmbH, Düsseldorf, Germany). Scattered light of λ = 860 nm laser is detected at an 
angle of 90 ° and the result is given in FNU (Formazine nephelometric units). 1.9 ml were 
pipetted in pre-rinsed turbidity glass cuvettes with a flat bottom and placed into the device. 
Measurement was performed twice with a 90 ° turn between measurements.  
II.2.9 LIGHT OBSCURATION 
Subvisible particles were determined using a PAMAS SVSS-35 particle counter (PAMAS - 
Partikelmess- und Analysesysteme GmbH, Rutesheim, Germany) equipped with an HCB-LD-
25/25 sensor which has a detection limit of approximately 120,000 particles > 1 µm per ml. 
The rinsing volume was 0.5 ml and was followed by three measurements of 0.3 ml. Before 
each measurement, the system was rinsed with highly purified water until the total particle 
concentration was less than 100 per ml and no particles larger than 10 µm were present in the 
measurement cell. The samples were analyzed in the turbidity cuvettes. Data collection was 
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done using PAMAS PMA software and particle diameters in the range of >1 µm to 200 µm 
were determined. All results are given in cumulative particles per milliliter.  
II.2.10 SIZE EXCLUSION CHROMATOGRAPHY (SE-HPLC) 
To determine protein monomer, dimer, fragment and high molecular weight soluble 
aggregates, size exclusion chromatography was performed using a Gynkotek HPLC system 
equipped with a M480 and a M300 pump, a coolable Gina 50T autosampler and an UVD 170U 
UV/VIS detector (Dionex, Idstein, Germany). For MabR1, a 50 mM sodium phosphate buffer 
with 300 mM sodium chloride at pH = 7.00 was used with a Tosoh SWXL 3000 column (Tosoh 
Bioscience, Stuttgart, Germany), because this buffer was found to be optimal for the Tosoh 
column [52]. For both h-GH and GCSF, a Sephadex 75 (GE Healthcare, Freiburg, Germany) 
column was used. Elution of h-GH was performed using a 50 mM sodium-phosphate buffer 
with 150 mM sodium chloride at pH = 7.00 and elution of GCSF was performed in a 100 mM 
sodium phosphate buffer, pH = 7.00. In all cases, sodium azide was added in a concentration 
of 0.05 % (w/v). 
II.2.11 ASYMMETRICAL FLOW-FIELD-FLOW SEPARATION (AF4) 
An orthogonal method to size exclusion chromatography is asymmetrical flow-field-flow 
fractionation. Protein fragments, monomer as well as higher molecular aggregates are 
separated by a liquid cross flow combined with a parabolic channel flow. A Postnova AF2000 
system (Postnova GmbH, Landsberg am Lech, Germany) was used for separation equipped 
with a PN 1122 pump, a PN 5300 autosampler. A Shimadzu SPD 10 UV detector was used to 
monitor protein absorption at λ = 280 nm. Furthermore, the system is equipped with a PN 3150 
refractive index detector and a PN 3620 or a Wyatt miniDawn MALLS detector. A spacer of 
500 µm was used. For Mab R1, A buffer with 10 mM sodium phosphate and 150 mM sodium 
chloride was used. Approximately 30 µg were injected into the separation channel equipped 
with a regenerated cellulose membrane (RC) with a cut off of 10 kDa and focused for 4 min 
with an injection flow of 0.2 ml/min and a cross flow of 2.0 ml/min. Subsequently, protein 
species were separated with a constant cross-flow of 2.0 ml/min and a detector flow of 1.0 
ml/min for 25 minutes. The cross flow is reduced to 0 ml/min within 5 minutes and elution is 
continued for additional 20 minutes at a detector flow of 1.0 ml/min. hGH was separated in the 
same manner except the the cross flow was changed to 2.5 ml/min, the detector flow was set 
to 0.5 ml/min and a 5 kDa RC membrane was used. The buffer was the same as for size-
exclusion chromatography of hGH. 
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II.2.12 FOURIER-TRANSFORM INFRARED SPECTROSCOPY (FTIR) 
To determine protein secondary structure, a Bruker Tensor 27 FTIR spectrometer (Bruker 
Optics, Ettlingen, Germany) was used. Samples were either measured in the BIO ATR II cell 
or in a calcium fluoride flow-through cell. The mercury cadmium telluride detector was cooled 
with liquid nitrogen and the beam path was purged with nitrogen. Each spectrum was recorded 
in 120 scans between 850 to 4000 cm-1 with a 4 cm-1 resolution and a corresponding blank 
spectrum was subtracted. The second derivative spectrum in the range between 1720 to 1480 
cm-1 was calculated using the Savitzky-Golay smoothing algorithm with 17 smoothing points 
by the Opus 6.5 software after vector normalization of the spectra and a correlation coefficient 
according to Prestrelski and coworkers [53] was calculated in Microsoft Excel.  
II.2.13 RESIDUAL MOISTURE CONTENT (HEADSPACE METHOD) 
To determine residual water content after freeze-drying, Karl Fischer titration was used. 
Between 10 and 50 mg of sample aliquots were prepared in a glove box with a relative humidity 
of less than 10 %, filled into DIN 2R Vials and crimped. The samples were then placed in an 
oven with 90 °C to enable fast extraction of water and the headspace gas is transported into a 
coulometric Karl Fischer titrator (Aqua 40.00, Elektrochemie Halle). The results are calculated 
in relative water content (m/m). 
II.2.14 RESIDUAL MOISTURE CONTENT (DIRECT INJECTION METHOD) 
To determine residual moisture of collapsed freeze-dried and spray-dried samples, the Karl-
Fischer direct injection method with methanol was used. Between 10 and 50 mg of sample 
aliquots were prepared in a glove box with a relative humidity of less than 10 %, filled into DIN 
2R Vials and crimped. Approximately 2.5 ml of methanol with very low water content was 
added to the sample for extraction of water. Subsequently, the sample was placed in an 
ultrasonic bath for 10 minutes. An aliquot of 1 ml was injected into a coulometric Karl Fischer 
titrator (737 KF Coulometer, Metrohm, Filderstadt, Germany). The results are calculated in 
relative water content (m/m). 
II.2.15 DYNAMIC SCANNING CALORIMETRY (TG’) 
The glass transition temperature of the maximally freeze-concentrated samples was 
determined using either a Netzsch DSC 204 (Selb, Germany) or a Mettler Toledo DSC 821e 
(Gießen, Germany) dynamic scanning calorimeter. Approximately 25 ul of the liquid samples 
were weighed into aluminium crucibles and crimped. The samples were cooled to -70 °C with 
a cooling rate of 10 K/min with the Netzsch system which was equipped with a liquid nitrogen 
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cooler. With the Mettler system, the samples were cooled to -40 °C with a cooling rate of -
10 K/min and to – 50 °C with a cooling rate of 2 K/min. Tg’ was determined by heating the 
samples with a heating rate of 10 K/min and the inflection point of the glass transition was 
evaluated.  
II.2.16 DYNAMIC SCANNING CALORIMETRY (TG) 
The glass transition of the dried lyophilizates was measured using either a Netzsch DSC 204 
(Selb, Germany) or a Mettler Toledo DSC 821e (Gießen, Germany) dynamic scanning 
calorimeter. Aliquots of 5 to 20 mg of dried lyophilized cake were compacted in an aluminium 
crucible and crimped in a glove box with a relative humidity of less than 10 %. Both devices 
cannot work in modulating mode, so the samples were cooled to -10 °C with a cooling rate of 
10 K/min, heated to 110 °C with a heating rate of 10 K/min to allow for relaxation of the samples 
and sample was heated again from -10 °C to 180 °C with 10 K/min. For samples which were 
based on 1 % HPβCD, no glass transition could be detected using a heating rate of 10 K/min, 
so those samples were heated with 50 K/min. The glass transition temperature was evaluated 
from the inflection point of the glass transition using the Netzsch Proteus software or the Mettler 
StarE Software.  
II.2.17 SPECIFIC SURFACE AREA 
Specific surface area of lyophilizates was determined using Brunauer-Emmet-Teller krypton 
gas adsorption in a liquid nitrogen bath at 77.3 K (Autosorb 1, Quantachrome, Odelzhausen, 
Germany). Samples were gently crushed with a spatula and weighed into glass tubes. 
Outgassing was performed at least for 2 h at room temperature and an outgassing test was 
performed before every measurement. An eleven point gas adsorption curve was measured, 
covering a p/p0 ratio of appr. 0.05 to 0.30. Data evaluation was performed according to the 
multipoint BET method fit of the Autosorb 1 software. 
II.2.18 X-RAY POWDER DIFFRACTION 
XRD was used to determine the solid state of the lyophilized product with an XRD 3000 TT 
diffractometer (Seifert, Ahrensburg, Germany). The device is equipped with a copper anode 
(40 kV, 30 mA) and has a wavelength of 0.154178 nm. The scintillation detector voltage was 
1000 V. The samples were placed on the sample holder and analysed in the range of 5-45 ° 
2-theta with steps of 0.05° 2-theta.  
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II.2.19 ELECTRON SPECTROSCOPY FOR CHEMICAL ANALYSIS (ESCA) 
The dried product was analysed using an AXIS Ultra DLD X-ray photoelectron spectrometer 
(Kratos Analytical, Manchester, England) to determine atom concentration at the interface 
(approximately 5 – 10 nm deep) of the lyophilizates. Where necessary the automatic charge 
neutraliser system was used. When used, the spectra were calibrated to 285.0 eV binding 
energy for the hydrocarbon C 1s peak post acquisition. Analysis times typically were 3 minutes 
with a XRAY power of 300 W and a large area of approximately 300 x 700 µm was measured. 
Data reduction and processing was performed using the Vision 2 processing software. 
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II.3 RESULTS 
II.3.1 CYCLODEXTRINS AS REPLACEMENT FOR POLYSORBATES - FORMULATION 
DEVELOPMENT FOR THE MODEL PROTEIN MABR1 
II.3.1.1 FORMULATION SCREENING 
In a first screening, various concentrations and combinations of the excipients sucrose, 
HPβCD, MβCD and polysorbate 80 were conventional freeze-dried with the model antibody 
MabR1 and analysis of the protein was performed after preparation (t0), after freeze-thaw 
studies (t1) and after freeze-drying (t2) for each of the formulations shown in Table II-3. 
Sucrose was used in a concentration of 1 %, which results in a protein-to-sugar mass ratio of 
1:1 or a molar ratio of 1:438, which is on the lower limit of sugar concentrations to create 
challenging conditions.  This limit usually is around 60 mM [3]. 60 mM equals approximately 
2 % Sucrose and a molar ratio of protein:disaccharide of 1:900 for the 10 mg/ml of antibody 
used in this study.  
Table II-3: Concentrations and combination of excipients for the screening of the model antibody MabR1. 
Form # Mab R1 [mg/ml] Sucrose [%] HPβCD [%] MβCD [%] Polysorbate 80 [%] 
1 10 - - - - 
2 10 - - - 0.04 
3 10 0.1 - - - 
4 10 1 - - - 
5 10 1 - - 0.04 
6 10 1 1 - - 
7 10 - 0.1 - - 
8 10 - 1 - - 
9 10 - 1 - 0.04 
10 10 - - 0.1 - 
11 10 - - 1 - 
12 10 - - 1 0.04 
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II.3.1.2 PROTEIN STABILITY DETERMINATION – SUBVISIBLE PARTICLES AND TURBIDITY 
Light obscuration and turbidity showed a high sensitivity of detecting protein instability by 
formation of subvisible particles. The model protein MabR1 proved to be a good model 
because it showed sensitivity to freezing as well as drying and rehydration, which is illustrated 
in Figure II-2. The addition of polysorbate 80 (PS80) reduced subvisible particle formation after 
freeze-thawing stress (t1 FT) but was not successful in stabilization during dehydration in the 
freeze-drying process and reconstitution (t2 FD). The addition of sucrose in combination with 
PS80 showed the lowest number of subvisible particles after the freeze-drying process and 
rehydration and turbidity values remained unchanged. For some formulations, the coincidence 
limit of the PAMAS SVSS system was exceeded; however, since the goal was to obtain stable 
formulations with acceptable particle numbers of appr.  
< 30.000 per ml, it was not important if actual numbers of particles are 120,000 or 200,000 per 
ml. 
 
Figure II-2: Results from light obscuration and turbidity for the model protein MabR1. t0=analysis after preparation, t1 FT = 
analysis after freeze-thaw stress, t2 FD: analysis after freeze-drying and rehydration.  
 
When both cyclodextrins derivatives, HPβCD and MβCD, were added as excipients, the 
concentrations of 1.0 % (w/v) showed the best results with respect to subvisible particle 
formation after freeze-thawing as well as after freeze-drying and rehydration, as shown in 
Figure II-3. However, turbidity was slightly increased in those formulations. The combinations 
of cyclodextrins with polysorbate 80 and sucrose with polysorbate 80 showed acceptable 
subvisible particle concentrations and almost unchanged turbidity values. HPβCD in 
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combination with sucrose was slightly inferior with respect to subvisible particles and turbidity 
to those combinations, as shown in Figure II-4. With respect to results from light obscuration, 
the formulations can be ranked as following: Formulation 5, 9 and 12 with low particle 
concentrations < 10,000 per ml and formulation 4, 6, 8, and 11 with acceptable particle 
concentrations of < 30,000. 
 
Figure II-3: Results from light obscuration and turbidity for formulations containing cyclodextrins in two concentrations in 
comparison to the bulk antibody formulation. t0=analysis after preparation, t1 FT = analysis after freeze-thaw stress, t2 FD: 
analysis after freeze-drying and rehydration. 
 
Figure II-4: Results from light obscuration and turbidity for various combinations of CDs, sucrose and PS80. t0=analysis after 
preparation, t1 FT = analysis after freeze-thaw stress, t2 FD: analysis after freeze-drying and rehydration. 
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As more extensively discussed in section II.3.14, HPβCD placebo particle formation was also 
investigated and it was found that 1.0 % HPβCD showed the highest amount of particles and 
turbidity whereas the combination of sucrose and HPβCD showed less subvisible particles but 
almost the same turbidity value, as displayed in Figure II-5. 
 
Figure II-5: Results from light obscuration and turbidity for formulations freeze-dried and rehydrated without protein.  
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II.3.1.3 SIZE-EXCLUSION CHROMATOGRAPHY 
A slight decrease in MabR1 monomer content was observed for all formulations after freeze-
drying and rehydration which is accompanied with a slight increase in dimer content (see 
Figure II-6) and high-molecular-weight aggregates (HMWA) (see Figure II-7). This trend was 
most pronounced for the formulation without excipients and less pronounced for the 
formulations containing sucrose or HPβCD at a concentration of 1.0 % independent of the 
presence of polysorbate 80. Total protein AUC remained more or less unchanged, indicating 
that only a small fraction of protein formed aggregates (Figure II-7, B). 
A 
 
B 
 
Figure II-6: Relative monomer (A) and dimer (B) content of MabR1 as determined with SE-HPLC. t0=analysis after preparation; 
t1=analysis after freeze-thawing; t2=analysis after freeze-drying and rehydration. 
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Figure II-7: Relative high molecular weight aggregates (A) and total protein area under the curve (AUC) (B) of MabR1 as 
determined with SE-HPLC. t0=analysis after preparation; t1=analysis after freeze-thawing; t2=analysis after freeze-drying and 
rehydration. The 100% border refers to the AUC of bulk t0. 
 
II.3.1.4 FOURIER-TRANSFORM INFRARED SPECTROSCOPY 
Results from FTIR showed that correlation coefficients were over 0.9 for all formulations and 
showed no differences by visual comparison, including the bulk formulation without excipient 
(spectra are not shown). These findings indicate that no changes in secondary structure lead 
to aggregation of MabR1 or the amount of aggregates, which is often less than 1 % of total 
protein amount [54], is not enough to be detectable by FTIR spectroscopy. 
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Table II-4: Calculated correlation coefficients according to Prestrelski for all formulations after freeze-thawing (FT) and freeze-
drying (FD). 
Formulation rt1
 (FT) r
t2
 (FD) 
MabR1 bulk     0.9954 0.9900 
MabR1 + 0.04 % PS80     0.9805 0.9771 
MabR1 + 0.1 % Sucrose     0.9756 0.9934 
MabR1 + 1.0 % Sucrose     0.9954 0.9965 
MabR1 + 1.0 % Sucrose + 0.04 % PS80     0.9969 0.9943 
MabR1 + 0.1 % HPβCD     0.9964 0.9957 
MabR1 + 1.0 % HPβCD     0.9588 0.9853 
MabR1 + 1.0 % HPβCD + 0.04 % PS80     0.9908 0.9696 
MabR1 + 0.1 % MβCD     0.9876 0.9915 
MabR1 + 1.0 % MβCD     0.9645 0.9815 
MabR1 + 1.0 % MβCD + 0.04 % PS80     0.9954 0.9900 
MabR1 + 1.0 % Sucrose + 1 % HPβCD     0.9763 0.9849 
 
II.3.1.5 PHYSICO-CHEMICAL CHARACTERIZATION OF THE FREEZE-DRIED CAKES 
Residual moistures of all formulations were below 2.0 %, and for all formulations containing at 
least 1.0 % of sucrose, HPβCD or MβCD, residual moisture values were between 0.5 % and 
1.0 % (w/w), as illustrated in Figure II-8. Glass transition temperatures could only be detected 
for the formulations which contain 1.0 % sucrose as excipient. Specific surface areas for 
selected formulations were in the range from 1.1 m²/g to 1.73 m²/g for MabR1-containing 
samples and higher for placebo samples, as shown in Table II-5. 
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Figure II-8: Residual moisture and glass transition temperature (Tg) for all formulations.  
 
Table II-5: Specific surface area of selected formulations of MabR1 or placebo. 
Formulation SSA [m²/g] 
MabR1 bulk 1.73 
MabR1 + 0.04 % PS80 1.16 
MabR1 + 1.0 % Sucrose 1.33 
MabR1 + 1.0 % HPβCD 1.40 
MabR1 + 1.0 % HPβCD + 0.04 % PS80 1.65 
Placebo 1.0 % Sucrose 1.95 
Placebo 1.0 % Sucrose + 1 % HPβCD 1.63 
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II.3.1.6 DISCUSSION AND SUMMARY 
Overlooking the results from the first screening experiment, it could be observed that MabR1 
is sensitive to freezing and freeze-drying followed by rehydration. Degradation of MabR1 was 
mainly observed with subvisible particle counting, which is a sensitive method to detect small 
fractions of degraded protein, since even a high number of particles (e.g. 10,000 particles 
> 2 µm per ml) represents only a small fraction of protein, (e.g. < 20 µg/ml) [54]. Consequently, 
small changes in aggregated protein mass result in large deviation in particle numbers. Based 
on results from light obscuration, the best formulations contained polysorbate 80 which was 
combined with a cryo/lyoprotectant such as sucrose or both cyclodextrin derivatives employed 
in this study, HPβCD and MβCD. The combination of sucrose and HPβCD also lead to 
acceptable but higher particle concentrations.  Consequently, polysorbate 80 was superior to 
HPβCD in this study. In the presence of a cryo- and lyoprotectant such as sucrose, only minor 
changes in relative monomer content and dimer content were observable immediately after 
freeze-drying and rehydration and protein recovery. Furthermore, this small amount of 
aggregated protein also poses a challenge for spectroscopic methods like FTIR and results 
did not show any significant changes in the amide I and II region. These results suggest that 
even if a small percentage of total protein is degraded, these fractions may not be detected by 
FTIR or aggregated species do not show differences in secondary structure. 
The buffer employed in this study was a sodium-phosphate buffer at pH=6.4 in a concentration 
of 10 mM. It has long been known that sodium phosphate buffers tend to crystallize during 
freezing with an accompanying pH-shift [55], and this crystallization can be reduced by adding 
amorphous stabilizers such as disaccharides or polymers [56] and by keeping buffer 
concentration as low as possible [2]. However, in the study presented, buffer concentration 
was very low and if sucrose was added, crystallization of sodium phosphate dibasic is unlikely. 
Moreover, addition of polysorbate 80 in a very low concentration lead to low numbers of 
subvisible particle numbers during freeze-thawing, indicating that interfacial denaturation of 
the antibody is the main degradation pathway and buffer crystallization as well as cold 
denaturation, that is unfolding of proteins at low temperatures, are probably no issue in this 
study.  
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II.3.2 FURTHER SCREENING OF FORMULATIONS FOR THE MODEL PROTEIN 
MABR1 
After the results for the formulation screening, further screening and fine-tuning of the 
formulation with MabR1 at 10 mg/ml was performed with different concentrations of HPβCD 
(0.1 %, 0.35 % and 0.60 %), all in combination with 1.0 % sucrose. Analysis was performed 
after preparation (t0), after freeze-thawing (t1 FT) and after freeze-drying and rehydration (t2 
FD). Two different lots of MabR1 were used to check for robustness of the formulations.  
II.3.2.1 PROTEIN STABILITY DETERMINATION – SUBVISIBLE PARTICLES AND TURBIDITY 
Similar to the first study, light obscuration and turbidity showed greatest sensitivity to detect 
protein instabilities due to aggregation. For both lots of MabR1, subvisible particles after 
freeze-thaw (t1) and freeze-drying and rehydration (t2) were almost identical and therefore 
average values were calculated for both lots. However, the results from the initial screening of 
MabR1 could not be reproduced and the subvisible particles for the formulation containing 
sucrose only was much higher; also the combination of sucrose with HPβCD, almost 
independent of concentration, resulted in large amounts of subvisible particle numbers, as 
shown in Figure II-9, A. For the concentrations of 0.35 % and 0.60% HPβCD, the number of 
particles larger 10 µm was slightly reduced (Figure II-9, B), indicating that 0.1 % HPβCD is 
most probably not enough for stabilization of the protein after freeze-drying and rehydration.  
After reconstitution of the formulations with a solution of 0.04 % polysorbate 80, a reduction in 
subvisible particles > 1 µm and turbidity was observed for all formulations except the 
formulation which contains 0.1 % HPβCD, as shown in Figure II-11. This result suggests that 
either fewer particles formed during the rehydration step or particles were “dissolved” or 
refolded in the presence of a surfactant. No significant differences between the HPβCD 
concentrations were observed after freeze-thawing and no increase in subvisible particles 
compared to t0 analysis was observed. Similar to the first screening study in section II.3.1, 
placebo particles and an increase of turbidity were observed with the formulation which 
contained HPβCD and the amount correlated with the concentration, as shown in Figure II-10.  
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Figure II-9: Results from light obscuration for particles > 1µm and turbidity (A) and particles > 10 µm (B) for the combinations of 
sucrose and HPβCD. t0=analysis after preparation; t1=analysis after freeze-thawing; t2=analysis after freeze-drying and 
rehydration. 
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Figure II-10: Subvisible particles and turbidity for placebo formulations containing only sucrose and variable amounts of HPβCD. 
t0=after preparation; t2=after freeze-drying and rehydration. 
 
 
Figure II-11: Results from light obscuration and turbidity for MabR1 formulations which were freeze-dried and either 
reconstituted with water (rec. with water) or with a solution of 0.04 % PS80 (rec. with PS80).  
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II.3.2.2 SIZE-EXCLUSION CHROMATOGRAPHY 
No significant differences in soluble protein species as well as total protein recovery (AUC) as 
determined with size-exclusion chromatography were observed for all formulations and both 
lots of MabR1 at all analytical time points, as shown in Figure II-12 and Figure II-13. 
 
A 
 
B 
 
Figure II-12: Relative amounts of MabR1 protein species as determined by SE-HPLC for Lot 1 (A) and Lot 2 (B). t0=analysis 
after preparation; t1=analysis after freeze-thawing; t2=analysis after freeze-drying and rehydration. 
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Figure II-13: Total protein recovery for Lot 1 (A) and Lot 2 (B) as determined by SE-HPLC. t0=analysis after preparation; 
t1=analysis after freeze-thawing; t2=analysis after freeze-drying and rehydration. 
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II.3.2.3 FTIR SPECTROSCOPY 
No major differences were observed with FTIR-spectroscopy as correlation coefficients are all 
> 0.98, as indicated in Table II-6 and spectra were almost perfectly superimposing each other, 
as shown in Figure II-14 for Lot 1 and Figure II-15 for Lot 2. However, correlation coefficients 
were highest for the formulation which contains 0.35% and 0.6 % HPβCD, which was most 
pronounced with Lot 1.   
Table II-6: Correlation coefficients (r) as determined with FTIR for both Lots and timepoints t1 and t2 compared to t0. 
 Lot 1 Lot 2 
Formulation rt1 (FT) rt2 (FD) rt1 (FT) rt2 (FD) 
MabR1 1% Sucrose 0.9852 0.9887 0.9972 0.9939 
MabR1 1% Sucrose + 0.10 % HPbCD 0.9934 0.9916 0.9973 0.9987 
MabR1 1% Sucrose + 0.35 % HPbCD 0.9986 0.9910 0.9950 0.9934 
MabR1 1% Sucrose + 0.60 % HPbCD 0.9989 0.9982 0.9953 0.9989 
 
A 
 
B 
 
C 
 
D 
 
Figure II-14: 2nd derivative FTIR spectra of the amide I (1600-1700 cm-1) and amide II band (1600 – 1500 cm-1) for all 
formulations of MabR1, Lot 1 with 0 % (A), 0.10 % (B), 0.35 % (C) and 0.60 % (D) and all timepoints. 
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Figure II-15: 2nd derivative FTIR spectra of the amide I (1600-1700 cm-1) and amide II band (1600 – 1500 cm-1) for all 
formulations of MabR1, Lot 2 with 0 % (A), 0.10 % (B), 0.35 % (C) and 0.60 % (D) and timepoints. 
II.3.2.4 PHYSICO-CHEMICAL ANALYSIS OF THE FREEZE-DRIED CAKES 
Acceptable glass transition temperatures of the freeze-dried cakes were obtained for both lots 
with Tgs > 60 °C as shown in Figure II-16. In addition, residual moisture levels were quite low 
at a level of around 0.2 % (w/w), and were slightly lower than in the first screening study. Table 
II-7 shows the results for specific surface area of these formulations.  
 
Table II-7: Specific surface area (SSA) for all formulations of Lot 2.  
Formulation BET SSA [m²/g] 
MabR1 1% Sucrose 1.45 
MabR1 1% Sucrose + 0.10 % HPbCD 1.62 
MabR1 1% Sucrose + 0.35 % HPbCD 1.56 
MabR1 1% Sucrose + 0.60 % HPbCD 1.45 
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Figure II-16: Glass transition temperatures of the freeze-dried cakes and corresponding residual moistures for Lot 1 (A) and 
Lot 2 (B).  
 
II.3.2.5 DISCUSSION AND SUMMARY 
The combination of sucrose with increasing concentrations of HPβCD (0.10, 0.35 and 0.60 %) 
lead to unacceptable high numbers of subvisible particles. In addition, the control with 1 % 
sucrose only showed slightly higher subvisible particle numbers, especially for the size class 
of > 10 µm. For this formulation, the results from the first screening study (section II.3.1) could 
not be reproduced. These batch-to-batch variations may originate due to different ice 
nucleation temperatures, which can lead to different interfacial areas, such as the ice-water 
interface and the liquid-air interface encountered during rehydration. This was the case for the 
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formulation of MabR1 formulated with 1 % sucrose with a SSA of 1.46 m²/g in this study and 
1.34 m²/g in the previous study in section II.3.1. Another hint that the SSA plays a major role 
in degradation of MabR1 is the experiment with reconstitution of the lyophilizates with a 
solution of PS80. This result suggests that HPβCD is not able to protect the antibody to the 
same extent or by the same mechanism as PS80. Interestingly, this is only true for the 
reconstituted but not for the freeze-thawed samples, which showed no significant increase in 
subvisible particles compared to the initial numbers prior to lyophilization. Here, a 
concentration of HPβCD as low as 0.1 %, was very effective in protecting the antibody during 
freeze-thawing. This observation is true for both lots of MabR1 investigated in this study. 
Reconstitution of protein lyophilizates with different qualities of degraded polysorbate could 
also help to identify the impact of those oxidized species on protein stability. 
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II.3.3 COLLAPSE FREEZE-DRYING OF MABR1 
With conventional freeze-drying, stabilization of the model antibody MabR1 with HPβCD was 
not successful because unacceptable subvisible particle levels were obtained. Collapse 
freeze-drying has been shown to effectively stabilize proteins in the freeze-dried state despite 
the unusual cake appearance [57, 58]. Moreover, with collapse freeze-drying, specific surface 
area is excessively reduced and residual moistures are somewhat higher. In this study, we 
want to investigate if the model protein MabR1 profits from collapse freeze-drying and the 
accompanying changed product quality attributes. 
II.3.3.1 FREEZE-DRYING PROCESS 
Aggressive freeze-drying results in in a process which is very fast comparable to conventional 
freeze-drying process and collapse results from viscous flow if Tc is exceeded. An aggressive 
freeze-drying cycle is characterized by a high shelf temperature and a high pressure set-point. 
The product temperature during steady state sublimation, as measured with a temperature 
probe, was approximately -13 °C, which results in a high sublimation rate. Sublimation is 
finished after 12.5 hours process time and is indicated by the convergence of the product 
temperature with shelf temperature. After this time point, desorption of unfrozen water takes 
place and residual moisture is further decreased.  
 
Figure II-17: Shelf temperature and pressure traces of the collapse freeze-drying run. A temperature sensor was placed in the 
formulation of MabR1 with 1% Sucrose and 0.6 % HPβCD. The pressure set-point was 2.56 mbar (Pirani manometer). 
II.3.3.2  PROTEIN STABILITY ANALYSIS – SUBVISIBLE PARTICLES AND TURBIDITY 
As in the previous studies, light obscuration and turbidity were quite sensitive to degradation 
of small amounts of protein. With collapse freeze-drying of MabR1, the formulation containing 
Sucrose and 0.6% HPβCD showed very acceptable particle levels and turbidity values after 
freeze-drying and rehydration which were even lower than the polysorbate containing 
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formulations, as illustrated in Figure II-18 and despite macroscopic collapse of the freeze-dried 
cake. Sucrose alone or in combination with only 0.1 % HPβCD both showed slightly less 
subvisible particles compared to conventional freeze-drying (section II.3.2.1) but still, 
subvisible particle levels were unacceptable high for those formulations. PS80 and HPβCD, 
independent of concentration, both inhibited formation of subvisible particles in freeze-thawing 
(t1 FT). The formulations containing 0.6 % HPβCD and PS80 resulted in very few particles > 
10 µm, with 17 and 80 particles per ml, respectively. 
 
Figure II-18: Results from light obscuration and turbidity for collapse freeze-dried and rehydrated MabR1. t0=analysis after 
preparation; t1=analysis after freeze-thawing; t2=analysis after freeze-drying and rehydration. 
Furthermore, with collapse freeze-drying, placebo particles of HPβCD could be reduced and 
were not significantly higher than the control of 1 % Sucrose, as shown in Figure II-19. Turbidity 
values were at baseline levels for all placebo formulations and unchanged compared to values 
after preparation which are usually around 0.5 FNU (data not shown).  
Chapter II: Cyclodextrins in freeze-drying and spray-drying of proteins 
52 
 
Figure II-19: Results from light obscuration and turbidity for collapsed freeze-dried and rehydrated placebo formulations.  
II.3.3.3 SIZE-EXCLUSION CHROMATOGRAPHY 
No changes in relative protein species were observed for all time points, indicating that the 
subvisible particles formed for all formulations were only a very small fraction of the total protein 
content, as suggested by Figure II-20 and Figure II-21.  
 
Figure II-20: Relative amounts of MabR1 protein species as determined by SE-HPLC. t0=analysis after preparation; t1=analysis 
after freeze-thawing; t2=analysis after freeze-drying and rehydration. 
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Figure II-21: Total protein recovery (AUC) of MabR1 as determined with size-exclusion chromatography. t0=analysis after 
preparation; t1=analysis after freeze-thawing; t2=analysis after freeze-drying and rehydration. 
II.3.3.4 FTIR SPECTROSCOPY 
FTIR was not able to detect small changes in protein stability and all correlation coefficients 
were close to 1.0 as displayed in Table II-8. Visual comparison of spectra also showed almost 
perfectly superimposing curves with no major differences for all formulations and time points, 
as suggested in Figure II-22. 
Table II-8: Correlation coefficients of FTIR spectra calculated for both timepoints t1 and t2 compared to t0.  
Formulation rt1 (FT) rt2 (FD) 
MabR1 1 % Sucrose 0.999 0.998 
MabR1 1 % Sucrose + 0.10 % HPβCD 1.000 1.000 
MabR1 1 % Sucrose + 0.60 % HPβCD 1.000 1.000 
MabR1 1 % Sucrose + 0.004 % PS80 0.998 0.998 
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Figure II-22: 2nd derivative FTIR spectra of the amide I (1600-1700 cm-1) and amide II band (1600 – 1500 cm-1) for all 
formulations of MabR1, with 0 % (A), 0.10 % (B) and 0.60 % HPβCD (C) and 0.004 % PS80  (D) and all timepoints. 
II.3.3.5 PHYSICO-CHEMICAL CHARACTERIZATION OF FREEZE-DRIED SAMPLES 
As expected, drying above Tc lead to macroscopic collapse of the freeze-dried cakes; Figure 
II-23 shows the macroscopic appearance of the lyophilized cakes. Collapse of the lyophilized 
samples can be quantified by specific surface area (SSA) measurements. Table II-9 shows the 
SSA of the freeze-dried samples. All values were between 0.1 and 0.2 m²/g and very low 
compared to conventional freeze-drying, which were between 1.3 to 1.7 m²/g. However, 
residual moistures and glass transition temperatures were acceptable with Tgs of above 70 °C 
and residual moistures below 2 %. Also reconstitution times were not significantly prolonged 
compared to conventional freeze-drying with a dissolution time of around 10 seconds with 
some schlieren present for approximately 60 sec, independent of formulation composition. 
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Table II-9: Specific surface area for all formulations as determined by krypton gas adsorption.  
Formulation BET SSA [m²/g] 
MabR1 1 % Sucrose 0.14 
MabR1 1 % Sucrose + 0.10 % HPβCD 0.21 
MabR1 1 % Sucrose + 0.60 % HPβCD 0.15 
MabR1 1 % Sucrose + 0.004 % PS80 0.12 
 
A 
 
B 
 
C 
 
D 
 
Figure II-23: Macroscopic appearance of collapse freeze-dried cakes. A: MabR1 + 1 % Sucrose; B: MabR1 + 1 % Sucrose + 
0.1 % HPβCD; C: MabR1 + 1 % Sucrose + 0.6 % HPβCD; D: MabR1 + 1 % Sucrose + 0.004 % PS80. 
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Figure II-24: Glass transition temperatures and residual moisture of collapse freeze-dried lyophilizates. 
II.3.3.6 SUMMARY AND DISCUSSION 
Most interestingly, it could be shown in this study that the freeze-drying process has a positive 
impact on protein stability despite or even due to collapse of the cake. As suggested in the 
previous chapter II.3.2, HPβCD was not able to stabilize the antibody at the liquid-air interface 
in a similar mechanism as PS80. However, if this interface is being decreased, as performed 
in this study by collapse of the lyophilized cake, successful stabilization of the antibody can be 
obtained, at least immediately after drying. By decreasing specific surface are of the freeze-
dried product, the fraction of protein located at this interface is also decreased and upon 
reconstitution, the amount of protein prone to aggregation is reduced. This was not only true 
for the formulation containing HPβCD but also for the formulation containing sucrose, which 
also showed less particles than with conventional freeze-drying. Aggregation of the interface-
sensitive MabR1 can be effectively mitigated by HPβCD during freeze-thawing as well as 
during reconstitution, if the interface is not too large. The concentration of 0.6 % (w/v) showed 
best subvisible particle concentrations compared to the lower concentration of 0.1 %. The 
mechanism by which HPβCD stabilizes must be different than that provided by polysorbates. 
Furthermore, placebo particles of HPβCD, which were present in the conventional freeze-dried 
samples, were eliminated by the collapse freeze-drying process. By decreasing specific 
surface area, one may expect longer reconstitution times, since the wetted area of the 
lyophilized cake becomes smaller. At least in this study, reconstitution times were not much 
prolonged and also residual moisture as well as glass transition temperatures both were in 
acceptable ranges. However, the reconstitution time may be responsible also for the improved 
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stability of MabR1 in collapsed samples, which has been shown in another study with 
interferon-γ to be beneficial for protein refolding. When reconstitution time was slowed by 
reconstitution with a solution of polysorbate 20 [59] or by a different way of preparation, spray-
freeze-drying, less aggregation of interferon-γ was observed [60]. The authors speculate that, 
by slower dissolution, less air is entrapped in the liquid, thus creating a less large air-liquid 
interface, at which the protein can adsorb and degrade. In addition, a prolonged dissolution 
time decreases maximum protein concentration of intermediate-state, aggregate-competent 
protein, thus allowing these proteins species to refold [59]. 
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II.3.4 CONTROLLED NUCLEATION FREEZE-DRYING OF MABR1 
In the collapse freeze-drying experiments, we observed that the formulations of 1 % Sucrose 
as well as the combinations of 1 % Sucrose and HPβCD, especially in concentrations of 0.6 %, 
profited from a low specific surface area. Another possibility to create a low specific surface 
area is ice nucleation at high product temperatures and a low degree of super-cooling. We 
found that inducing ice nucleation at a high product temperature of around -4 °C followed by a 
long isothermal hold time results in the lowest achievable SSA (see section III.6). In this study, 
we wanted to find out, if MabR1 formulations also profit from controlled ice nucleation and 
intermediate to low SSAs.  
II.3.4.1 LYOPHILIZATION PROCESS 
Ice nucleation was induced at a product temperature of approximately -3.5 °C and was 
followed by a 2h isothermal hold post-nucleation to allow slow crystallization and Ostwald 
ripening to create a SSA as low as possible. Ice nucleation was induced within several seconds 
and 100 % of vials were nucleated. After approximately 90 minutes, phase transformation from 
water to ice was finished, as indicated by convergence of the product temperature sensors 
with the shelf temperature. Temperature probes were placed into water to only monitor the 
product temperature during the ice nucleation process; hence drying steps were excluded from 
Figure II-25. 
 
Figure II-25: Magnification of the freezing step of the controlled nucleation lyophilization run. Both temperature probes were 
placed in water to monitor product temperature before induction of ice nucleation.  
II.3.4.2 PROTEIN STABILITY– SUBVISIBLE PARTICLES AND TURBIDITY 
Controlled ice nucleation leads to a reduction in specific surface area to intermediate values 
between conventional and collapse freeze-drying. Both formulations investigated in this study 
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profited from the decrease in SSA, which is shown in Figure II-26. As SSA could not be 
decreased as low as with collapse drying (~ 0.15 m²/g, section II.3.3.5) but was significantly 
lower than with conventional freeze-drying (~ 1.5 m²/g, section II.3.1.5), controlled nucleation 
also lead to intermediate particle levels for both formulations. The formulation with 0.6 % 
HPβCD profited more from lowering of SSA and also subvisible particles formed by HPβCD in 
the placebo formulation were reduced, as displayed in Figure II-27. 
 
Figure II-26: Overview of subvisible particles > 1 µm and turbidity for different drying processes for the formulations of MabR1 
and 1 % Sucrose with and without the addition of 0.6 % HPβCD. 
 
Figure II-27: Comparison of subvisible particles > 1 µm of the Formulations 1 % Sucrose and 0.6 % HPβCD with MabR1 and 
without MabR1 (Placebo).  
II.3.4.3 SIZE-EXCLUSION CHROMATOGRAPHY 
In agreement with the previous studies on MabR1, only minor changes in dimer or monomer 
content were observed in size-exclusion chromatography after lyophilisation and rehydration 
(t2), as shown in Table II-10. However, a small increase of relative amount of high-molecular-
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weight aggregates as well as dimer was observed after freeze-drying and rehydration 
compared to samples after preparation (t0) for both formulations studied.  
Table II-10: Relative amount of protein species as determined with SE-HPLC for several freeze-drying processes of MabR1. t0 
= after preparation, t2: after freeze-drying and rehydration. 
 
 HMWA Dimer Monomer Fragment 
Controlled nucleation FD (with 2h post-nucleation hold) 
MabR1 + 1 % Sucrose 
t0 0.09 ± 0.01 4.43 ± 0.04 94.24 ± 0.05 1.23 ± 0.03 
t2 0.22 ± 0.01 4.60 ± 0.02 94.31 ± 0.07 0.87 ± 0.04 
MabR1 + 1 % Sucrose  
+ 0.6 % HPβCD 
t0 0.09 ± 0.01 4.44 ± 0.01 94.22 ± 0.06 1.25 ± 0.07 
t2 0.22 ± 0.01 4.57 ± 0.03 94.29 ± 0.09 0.93 ± 0.06 
Collapse FD 
MabR1 + 1 % Sucrose 
t0 - - 2.71 ± 0.04 95.45 ± 0.07 1.84 ± 0.04 
t2 - - 2.36 ± 0.02 95.79 ± 0.02 1.86 ± 0.04 
MabR1 + 1 % Sucrose  
+ 0.6 % HPβCD 
t0 - - 2.77 ± 0.02 95.42 ± 0.06 1.81 ± 0.04 
t2 - - 2.25 ± 0.08 95.82 ± 0.05 1.93 ± 0.12 
Conventional FD 
MabR1 + 1 % Sucrose 
t0 - 
- 
2.60 ± 0.32 96.02 ± 0.09 1.38 ± 0.23 
t2 - - 2.24 ± 0.02 96.12 ± 0.05 1.64 ± 0.07 
MabR1 + 1 % Sucrose  
+ 0.6 % HPβCD 
t0 - 
- 
2.78 ± 0.07 95.97 ± 0.14 1.26 ± 0.07 
t2 - - 2.32 ± 0.04 96.09 ± 0.03 1.59 ± 0.01 
 
II.3.4.4 PHYSICO-CHEMICAL CHARACTERIZATION OF LYOPHILIZATES 
Freeze-drying with controlled nucleation resulted in a decrease of specific surface area 
compared to conventional freeze-drying. As there is an inverse correlation between SSA and 
residual moisture [61], a low SSA leads to increased residual moistures if secondary drying is 
not adjusted, which was also the case here. Nevertheless, residual moistures were around 
1 % and also glass transition temperatures were acceptable with Tgs of > 60 °C. Reconstitution 
times were less than 10 s for all formulations.  
Table II-11: Glass transition temperatures, residual moisture and specific surface area for both formulations in the controlled 
nucleation freeze-drying run.  
Formulation Tg [°C] Residual moisture [% w/w] SSA [m²/g] 
MabR1 + 1% Sucrose 66.00 ± 4.063 1.186 ± 0.121 0.531 
MabR1 + 1 % Sucrose  
+ 0.6 % HPβCD 74.73 ± 4.539 0.952 ± 0.056 0.588 ± 0.188 
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Lyophilizate cakes appeared different than conventional freeze-dried ones with some crack 
formation and shiny surfaces as shown in Figure II-28. However, both formulations as well as 
placebo controls were fully amorphous with no detectable peaks in the x-ray powder diffraction 
patterns (see Figure II-29). 
A 
 
B 
 
Figure II-28: Macroscopic appearance of lyophilizate cakes of formulation MabR1 + 1 % Sucrose (A) and MabR1 + 1 % Sucrose 
+ 0.6 % HPβCD (B). 
 
 
Figure II-29: Results from XRD for controlled nucleation freeze-drying samples.   
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II.3.4.5 SUMMARY AND DISCUSSION 
Controlled nucleation at a relatively high product temperature of -3.5 °C lead to intermediate 
specific surface areas and also intermediate particle levels compared to collapse freeze-drying 
and conventional freeze-drying. At least for MabR1, a good correlation of the SSA and the 
subvisible particle number could be observed for the formulations without a surfactant and 
0.6 % HPβCD and this correlation could also be established for the placebo particles formed 
by HPβCD. Currently, controlled nucleation is the easiest possibility to create lyophilizates with 
a low SSA and a freeze-dried cake featuring “elegance”. However, at least with the freezing 
protocol applied here to achieve the lowest possible specific surface area, a slight increase of 
high-molecular weight aggregates was observed. With this result in mind, it is not reasonable 
to use a thermal treatment step, also called annealing, to decrease SSA. Annealing is known 
to foster ice crystal growth by keeping the product temperature at a value above Tg’ and smaller 
ice crystals melt in favour of larger ones, an interfacially driven process. However, during the 
hold step at Tp > Tg’, freeze-concentration-associated stress is exerted on the product. In this 
study, this was possibly the case when crystallization proceeds post-nucleation and the 
fraction of HMWAs was slightly increased. This would have most likely also been observed 
with a thermal treatment step but was not observed in the other studies of MabR1 without 
controlled nucleation. Of course, the long isothermal hold post-nucleation can be shortened or 
completely left out, if a product is sensitive towards freeze-concentration associated stresses. 
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II.3.5 STORAGE STABILITY OF MABR1 FORMULATED WITH 1 % SUCROSE 
The previous chapters showed that a stable freeze-dried formulation of MabR1 in combination 
with HPβCD with acceptable subvisible particle levels, similar to the addition of polysorbate, 
can be obtained by collapse freeze-drying of those formulations. The next step is to investigate 
isothermal storage stability of those lyophilizates. Due to the high Tgs obtained for both 
formulations, high temperatures for storage stability were chosen for accelerated stability 
studies, 60 °C, 40 °C and 25 °C for the formulation of MabR1 with 1 % Sucrose and 0.004 % 
PS80 or 0.6 % HPβCD, respectively. 
II.3.5.1 PROTEIN STABILITY – SUBVISIBLE PARTICLES AND TURBIDITY 
After the freeze-drying process at t0, subvisible particles and turbidity were somewhat higher 
for both formulations than in the previous experiment in section II.3.3.2. For both formulations 
and temperatures of 60 °C and 40 °C, large standard deviations and an increase in subvisible 
particles were observed, especially for the formulation which contained 0.6 % HPβCD, which 
is displayed in Figure II-30 and Figure II-31. Only the formulation with PS80 which was stored 
at 25 °C showed almost unchanged particle levels and turbidity (see Figure II-32), which points 
to a general instability of both formulations at the chosen storage conditions. For the size class 
> 10 µm, a similar picture was obtained with many particles and high standard deviations for 
the formulation which contained HPβCD, stored at 60 °C, as displayed in Figure II-33. For the 
PS80 formulation and the lower storage temperatures of the HPβCD formulation, particle 
concentrations were around 2000 per ml over storage time. Despite the huge standard 
deviations, the large amount of particles and the non-linearity of the particle concentrations, 
no visible particles could be detected by visual inspection. However, the results suggest that 
larger aggregates were formed by continuous degradation of the protein and may have been 
unnoticed due to the high turbidity observed. 
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Figure II-30: Subvisible particles > 1 µm per ml for the formulation MabR1 + 1 % Sucrose + 0.6 % HPβCD stored at three 
different temperatures for 12 weeks.  
 
Figure II-31: Subvisible particles > 1 µm per ml for the formulation MabR1 + 1 % Sucrose + 0.004 % PS80 stored at three 
different temperatures for 12 weeks. 
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Figure II-32: Results from turbidity for both formulations at all timepoints and storage temperatures.  
 
Figure II-33: Subvisible particles > 10 µm per ml for both formulations of MabR1 stored at three different temperatures for 
12 weeks. 
II.3.5.2 SIZE-EXCLUSION CHROMATOGRAPHY AND ASYMMETRICAL FLOW-FIELD-FLOW 
FRACTIONATION 
Size-exclusion chromatography as well as asymmetrical flow-field-flow fractionation (AF4) 
showed a loss in relative monomer content for both formulations. The decrease in monomer 
content was most exaggerated at higher temperatures, especially at 60 °C. The formulation 
containing HPβCD showed a somewhat faster degradation than the Polysorbate 80 containing 
formulation as measured with SE-HPLC (Figure II-34). This trend was not observable in AF4 
(Figure II-36). However, the formulation containing PS80 showed significantly more dimer 
formation in SE-HPLC and this trend was observable with both orthogonal methods, as shown 
in Figure II-35 and Figure II-37. At 40 °C, no significant difference between the formulations 
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was observed although both formulations showed an increase in dimer and a loss of monomer. 
At 25 °C, only minor changes in monomer content and dimer content could be detected with 
both methods. Total protein recovery as shown in Figure II-38 did not show significant 
differences between formulations, time points and storage temperatures, suggesting that the 
minor changes in AUC which were observed are method artefacts. 
 
Figure II-34: Relative MabR1 monomer content as determined by SE-HPLC for both formulations stored at three different 
temperatures for 12 weeks. 
 
Figure II-35: Relative MabR1 dimer content as determined by SE-HPLC for both formulations stored at three different 
temperatures for 12 weeks. 
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Figure II-36: Relative MabR1 monomer content as determined by AF4 for both formulations stored at three different 
temperatures for 12 weeks. 
 
Figure II-37: Relative MabR1 dimer content as determined by AF4 for both formulations stored at three different temperatures 
for 12 weeks. 
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Figure II-38: Total protein recovery as determined with SE-HPLC for both formulations at all timepoints at three different storage 
temperatures.  
II.3.5.3 FTIR SPECTROSCOPY 
Although a lot of subvisible particles were formed and SE-HPLC as well as AF4 indicate 
substantial dimer formation with accompanying loss of monomer, no changes in FTIR spectra 
could be observed and correlation coefficients remained unchanged, as shown in Figure II-40. 
These findings suggest that not changes in protein secondary structure were occurred in 
degradation of MabR1 and no intermolecular β-sheets have been formed during storage in the 
dried state. Also, visible comparison of spectra showed no significant differences, as shown 
for representative spectra of t0 (after freeze-drying) and stored for 12 weeks at 60 °C (t4) in 
Figure II-39.  
A B 
Figure II-39: Representative 2nd derivative FTIR spectra for HPβCD-containing formulations (A) and PS80-containing 
formulations (B) at t0 (after freeze-drying) and stored for 12 weeks at 60 °C (t4).  
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Figure II-40: FTIR correlation coefficients for both formulations at all timepoints at three different storage temperatures. 
II.3.5.4 PHYSICO-CHEMICAL CHARACTERIZATION OF LYOPHILIZED CAKES 
During storage, residual moisture slightly increased within all samples, as shown in Figure 
II-41, especially with higher temperatures from 0.4 % to approximately 1.0 % to 1.5 %. 
Although stoppers were dried after steam-sterilization, a certain uptake of water vapour cannot 
be completely avoided and for these formulations with a low concentration of solutes, already 
an uptake of some µg results in an increase in residual moisture, which is stated as relative 
mass of water per total mass. However, the uptake of water did neither result in a significant 
decrease of the glass transition temperature which were all above 70 °C nor in a change in 
specific surface area, as shown in Figure II-42 and Figure II-43. Reconstitution times were 
approximately 10 seconds followed by schlieren for around 60 seconds and were unchanged 
over storage time.  
 
Figure II-41: Residual moisture for both formulations stored at three different temperatures for 12 weeks.  
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Figure II-42: Glass transition temperatures of both formulations stored at three different temperatures over storage time.  
 
Figure II-43: Specific surface area for both formulations stored at three different temperatures for 12 weeks. 
 
II.3.5.5 DISCUSSION AND SUMMARY 
During storage of the two formulations employed in this study, degradation of the antibody 
MabR1 was observed, especially at the storage temperatures of 60 °C and 40 °C. At these 
temperatures, degradation of the antibody was also confirmed by size-exclusion 
chromatography and asymmetrical flow-field-flow fractionation. The formation of dimer during 
storage of lyophilizates is usually prevented by a lyoprotectant such as sucrose or trehalose 
and is less dependent on interface areas which were very low due to the collapse freeze-drying 
process. In this study, as already mentioned, a very low amount of sucrose was used to create 
challenging conditions for the formulation study; however, during storage of the lyophilizates, 
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the concentration of sucrose was possibly too low to achieve sufficient stabilization of the 
protein. In the next studies, the concentration of sucrose will be increased to create storage 
stable lyophilizates.  
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II.3.6 CONTROLLED NUCLEATION FREEZE-DRYING OF MABR1 FORMULATED 
WITH 5 % SUCROSE 
The stability study of MabR1 formulated with 1 % sucrose in combination with 0.6 % HPβCD 
or 0.004 % PS80 had shown that only poor stability of the lyophilizates was obtained, 
especially at 60 °C, but also at 40 °C an increase in dimer formation was observed. These 
findings indicate that the protein-to-sugar mass ratio of 1:1 was not enough and as a next step, 
we increased this ratio to 1:5 (m/m) and employed controlled ice nucleation at low degrees of 
super-cooling to reduce SSA. MabR1 was formulated at 10 mg/ml with 5 % Sucrose and 0 %, 
0.35 % and 0.60 % of HPβCD was added. 0.004 % polysorbate 80 instead of HPβCD served 
as positive control. Protein stability was assessed directly after the freeze-drying process and 
rehydration (t2) and compared to pre-process formulations (t0). 
II.3.6.1 FREEZE-DRYING PROCESS 
Ice nucleation was induced at a product temperature of approximately -5 °C followed by an 
isothermal hold post-nucleation of -8 °C for 2 hours, as shown in Figure II-44. Secondary drying 
temperature was increased to 35 °C, to achieve residual moisture levels of around 1 % (w/w) 
as obtained for the formulations based on 1 % sucrose similar as in chapter 0.  Table II-12 
shows product temperatures during steady-state primary drying of the formulations containing 
HPβCD. Primary drying is finished for all formulations after approximately 26 hours.    
 
Table II-12: Product temperatures (Tp) of 4 formulations during steady-state freeze-drying (5 h after constant shelf temperature 
of -20 °C). 
Formulation Tp after 5h of primary drying [°C] Primary drying duration [h] 
MabR1 + 5 % Sucrose  
+ 0.6 % HPβCD -39.0 24.6 
MabR1 + 5 % Sucrose  
+ 0.35 % HPβCD -39.3 24.9 
5 % Sucrose + 0.6 % HPβCD -39.8 21.6 
5 % Sucrose + 0.35 % HPβCD -40.0 25.7 
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Figure II-44: Controlled nucleation freeze-drying run of MabR1 formulated with 5 % Sucrose. Thermocouples were placed in 
formulations of 5 % Sucrose with 0.35 % or 0.6 % HPβCD and with MabR1 or with placebos only.  
II.3.6.2 PROTEIN STABILITY IMMEDIATELY AFTER FREEZE-DRYING – SUBVISIBLE 
PARTICLES AND TURBIDITY 
After freeze-drying and rehydration the formulation containing 5 % Sucrose in combination with 
0.004 % PS80 showed lowest particulate concentrations and turbidity as shown in Figure II-45. 
Further, the formulation containing no surfactant showed slightly less particles than both 
formulations containing HPβCD. Having a closer look on placebo particles, it was observed 
that both HPβCD formulations showed significantly higher concentrations of subvisible 
particles than the formulations without HPβCD. Interestingly, the placebo formulation showed 
higher particle levels than the corresponding antibody formulation. It is difficult to compare 
antibody formulations with the placebo formulation, since the situation at the interface is 
probably completely different. However, placebo particles formed by HPβCD probably 
contribute to the total amount of particles in the antibody formulation. The number of placebo 
particles formed in the antibody formulation is probably a lot lower, as it is suggested by Figure 
II-45. Besides that, the increase in sucrose concentration also leads to a great reduction in 
subvisible particles compared to the formulation with 1 %, as shown in section II.3.4.  Particle 
concentrations > 10 µm were higher with 5 % sucrose only compared to the formulations 
containing HPβCD or PS80, as displayed in Table II-13. The formulation with PS80 showed 
the lowest amount of subvisible particles also in the size class > 10 µm. 
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Figure II-45: Subvisible particles and turbidity after rehydration for controlled-nucleation freeze-drying of MabR1. The light grey 
bars show particles of formulations without protein. 
 
Table II-13: Subvisible particles > 10 µm for all formulations. 
Formulation Subvisible particles > 10 µm per ml 
MabR1 + 5 % Sucrose 190 ± 77 
MabR1 + 5 % Sucrose + 0.35 %HPβCD 104 ± 31 
MabR1 + 5 % Sucrose + 0.6 % HPβCD 103 ± 47 
MabR1 + 5 % Sucrose + 0.004 % PS80 22 ± 4 
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II.3.6.3 SIZE-EXCLUSION CHROMATOGRAPHY 
As already observed in the other studies, no significant changes in relative protein amounts 
and no major changes in total AUC were detected after lyophilization and rehydration, as 
shown in Figure II-46 and Figure II-47.  
 
Figure II-46: Relative amount of high-molecular weight aggregates (HMWA), dimer, monomer and fragment for all formulations 
after preparation (t0) and after freeze-drying and rehydration (t2). 
 
Figure II-47: Total protein AUC for all formulations after preparation (t0) and after freeze-drying and rehydration (t2). 
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II.3.6.4 PHYSICO-CHEMICAL CHARACTERIZATION OF LYOPHILIZATES 
Residual moisture for freeze-dried MabR1 with 5 % Sucrose was between 1.0 and 1.25 % and 
specific surface area was between 0.4 and 0.5 m²/g, as shown in Table II-14. Glass transition 
temperatures were approximately 60 °C. Although these values were quite similar to those for 
the formulations with 1 % sucrose (see section II.3.4), it should be stated that specific surface 
area is mass normalized. Due to the higher amount of solids in the 5 % Sucrose formulations, 
the absolute surface area is increased in those formulations compared to the 1 % Sucrose 
based formulations.  
Table II-14: Residual moisture, glass transition temperatures (Tg) and specific surface area (SSA) for all formulations after 
lyophilization. 
 Residual moisture [% w/w] BET SSA [m²/g] Tg [°C] 
MabR1 + 5 % Sucrose 1.22 ± 0.01 0.44 ± 0.08 64.0 
MabR1 + 5 % Sucrose  
+ 0.35 % HPβCD 1.12 ± 0.06 0.42 ± 0.02 58.2 
MabR1 + 5 % Sucrose  
+ 0.6 % HPβCD 1.04 ± 0.04 0.415 - 
MabR1 + 5 % Sucrose 
+ 0.004 % PS80 1.16 ± 0.15 0.50 ± 0.01 63.2 
 
II.3.6.5 SUMMARY AND DISCUSSION 
By increasing the amount of sucrose to 5 % w/v, an interesting observation could be made. 
While the formulation containing polysorbate was the best formulation with regard to subvisible 
particles after freeze-drying, the results for the HPβCD formulations were somewhat 
unexpected with similar amounts of subvisible particles than the control formulation containing 
5 % sucrose. However, it is very difficult to distinguish between proteinacious and HPβCD 
particles, which would have been very helpful in this study because a significant amount of 
placebo particles of HPβCD was observed in the formulations without MabR1. Although 
controlled nucleation was able to significantly reduce the specific surface area of the freeze-
dried formulations compared to conventional freeze-drying, the absolute surface areas 
become higher by increasing the mass of solutes. Hence, compared to the studies with 
controlled nucleation from section II.3.4, the total surface area for the formulations in this study 
is approximately 2.5-fold higher. As observed in the previous chapters, HPβCD is able to 
stabilize the model antibody if the surface area is very small as with collapse freeze-drying. 
Generally, the increase in sucrose concentration from 1 % to 5 % was beneficial for MabR1 
stability. After ice nucleation, freeze-concentration takes place and the protein is diluted in an 
amorphous matrix formed by sucrose. By increasing the amount of amorphous stabilizer, the 
protein gets more diluted and aggregation is therefore hindered. It has been found that 0.3 M, 
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which equals approximately 10 % (w/v) for disaccharides, is the minimum needed 
concentration [4]. For LDH, it has been shown that increasing concentrations of sucrose can 
increase recovery of the enzyme and best recovery was obtained with a sucrose concentration 
as high as 34 % [62]. More examples are summarized in the review by Wang [1]. While these 
results may not be true for any protein, an increase in sucrose concentration was also 
beneficial in this study; however, the addition of PS80 could further decrease subvisible 
particles indicating that interfacial degradation of MabR1 still is a major degradation pathway. 
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II.3.7 COLLAPSE FREEZE-DRYING OF 5 % SUCROSE 
After the controlled nucleation experiment with the formulations containing 5 % sucrose in 
section II.3.6, the effect of the increased concentration of the disaccharide was already visible 
with regard to subvisible particles and a positive impact of PS80 was observed. Placebo 
particles formed by HPβCD dominated the results for the controlled nucleation study. Thus, a 
collapse freeze-drying run is expected to eliminate placebo particle formation and the effect of 
HPβCD is expected to be more reliably observed.  
II.3.7.1 LYOPHILIZATION PROCESS 
The collapse freeze-drying process was carried out at a pressure of 2.53 mbar (pirani sensor 
controlled) and product temperatures were approximately -13 °C for investigated formulations 
at a shelf temperature of 45 °C.  
 
Figure II-48: Lyophilization process for collapse freeze-dried MabR1 with 5% Sucrose. 
II.3.7.2 PROTEIN STABILITY – SUBVISIBLE PARTICLES AND TURBIDITY 
After collapse freeze-drying of formulations of MabR1 with 5 % Sucrose, a similar picture was 
obtained as with the formulations containing 1 % Sucrose, as described in section II.3.3. All 
formulations profited from the collapse freeze-drying procedure with regard to total subvisible 
particle formation, however, formulations containing HPβCD and PS80 contained significantly 
less particles than the formulations without surfactant, as displayed in Figure II-49. Turbidity 
values were almost the same for all formulations. Furthermore, as expected, collapse freeze-
drying eliminated particle formation also in placebo samples. Subvisible particles > 10 µm were 
less than 55 per ml for all formulations as shown in Table II-15. 
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Figure II-49: Subvisible particles and turbidity after rehydration for collapse freeze-dried MabR1. The light grey bars show 
particles of formulations without protein. 
 
Table II-15: Subvisible particles > 10 µm per ml for collapse freeze-dried MabR1. 
Formulation Subvisible particles > 10 µm per ml 
MabR1 + 5 % Sucrose 23 ± 15 
MabR1 + 5 % Sucrose + 0.35 % HPβCD 52 ± 57 
MabR1 + 5 % Sucrose + 0.6 % HPβCD 10 ± 8 
MabR1 + 5 % Sucrose + 0.004 % PS80 28 ± 27 
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II.3.7.3 SIZE-EXCLUSION CHROMATOGRAPHY 
No changes in relative amounts of protein species could be observed, as shown in Figure II-50 
and also, no change in total protein AUC was detected, as displayed in Figure II-51. 
 
Figure II-50: Relative amount of protein species of MabR1 after preparation (t0) and collapse-freeze-drying and rehydration (t2).  
 
 
Figure II-51: Total protein AUC for collapse freeze-dried MabR1 after preparation (t0) and freeze-drying and rehydration (t2). 
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II.3.7.4 PHYSICO-CHEMICAL CHARACTERIZATION OF LYOPHILIZATES 
Freeze-drying above Tc in this case resulted in very low specific surface areas of approximately 
0.1 m²/g. This very low SSA resulted in residual moistures of around 2 % [w/w] and in glass 
transition temperatures of 50 °C to 55 °C, as displayed in Table II-16. 
Table II-16: Residual moisture, SSA and glass transition temperatures (Tg) for all formulations of collapse freeze-dried MabR1. 
 Residual moisture [% w/w] BET SSA [m²/g] Tg [°C] 
MabR1 + 5 % Sucrose 2.21 ± 0.16 0.09 51.3 ± 1.5 
MabR1 + 5 % Sucrose 
+ 0.35 % HPβCD 1.84 ± 0.02 - 54.8 ± 2.0 
MabR1 + 5 % Sucrose 
+ 0.6 % HPβCD 1.96 ± 0.37 0.093 54.8 ± 2.1 
MabR1 + 5% Sucrose 
+ 0.004 % PS80 2.10 ± 0.06 0.104 54.3 ± 2.3 
 
II.3.7.5 SUMMARY AND DISCUSSION 
In comparison to the samples which were freeze-dried using controlled ice-nucleation (see 
section II.3.6), the specific surface area was reduced to approximately one fifth by viscous flow 
of the freeze-dried cake. The reduction of SSA lead to fewer particles than in the previous 
chapter for all formulations investigated and the formulations containing HPβCD or PS80 
showed fewer particles than the formulation without surfactant. By employing collapse freeze-
drying to intentionally keep the surface area as low as possible, stable protein formulations 
with HPβCD could be obtained with similar subvisible particle counts as with polysorbate and 
both formulations are subjected to storage stability studies in the next chapter. 
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II.3.8 STORAGE STABILITY OF COLLAPSE FREEZE-DRIED MABR1 FORMULATED 
WITH 5 % SUCROSE 
After the promising and successful collapse freeze-drying run with the formulations containing 
MabR1 at 10 mg/ml, 5% Sucrose; two formulations containing 0.6 % HPβCD or 0.004 % 
polysorbate 80 were again collapse freeze-dried and stored at 40 °C, 25 °C and at 2-8 °C (KS).  
II.3.8.1 FREEZE-DRYING PROCESS 
In order to reduce residual moisture in comparison to the pre-test, the pressure during freeze-
drying was 1.03 mbar (pirani sensor controlled) in contrast to 2.53 mbar in the pre-test. This 
resulted in a product temperature of around -24 °C during steady-state sublimation. The 
thermocouple was placed in a 5 % Sucrose shielding vial.  
II.3.8.2 PROTEIN STABILITY– SUBVISIBLE PARTICLES AND TURBIDITY 
Collapse freeze-drying of both formulations of MabR1 based on 5 % Sucrose showed 
unchanged turbidity values, as shown in Figure II-52, acceptable particle levels > 1 µm and 10 
µm, as displayed in Figure II-53 and Figure II-54 for all storage temperatures. The formulation 
containing 0.004 % PS80 showed slightly higher particle levels for both size classes than the 
formulation with 0.6 % HPβCD. 
 
Figure II-52: Turbidity of both formulations stored at 40 °C, 25 °C and 2-8 °C (KS) versus storage time. 
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Figure II-53: Particles > 1 µm of both formulations stored at 40 °C, 25 °C and 2-8 °C (KS) versus storage time. 
 
Figure II-54: Particles > 10 µm of both formulations stored at 40 °C, 25 °C and 2-8 °C (KS) versus storage time. 
II.3.8.3 SIZE-EXCLUSION CHROMATOGRAPHY AND AF4 
No change in monomer and dimer content was observed with SE-HPLC and these findings 
were confirmed by AF4. However, higher standard deviations were observed with AF4. 
Furthermore, relative amounts of monomer and dimer species are slightly lower with AF4 than 
SE-HPLC, because a larger fraction of high-molecular-weight aggregates was observed with 
MabR1 after end of cross-flow, as shown in a sample chromatogram in Figure II-59. 
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Figure II-55: Relative monomer content of MabR1 as determined with SE-HPLC for both formulations stored at three different 
temperatures. 
 
Figure II-56: Relative monomer content of MabR1 as determined with AF4 for both formulations stored at three different 
temperatures. 
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Figure II-57: Relative dimer content of MabR1 as determined with SE-HPLC for both formulations stored at three different 
temperatures. 
 
Figure II-58: Relative dimer content of MabR1 as determined with AF4 for both formulations stored at three different 
temperatures. 
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Figure II-59: Sample chromatogram for MabR1 in AF4 separation. Fragment (a), Monomer (b) and dimer (c) are separated from 
high-molecular-weight aggregates (d), which are not eluting in SEC, because of their size of approximately ~ 50 nm.  
II.3.8.4 PHYSICO-CHEMICAL CHARACTERIZATION 
All lyophilizate cakes were macroscopically collapsed without visible solid “bubbles”, as 
depictured in Figure II-60. No changes in cake appearance were observed during storage and 
no browning was visible. Residual moistures were between 2.0 and 3.0 %, as shown in Figure 
II-61 and were slightly higher than in the freeze-drying process in section II.3.7. Interestingly, 
the reduction of the freeze-drying pressure from 2.56 mbar to 1.03 mbar with the 
accompanying product temperature drop lead to an increase in residual moisture. However, 
glass transition temperatures were acceptable with around 45 °C and both product quality 
attributes did not change significantly over storage time, as shown in Figure II-62.  Specific 
surface area was very low with SSAs of less than 0.1 m²/g, as shown in Figure II-63 and did 
not change over storage time. 
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Figure II-60: Pictures of lyophilized cakes; A: MabR1 formulated with 5 % Sucrose and 0.6 % HPβCD and stored for 76 days in 
the fridge at 2-8° B: MabR1 formulated with 5 % Sucrose and 0.004 % PS80 and stored for 76 days in the fridge at 2-8°C. 
 
Figure II-61: Residual moisture of lyophilized cakes for both formulations stored at three different temperatures. 
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Figure II-62: Glass transition temperatures of lyophilized cakes for both formulations stored at three different temperatures. 
 
Figure II-63: Specific surface area of lyophilized cakes for both formulations stored at three different temperatures. 
II.3.8.5 SUMMARY AND DISCUSSION 
In this study, successful storage stability of both formulations of MabR1 with 5 % sucrose and 
HPβCD or PS80 was obtained compared to the storage study with 1.0 % sucrose in section 
II.3.5. Increasing sucrose concentration to 5 % decreased the Tg to only 45 °C since fully 
amorphous systems follow the Gordon-Taylor equation which describes the resulting glass 
transition temperature of a blend of polymers [63]. Increasing the content of sucrose with a 
lower Tg compared to that of proteins hence results in a decrease of Tg of the blend, both during 
dehydration (usually stated as Tg’) as well as in the dried product. Consequently, with decrease 
of Tg’, also Tc is decreased and the amorphous matrix features a lower viscosity which allows 
for increased viscous flow during sublimation. Macroscopic collapse of higher-concentrated 
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sucrose formulations thus was more excessive than for the formulations containing 1 % 
sucrose and MabR1. Hence, lower specific surface areas, higher residual moistures and lower 
glass transition temperatures of samples based on 5 % Sucrose compared to 1 % Sucrose 
were obtained. While it is known that Tg-TStorage is not a good predictor of storage stability [3], 
storage of lyophilizates above its Tg results in increased mobility and possible faster 
degradation of proteins [64]. Hence, maximum storage temperature of the lyophilizates 
containing 5 % sucrose was 40 °C. Although Tg-TStorage was only ~ 5 °C for the samples stored 
at 40 °C, remarkable storage stability of MabR1 was observed even at this temperature and 
despite the relatively high residual moisture of the dried product no loss in monomer was 
detected. A possible explanation of this remarkable stability can be derived from the theory of 
glassy dynamics or molecular mobility in lyophilizates. Amorphous glasses are kinetically 
stable systems, featuring a high viscosity, which greatly slows reaction rates; however, they 
are not completely ceased [3]. Molecular mobility can be described by α- and β-relaxations 
which is mobility on a global scale, which is often coupled to viscosity and local, fast dynamics, 
respectively [65]. When amorphous glasses undergo aging, the enthalpy ∆H and the free 
volume, ∆V, that is the volume in which a molecule can move [65], are decreased [66, 67]. It 
is imaginable that, by the onset of collapse during sublimation phase, the glass is annealed 
and α-relaxations are slowed down, thus enhancing storage stability. Due to technical 
restrictions, neither α- nor β-relaxations could be measured in this study.   
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II.3.9 THE SITUATION AT THE INTERFACE - RESULTS FROM ESCA-STUDIES 
II.3.9.1 INTRODUCTION 
With ESCA, it is possible to study the interface of a lyophilized cake in the first 5 to 10 nm from 
the surface [68]. This allows quantification of protein surface coverage at the solid/gas interface 
by the nitrogen atom signal [30]. In addition, the contribution of N-C=O / C=O signals from 
peptide bonds to total carbon surface coverage is indicating protein presence at the interface. 
It is expected that the ice/liquid interface during the freezing step is kinetically stable after 
complete crystallization of water and the amorphous matrix is cooled below Tg’, which leads to 
a dramatic increase in viscosity of those systems [69]. If viscous flow of the amorphous solid 
is avoided during primary and secondary drying, data from the dried cake is transferrable also 
to the ice/liquid interface formed during freezing of the liquids. 
II.3.9.2 RESULTS 
Results from conventional freeze-drying show that the addition of PS80 decreases the amount 
of nitrogen surface coverage as well as peptide-bond surface coverage significantly, as shown 
in Table II-17. This is also true for the combination of Sucrose and PS80 but not for the 
combination of HPβCD and PS80. In general, the addition of HPβCD did not lead to such a 
decrease in nitrogen coverage as the addition of PS80 did and is in good agreement to other 
studies performed with proteins and surfactants for dried proteins [30, 70] and for liquid 
formulations of proteins [71]. Interestingly, also MβCD showed a significant decrease in 
nitrogen surface coverage. The MβCD derivative employed in this study had a significantly 
higher degree of substitution, thus, surface tension of water is lowered compared to HPβCD 
when employed in the same concentration [24].It may be concluded that the most surface 
active component is enriched at a surface [70]. 
A slightly different picture is observed with collapse freeze-drying when the amorphous matrix 
undergoes viscous flow. Also the formulations containing either 0.1 % or 0.6 % HPβCD to 
MabR1 with Sucrose lead to a significant reduction in nitrogen surface coverage, comparable 
to the combination of sucrose and polysorbate 80, as shown in Table II-18. However, this result 
is not representative for the ice/liquid interface established during the freezing step. For the 
spray-dried samples (see section II.3.12), both, HPβCD and PS80, decreased nitrogen surface 
coverage compared to the formulation with trehalose to a higher extent than conventional 
freeze-drying, as shown in Table II-19. During spray-drying, evaporation of water at the 
interface reaches a steady-state phase in the first phase (constant rate period [65]) and a crust 
of solids is formed when solubility of excipients is exceeded. During concentration increase 
due to evaporation of water, diffusion of smaller molecules like surfactants might occur and 
those molecules might then more easily accumulate to the interface than proteins. This 
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complex, highly dynamic situation then does not reflect the situation right after atomization, 
with a possible higher protein surface coverage.  
Table II-17: Results from ESCA for surface coverage of Carbon, Oxygen and Nitrogen. The percentage of the C=O signal 
relative to total carbon signal is also shown. All results are from conventional freeze-drying.  
Formulation 
Surface 
coverage 
Carbon [%] 
Percent of 
N-C=O or C=O 
of total Carbon 
[%] 
Surface 
coverage of 
Oxygen 
Surface 
coverage of 
Nitrogen 
MabR1 52.78 22.44 22.46 13.81 
MabR1 + 0.04 % PS80 73.17 9.58 21.42 3.70 
MabR1 + 1.0 % HPβCD 58.93 20.35 29.70 8.01 
MabR1 + 1.0 % Sucrose 
+ 1 % HPβCD 57.84 22.98 33.95 5.94 
MabR1 + 1.0 % Sucrose 54.67 21.05 32.78 8.29 
MabR1 + 1.0 % Sucrose  
+ 0.04 % PS80 70.72 7.58 24.41 3.49 
MabR1 + 1.0 % HPβCD  
+ 0.04 % PS80 61.66 16.66 27.48 7.49 
MabR1 + 1.0 % MβCD 59.09 16.57 33.15 3.30 
 
Table II-18: Results from ESCA for surface coverage of Carbon, Oxygen and Nitrogen. The percentage of the C=O signal 
relative to total carbon signal is also shown. All results are from collapse freeze-drying.  
Formulation 
Surface 
coverage 
Carbon [%] 
Percent of 
N-C=O or C=O 
of total Carbon 
[%] 
Surface 
coverage of 
Oxygen 
Surface 
coverage of 
Nitrogen 
MabR1 + 1.0 % Sucrose 60.30 19.52 25.72 9.98 
MabR1 + 1.0 % Sucrose 
+ 0.1 % HPβCD 57.62 16.15 33.52 4.74 
MabR1 + 1.0 % Sucrose 
+ 0.60 % HPβCD 59.18 13.66 33.60 2.65 
MabR1 + 1.0 % Sucrose 
+ 0.004 % PS80 66.02 7.64 25.55 3.72 
MabR1 + 1.0 % HPβCD 59.35 15.30 32.51 4.58 
MabR1 + 1.0 % HPβCD  
+ 0.004 % PS80 59.46 12.92 32.04 3.63 
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Table II-19: Results from ESCA for surface coverage of Carbon, Oxygen and Nitrogen. The percentage of the C=O signal 
relative to total carbon signal is also shown. All results are from spray-drying. PS80 = polysorbate 80 
Formulation 
Surface 
coverage 
Carbon [%] 
Percent of 
N-C=O or 
C=O of total 
Carbon[%] 
Surface 
coverage of 
Oxygen 
Surface 
coverage of 
Nitrogen 
MabR1 + 5.0 % Trehalose 61.10 18.68 30.81 6.91 
MabR1 + 5.0 % Trehalose  
+ 0.35 % HPβCD 58.54 20.65 39.23 1.68 
MabR1 + 5.0 % Trehalose  
+ 0.60 % HPβCD 57.81 18.73 39.76 1.79 
MabR1 + 5.0 % Trehalose  
+ 0.04 % PS80 69.88 11.30 29.30 1.59 
 
II.3.9.3 SUMMARY AND DISCUSSION 
In contrast to PS80, HPβCD seems not to be able to displace the protein from the interface 
but a co-existence of the cyclodextrin derivative and MabR1 is suggested by the data set. Such 
a behaviour was also observed for the liquid/air interface for HPβCD and an IgG antibody [71]. 
The authors of this study state that polysorbate occupies a generated interface and displaces 
proteins from that interface; this is also true, if a protein monolayer was already present at this 
interface. In contrast, HPβCD was present at the interface together with the IgG studied when 
a solution of both was studied and an IgG, already present at a surface, could not be displaced 
by the addition of HPβCD. The potency to occupy a given interface possibly correlates with 
the degree of reduction of the surface tension of water and this reduction is far lower for HPβCD 
than for polysorbate. In addition, polysorbate can faster occupy an interface compared to 
HPβCD. The stabilization mechanism of HPβCD hence must be different than those provided 
by non-ionic surfactants. Interestingly, as can be derived from our results, it may be speculated 
that during the viscous flow of the amorphous matrix during collapse freeze-drying, the nitrogen 
content at the interface is slightly lowered. This observation, together with the very low surface 
area obtained in these processes, may both contribute to the overall good stability observed 
for these samples. 
 
.  
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II.3.10 STORAGE STABILITY OF h-GH 
After the successful stabilization of MabR1, it was tested, if the formulation of 5 % Sucrose and 
0.6 % HPβCD as well as the collapse freeze-drying process could be transferred to another 
protein, human growth hormone (hGH). hGH is a model protein, which is sensitive towards 
interfaces and hence a good model to study the impact of surfactants on protein degradation. 
Although a lot of marketed formulations are lyophilizates, also liquid formulations of hGH are 
available. hGH was formulated at 1.0 mg/ml in a sodium phosphate buffer, pH = 7.00 and in a 
first pre-test, hGH was collapse freeze-dried with 5% Sucrose and 0, 0.35 or 0.6 % HPβCD or 
0.004 % PS80. Subsequently, formulations with 0.6 % HPβCD and 0.004 % PS80 were stored 
at 40 °C, 25 °C and at 2-8 °C (KS). Storage stability of the protein was investigated for 118 
days. 
II.3.10.1 FREEZE-DRYING PROCESS 
The collapse freeze-drying process was carried out at the FTS Lyostar 3 at a pressure of 
1 mbar (capacitance manometer controlled). Steady-state product temperature, as determined 
with thermocouples placed in 5 % Sucrose shielding vials was approximately  
-17 °C.  
II.3.10.2 PROTEIN STABILITY – SUBVISIBLE PARTICLES AND TURBIDITY 
Figure II-64 shows the results from light obscuration and turbidity for hGH samples and 
corresponding placebo formulations. The addition of 0.35 % and 0.60 % HPβCD as well as the 
addition of PS80 significantly reduced subvisible particle formation and turbidity of hGH 
compared to the formulation without surfactant. The formulation with 0.6 % HPβCD showed 
lowest turbidity values and subvisible particles. In addition, the combinations of Sucrose with 
0.6 % HPβCD or PS80 both also showed the lowest numbers of subvisible particles > 10 µm, 
as shown in Table II-20. 
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Figure II-64: Subvisible particles > 1 µm and turbidity for hGH formulations and subvisible particles for corresponding 
formulations without protein (Placebo, dark grey bars). 
Table II-20: Subvisible particles > 10 µm per ml for all formulations after freeze-drying and rehydration.  
Formulation Subvisible particles  
> 10 µm 
hGH 5 % Sucrose  1829 ± 603 
hGH 5 % Sucrose + 0.35 % HPβCD 175 ± 7   
hGH 5 % Sucrose + 0.60 % HPβCD 88 ± 28 
hGH 5 % Sucrose + 0.004 % PS80 63 ± 13 
 
II.3.10.3 PROTEIN STABILITY – SIZE-EXCLUSION CHROMATOGRAPHY 
A slight increase in dimer formation was visible for all formulations except the formulation 
containing 5 % Sucrose and 0.6 % HPβCD. The formulation without surfactant showed the 
highest increase in dimer content after freeze-drying and rehydration, as shown in Figure II-65.  
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Figure II-65: Relative amount of protein species as determined with SE-HPLC for all formulations after preparation (t0) and 
collapse freeze-drying and rehydration (t2).  
II.3.10.4 PHYSICO-CHEMICAL CHARACTERIZATION OF LYOPHILIZATES 
The formulation containing only 5 % sucrose and hGH showed the lowest specific surface area 
and highest residual moisture, as shown in Table II-21. In addition, as shown in Figure II-66, 
this formulation also appeared most collapsed whereas the other formulations showed some 
solid bubble formation, slightly higher SSAs and lower residual moistures. Reconstitution times 
were 30 seconds followed by 90 seconds of visible schlieren formation.  
Table II-21: Residual moisture and SSA for all dried formulations.  
Formulation Residual moisture  [% w/w] (n=2) SSA [m²/g] 
hGH 5 % Sucrose  2.43 ± 0.48 0.06 
hGH 5 % Sucrose + 0.35 % HPβCD 1.19 ± 0.16 0.17 
hGH 5 % Sucrose + 0.60 % HPβCD 1.23 ± 0.05 0.14 
hGH  5% Sucrose + 0.004 % PS80 1.22 ± 0.21 0.14 
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Figure II-66: Macroscopic appearance of lyophilizate cakes. hGH + 5 % Sucrose (A); hGH + 5 % Sucrose + 0.35 % HPβCD (B); 
hGH + 5 % Sucrose + 0.60 % HPβCD (C), hGH + 5 % Sucrose + 0.004 % PS80 (D). 
 
II.3.10.5 STORAGE STABILITY OF HGH – SUBVISIBLE PARTICLES AND TURBIDITY 
Results from the pre-test could very well be reproduced with the samples subjected for storage 
stability and turbidity as well as particles > 1 µm and > 10 µm did not change significantly over 
the storage period, as shown in Figure II-67, Figure II-68 and Figure II-69. The formulation with 
0.6 % HPβCD showed slightly lower turbidity values but comparable subvisible particle levels 
to the formulation containing 0.004 % PS80. 
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Figure II-67: Turbidity for stored formulations of hGH (5 % Sucrose + 0.6 % HPβCD or 0.004 % PS80) at three different 
temperatures, 40 °C, 25 °C and 2-8 °C (KS) over storage time.  
 
Figure II-68: Subvisible particles > 1 µm for both formulations of hGH stored at 40 °C, 25 °C and 2-8 °C (KS). 
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Figure II-69: Subvisible particles > 10 µm for both formulations of hGH stored at 40 °C, 25 °C and 2-8 °C (KS). 
II.3.10.6 STORAGE STABILITY OF HGH – SIZE-EXCLUSION CHROMATOGRAPHY AND AF4 
During storage period, no changes were observable in monomer and dimer content at all 
temperatures, as displayed in Figure II-70 and Figure II-71. The formulation with polysorbate 
80 showed a little higher dimer content than the formulation with 0.6 % HPβCD. This was also 
confirmed by AF4, for samples stored for 118 days. The formulation with HPβCD showed 
slightly higher relative monomer contents and less dimer content than the formulation 
containing polysorbate 80, as shown in Figure II-72. 
 
Figure II-70: Relative monomer content of hGH as determined by SE-HPLC for all storage temperatures of both formulations.  
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Figure II-71: Relative dimer content of hGH as determined by SE-HPLC for all storage temperatures of both formulations. 
 
Figure II-72: Results from AF4 for samples of collapse freeze-dried hGH with 0.6 % HPβCD (left) and 0.004 % PS80 (right) 
stored at three different temperatures for 118 days. 
II.3.10.7 PHYSICO-CHEMICAL INVESTIGATION OF FREEZE-DRIED LYOPHILIZATES 
Residual moistures were in the range of 1.0 – 1.5 % during the storage study (Figure II-73) 
and glass transition temperatures were between 60 °C and 70 °C, as shown in Figure II-74. 
Furthermore, SSA did not change during the storage period (Figure II-75) and reconstitution 
times were 30 seconds followed by some schlieren for approximately 90 seconds and did not 
change over observed storage time. 
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Figure II-73: Residual moisture of both formulations of hGH stored at three different temperatures.  
 
Figure II-74: Glass transition temperatures (Tg) for both formulations of hGH stored at three temperatures.  
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Figure II-75: SSA for both formulations of hGH stored at three temperatures. 
II.3.10.8 SUMMARY AND DISCUSSION 
While the aforementioned impact of the freeze-drying process and specific surface area are in 
general applicable to any protein, we intended to show applicability of the combination of  
formulation (with HPβCD) and the collapse freeze-drying process on hGH. hGH is structurally 
completely different from antibodies and features a molecular weight of approximately 22 kDa. 
Further, it is known that hGH is exposing aromatic amino acids and is prone to aggregation 
[72]. It has been shown that HPβCD is interacting with hGH by possible complexation of amino 
acid residues and prevents hGH from aggregating [43, 72]. Further, surfactants, like 
polysorbates, prevent hGH from aggregating during agitation by directly binding to the protein 
in molar ratios of > 4:1 [49] and help refolding of molten hGH intermediates [73]. hGH has been 
shown to be stabilized by HPβCD in liquid formulations in very low concentrations (2.5 mM) 
during agitation and freeze-thaw studies [50], and in this study, storage stable formulations of 
freeze-dried hGH could be obtained and the formulation containing 0.6 % HPβCD was superior 
to the formulation which contained polysorbate and an increase in dimer was observed for the 
polysorbate-containing formulation directly after freeze-drying and remained unchanged 
during the storage period. These findings suggest that the stabilizing effects found for liquid 
formulations of hGH and HPβCD can also be transferred to freeze-drying. 
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II.3.11 STORAGE STABILITY OF GCSF 
After the positive results with MabR1 and hGH, another interfacial-sensitive protein, GCSF 
was investigated. Similar to hGH, GCSF is storage stable in liquid formulations and there is no 
need to freeze-dry this protein; however, due to its sensitivity towards interfaces, it is a good 
model protein to study effects of surfactants on protein stability. GCSF was dialyzed into a 10 
mM citrate buffer pH = 4.00 and 5 % Sucrose, and either 0.60 % HPβCD or 0.004 % PS80 
were added. Serving as a negative control, 5 % Sucrose and GCSF was also freeze-dried but 
not subjected to storage stability. 
II.3.11.1 LYOPHILIZATION PROCESS 
Collapse lyophilization was carried out at the FTS Lyostar III with a pressure of 1 mbar. The 
steady-state product temperature as shown in Figure II-76 was approximately -17 °C. 
 
Figure II-76: Lyophilization process for GCSF. Thermocouples were placed in each formulation of GCSF.  
 
II.3.11.2 PROTEIN STABILITY– OVERVIEW AFTER FREEZE-DRYING 
After freeze-drying and rehydration, a positive influence of both, HPβCD and PS80 compared 
to the formulation without surfactant could be observed. PS80 was superior to HPβCD with a 
lower turbidity and less subvisible particles > 1 µm, as illustrated in Figure II-77.  
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Figure II-77: Subvisible particles and turbidity for all GCSF formulations after freeze-drying and rehydration.  
II.3.11.3 PROTEIN STABILITY– STORAGE STABILITY 
During storage, no major changes in turbidity or subvisible particles > 1 µm and > 10 µm were 
observable, as shown in Figure II-78, Figure II-79 and Figure II-80. However, a small trend 
towards lower total particle numbers is observed and also a trend towards lower turbidity of 
GCSF formulated with 0.6 % HPβCD. With both formulations, visible particles were observed 
after 48 and 106 days. The study of GCSF hence was cancelled after 106 days. 
 
Figure II-78: Turbidity for both formulations stored at three temperatures (40 °C, 25 °C and 2-8 °C (KS)). 
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Figure II-79: Subvisible particles > 1 µm for both formulations stored at three temperatures. At time points of 48 and 106 days, 
visible particles appeared in both formulations. 
 
 
Figure II-80: Subvisible particles > 10 µm for both formulations stored at three temperatures. 
II.3.11.4 SIZE-EXCLUSION CHROMATOGRAPHY 
After freeze-drying and rehydration, a decrease of monomer content accompanied by an 
increase of dimer fraction for the formulation of GCSF containing HPβCD was observed, as 
shown in Figure II-81 and Figure II-82. However, after 104 days, an increase in dimer and a 
decrease in monomer content could also be observed for the formulation of GCSF formulated 
with sucrose and PS80 which was stored at 40 °C. A trend to lower protein AUC with high 
standard deviations could be observed in Figure II-83. 
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Figure II-81: Relative monomer content as determined by SE-HPLC for both formulations stored at three temperatures. 
 
Figure II-82: Relative dimer content as determined by SE-HPLC for both formulations stored at three temperatures. 
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Figure II-83: Total protein recovery (AUC) as determined with SE-HPLC for GCSF stored at three temperatures. 
 
II.3.11.5 PHYSICO-CHEMICAL INVESTIGATION OF LYOPHILIZATE CAKES 
All lyophilizate cakes were visibly collapsed, as shown in Figure II-84. However, the formulation 
which contains HPβCD showed a more solid-bubble-like appearance whereas the formulations 
containing mainly 5 % sucrose were collapsed and shrunken. This difference was also 
observable with a lower SSA as depictured in Figure II-87 of the formulation which contains 
PS80 compared to HPβCD with approximately 0.05 m²/g and 0.15 m²/g, respectively. The 
SSAs did not change significantly over storage time. This difference in SSA also translated to 
slightly higher residual moistures of the PS80 formulation and both formulations showed a 
slight increase in residual moisture over storage time (see Figure II-85). Glass transition 
temperatures remained over 50 °C for 48 days with a trend to lower Tgs, especially for the 
samples stored at 40 °C, as depictured in Figure II-86.  
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Figure II-84: Macroscopic appearance of collapse freeze-dried lyophilizate cakes. GCSF + 5 % Sucrose (A);  
GCSF + 5 % Sucrose + 0.6 % HPβCD (B); GCSF + 5 % Sucrose + 0.004 % PS80 (C). 
 
 
Figure II-85: Residual moisture for stored GCSF formulations.  
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Figure II-86: Glass transition temperatures for stored GCSF formulations. 
 
Figure II-87: Specific surface area for stored GCSF formulations.  
II.3.11.6 SUMMARY AND DISCUSSION 
In contrast to MabR1 and hGH, it was difficult to apply collapse freeze-drying with polysorbate 
80 and HPβCD to GCSF. Both surfactants showed a positive impact on subvisible particle 
formation compared to the formulation containing sucrose only. Polysorbate 80 was superior 
to HPβCD with less subvisible particles formed after freeze-drying and rehydration. However, 
during accelerated storage of those samples, visible particles appeared in all formulations, 
which suggest a general instability of GCSF in the dried state and hence the study was 
cancelled. In a study using FTIR spectroscopy to detect drying-induced variations in the 
secondary structure of several proteins including GCSF, it was found that especially G-CSF 
showed relatively high correlation values (r) between protein in buffer solution and in the dried 
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state, what is usually associated with superior stability of the protein. However, particulate 
matter was not a focus of this study and as shown in the previous chapter II.3.5, FTIR is not 
always able to detect small amounts of degraded protein.  
 
  
Chapter II: Cyclodextrins in freeze-drying and spray-drying of proteins 
110 
II.3.12 HPβCD EMPLOYED IN SPRAY DRYING OF MABR1 
II.3.12.1 INTRODUCTION 
After successful freeze-drying of MabR1 with HPβCD and polysorbate and low specific surface 
areas, spray-drying as a control experiment was performed to elucidate the impact of higher 
SSAs. In addition to analysis after spray-drying and rehydration, analysis was also performed 
after atomization without drying. Sucrose was replaced with trehalose in the spray-drying study 
because of its higher glass transition temperatures. Sucrose is very difficult to spray dry and 
yields are usually quite low. Furthermore, due to the expected high interfacial area generated 
by atomization of the liquid, the amount of polysorbate 80 was increased to 0.04 %. Table II-22 
shows the formulations investigated in this study. In addition, for each formulation, a placebo 
formulation was prepared. 
Table II-22: Study design for spray drying of MabR1. 
Formulation MabR1 [mg/ml] Trehalose [%] HPβCD [%] PS 80 [%] 
Storage 
stability study 
1 10 5 - - - 
2 10 5 0.35 - - 
3 10 5 0.6 - 40 °C, 25 °C,  2-8 °C 
4 10 5 - 0.04 40 °C, 25 °C,  2-8 °C 
 
II.3.12.2 SPRAY DRYING PROCESS AND YIELD 
Table II-23 shows the yields of spray-dried MabR1 and placebo formulations. Acceptable 
yields for MabR1 were obtained with values of > 80 % for the formulations containing 
Trehalose and HPβCD. However, yields for the polysorbate-containing formulations were 
slightly lower because unlike the other formulations, the formulation containing polysorbate 
stuck to the cyclone to some extent and had to be removed by continuous agitation during the 
spray drying process; separation of powder from the gas stream was probably less effective 
than with the formulations without PS80 with no product remaining in the cyclone.  
Chapter II: Cyclodextrins in freeze-drying and spray-drying of proteins 
111 
Table II-23: Product yield of spray dried placebo and MabR1 formulations. 
Formulation Yield Placebo [%] Yield MabR1 [%] 
5 % Trehalose 40.1 80.4 
5 % Trehalose + 0.35 % 
HPβCD 77.1 81.7 
5 % Trehalose + 0.60 % 
HPβCD 77.7 83.7 
5 % Trehalose + 0.04 % PS80 65.8 68.2 
 
II.3.12.3 PROTEIN STABILITY– SUBVISIBLE PARTICLES AND TURBIDITY 
Immediately after spray-drying and rehydration, only the formulation of MabR1 which contains 
5 % Trehalose and 0.04 % PS80 showed subvisible particle numbers below 50,000 per ml and 
turbidity values of less than 10 FNU as shown in Figure II-88. With increasing HPβCD 
concentration up to 0.6 %, a decrease in subvisible particles and turbidity after rehydration was 
observed compared to the control formulation without surfactant. PS80 also showed better 
performance in stabilization of the antibody after atomization only. Subvisible particles in the 
size class > 10 µm did not significantly differ for the different formulations, as depicted in Figure 
II-89. Subvisible particles and turbidity in placebo formulations also increased from atomization 
to spray-drying and rehydration, as shown in Figure II-90. Even the placebo formulations had 
subvisible particle concentrations of around 20,000 after rehydration.  
 
Figure II-88: Turbidity and subvisible particles for atomized and spray-dried and rehydrated formulations of MabR1. 
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Figure II-89: Subvisible particles > 10 µm for atomized and spray-dried and rehydrated MabR1. 
 
Figure II-90: Turbidity and subvisible particles for atomized and spray-dried and rehydrated placebo formulations without protein. 
II.3.12.4 SIZE-EXCLUSION CHROMATOGRAPHY 
After spray-drying and rehydration, the relative amount of high-molecular weight aggregates 
as well as dimer was increased in the formulation of MabR1 which contains  
0.04 % polysorbate 80. This was not observed with the other formulations containing no PS80, 
as shown in Figure II-91 and was also not observed in the previous freeze-drying chapters. 
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Figure II-91: Relative amount of protein species after spray-drying and rehydration of all formulations of MabR1. 
II.3.12.5 PROTEIN STABILITY– STORAGE STABILITY 
When stored for 62 days, a slight decrease in turbidity was observed for the formulation 
containing 0.6 % HPβCD whereas a tendency to higher values was observed for the 
formulations which contain 0.04 % PS80 (see Figure II-92), independent on storage 
temperature for both formulations. Subvisible particles > 1 µm remained almost unchanged in 
all formulations, which is shown in Figure II-93. The polysorbate containing formulations, which 
showed a higher amount of dimer immediately after spray-drying, showed a temperature-
dependent increase in dimer and a decrease in monomer content as determined with SE-
HPLC; this was not observed for HPβCD-containing formulations, as shown in Figure II-94 and 
Figure II-95. Also in AF4, these trends were only partly visible with a slight decrease of 
monomer content of PS80-formulations as illustrated in Figure II-96. Large standard deviations 
for relative monomer and dimer amounts (see Figure II-97) impedes evaluation of these 
samples.  
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Figure II-92: Turbidity for all formulations of MabR1 with 5 % Trehalose and  0.04 % PS80 or 0.6 % HPβCD stored at three 
different temperatures.  
 
Figure II-93: Subvisible particles > 1 µm for all formulations of MabR1 stored at three different temperatures.  
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Figure II-94: Relative monomer content as determined with SE-HPLC for all formulations of MabR1 stored at three different 
temperatures. 
 
Figure II-95: Relative dimer content as determined with SE-HPLC for all formulations of MabR1 stored at three different 
temperatures. 
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Figure II-96: Relative monomer content as determined with AF4 for all formulations of MabR1 stored at three different 
temperatures. 
 
Figure II-97: Relative dimer content as determined with AF4 for all formulations of MabR1 stored at three different temperatures. 
II.3.12.6 PHYSICO-CHEMICAL INVESTIGATION OF SPRAY-DRIED SAMPLES - STORAGE 
STABILITY 
The formulation of MabR1 with HPβCD exhibited higher residual moistures than the 
formulation with PS80 and the differences in residual moistures were also visible in glass 
transition temperatures, which were consequently higher in PS80 formulations, as shown in 
Figure II-98 and Figure II-99 while both formulations had approximately the same specific 
surface areas, as depicted in Figure II-100. Interestingly, the HPβCD formulations showed a 
small temperature-dependent decrease in residual moisture and an increase in Tg over storage 
period. These differences may also be attributed to inhomogeneities in the powder. 
Reconstitution times varied greatly between formulations from 2 to more than 11 minutes. 
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Especially PS80 containing formulations reconstituted faster (2-3 minutes) because the spray 
dried powder immersed in the added liquid whereas the powder of the HPβCD-containing 
formulation was floating on top of the liquid, thus the wetted area was relatively small and 
dissolution is slow.  
 
Figure II-98: Residual moisture of all formulations of MabR1 stored at three temperatures. 
 
Figure II-99: Glass transition temperatures (Tg) of all formulations stored at three different temperatures.  
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Figure II-100: Specific surface area for all formulations of MabR1 stored at three different temperatures. 
II.3.12.7 SUMMARY AND DISCUSSION 
Spray-drying of MabR1 was performed as a control experiment to the freeze-drying processes. 
In the previous chapters, it was found that a low SSA was general beneficial for MabR1 stability 
with regard to subvisible particles. As spray-drying usually produces higher values of surface 
areas due to atomization of the liquid prior to drying [65], HPβCD was expected to be inferior 
to polysorbate in this study. This hypothesis was confirmed by subvisible particle analysis after 
atomization as well as after rehydration of the dried powder. Atomization and subsequent 
drying of the liquid droplet is usually finished within less than a second. Fast diffusion to the 
produced air-water-interface thus is necessary for an excipient to enrich at this interface. It has 
been shown that polysorbate is more quickly decreasing surface tension and equilibrium is 
reached faster compared to HPβCD [71]. However, with the formulation containing polysorbate 
80, an increase in dimer content and high-molecular weight aggregates was observed in size-
exclusion chromatography. This was observed immediately after spray drying and became 
more pronounced during isothermal storage with a significant reduction in monomer content. 
This dual effects of polysorbate – stabilization at interfaces, but destabilization due to oxidation 
has already been reported for IL-2 mutein [74]. Oxidation of especially antibodies is not easy 
to detect without mass spectroscopy and we could not directly measure oxidized species of 
antibodies; however in this study, the temperature-dependent reduction of protein monomer 
may be attributed to oxidation of the antibody by polysorbate 80. Degradation of polysorbates 
has been extensively studied [75-78] and includes formation of peroxides and fatty-acid 
release by hydrolization [76]. It has been shown that polysorbates can oxidize proteins in 
liquids as well as in lyophilizates [74, 78]. It is suggested to use the minimum effective 
concentration of polysorbates to minimize degradation products [76] and also a concentration 
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dependency in protein degradation was observed [74]. In our studies, we chose a 
concentration of 0.004 % of PS80 which is only little above the CMC for freeze-drying but a 
10-fold higher concentration of 0.04 % for the spray drying experiments because surfaces 
areas generated by atomization were expected to be higher in spray-drying. This difference in 
concentrations may be the reason why we did not observe loss of monomer in freeze-drying 
experiments. In addition, spray drying is performed at high temperatures and in this study air 
was used as drying gas, which may have fostered degradation of polysorbates already during 
the drying process.  
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II.3.13 HPβCD AS BULKING AGENT IN FREEZE-DRYING 
II.3.13.1 INTRODUCTION 
A potential use of HPβCD, as presented in the introduction, is the ability to serve as a bulking 
agent, forming an amorphous glass and providing hydrogen bonds to stabilize proteins in the 
dried state. However, as will be shown in chapter II.3.14, HPβCD needs to be formulated with 
PS80 to attenuate subvisible placebo particles formed by HPβCD alone. HPβCD, since not 
used alone, could then be used as a replacement to the commonly employed disaccharides 
sucrose and trehalose. Benefits of HPβCD compared to the well-established, relatively cheap 
and efficiency-proven disaccharides would be the possibility to design more economic and 
faster freeze-drying processes due to the high glass transition temperatures of HPβCD (appr. 
-13 °C to -14 °C for the pure excipient). HPβCD was formulated at 1.0% (w/v) and polysorbate 
80 was added in a concentration of 0.004 %. Storage stability studies were performed with 10 
mg/ml MabR1, 1.0 mg/ml hGH and 1.0 mg/ml GCSF. Data from GCSF samples are not 
presented here because after storage for 48 days, visible particles appeared in all formulations 
with 1 % HPβCD, similar to the results obtained for sucrose based formulations. 
II.3.13.2 LYOPHILIZATION PROCESS CONSIDERATIONS 
Due to the relatively high Tg’ of pure HPβCD, even aggressive lyophilization of these 
lyophilizates did not lead to macroscopic collapse of the freeze-dried cake. For this reason, the 
process is called “aggressive freeze-drying”. As postulated, economic freeze-drying processes 
are possible with HPβCD as bulking agent.  
II.3.13.3 PROTEIN STABILITY IMMEDIATELY AFTER FREEZE-DRYING OF MABR1 
When polysorbate was added to lyophilized formulations of MabR1, subvisible particles and 
turbidity could be significantly reduced compared to formulations without PS80, as shown in 
Figure II-101. Furthermore, no changes in fragments or dimers could be observed with size 
exclusion chromatography for the aggressive freeze-drying run, as illustrated in Figure II-102, 
similar to sucrose-based formulations, as discussed earlier. Based on these results, samples 
were subjected to storage stability. 
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Figure II-101: Subvisible particles > 1 µm and turbidity for HPβCD-based formulations of MabR1. 
 
Figure II-102: Relative amount of protein species for HPβCD-based formulations, as determined with SE-HPLC. t0 = analysis 
after preparation; t1 = analysis after freeze-thawing; t2 = analysis after freeze-drying and rehydration. 
II.3.13.4 STORAGE STABILITY STUDY OF MABR1 
MabR1 was stored at 60 °C, 40 °C and 25 °C to compare results with the first study of MabR1 
stored at the same concentration with sucrose and PS80. Over storage time, a large number 
of subvisible particles formed, as shown in Figure II-104 and also turbidity increased, as 
illustrated in Figure II-103. This was most pronounced with the formulation which was stored 
at 60 °C and formulations based on HPβCD showed higher turbidities and subvisible particles, 
however, only turbidity can be considered to be linear in this range. The samples which were 
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stored at 40 °C and 25 °C showed less increase in subvisible particles with appr. 50,000 and 
35,000 particles > 1 µm per ml, respectively and were comparable to the sucrose reference 
formulation. Temperature-dependent degradation of MabR1 was further confirmed by size 
exclusion chromatography and AF4. Protein monomer content decreased and dimer content 
increased, as shown in Figure II-105 and Figure II-106 and HPβCD-containing formulations 
showed slightly faster degradation kinetics than sucrose based formulations. Interestingly, 
decrease in relative monomer content seemed to level off between the second-last and last 
analysis time point. The higher the temperature, the higher the reduction of monomer and 
increase in dimer content was. These results were basically also confirmed by AF4 
measurements, as shown in Figure II-107 and Figure II-108. The loss in monomer goes along 
with a reduction of protein recovery, especially for the samples stored at 60 °C, as shown in 
Figure II-109. Consequently, protein degradation was more exaggerated with HPβCD-based 
formulations compared to the collapse freeze-dried sucrose formulations.  
 
Figure II-103: Turbidity for MabR1 formulated with 1 % HPβCD and 0.004 % PS80 over storage time. Storage stability was 
performed at 60 °C, 40 °C and 25 °C. 
Chapter II: Cyclodextrins in freeze-drying and spray-drying of proteins 
123 
 
Figure II-104: Results from light obscuration for MabR1, formulated with 1 % HPβCD + 0.004 % PS80 or 1 % Sucrose and 
0.004 % PS80.  
 
Figure II-105: Relative monomer content as determined by SE-HPLC over storage time for MabR1 and 1 % HPβCD + 
0.004 % PS80 or 1 % Sucrose + 0.004 % PS80. 
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Figure II-106: Relative dimer content as determined by SE-HPLC over storage time for MabR1 and 1 % HPβCD +  
0.004 % PS80 or 1 % Sucrose + 0.004 % PS80. 
 
Figure II-107: Relative monomer content as determined by AF4 over storage time for MabR1 and 1 % HPβCD + 0.004 % PS80 
or 1% Sucrose + 0.004% PS80. 
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Figure II-108: Relative dimer content as determined by AF4 over storage time for MabR1 and 1 % HPβCD + 0.004 % PS80 or 1 
% Sucrose + 0.004 % PS80. 
 
Figure II-109: Protein recovery as determined with SE-HPLC for MabR1 stored at three different temperatures. 
II.3.13.5 PHYSICO-CHEMICAL INVESTIGATION ON 1 % HPβCD-BASED FORMULATIONS OF 
MABR1 
Reconstitution of all samples was very fast with less than 10 seconds required for complete 
dissolution. Residual moistures for samples increased over storage time with increasing 
temperatures, as shown in Figure II-110. Residual moisture uptake is favoured by the high 
specific surface area and low amount of solids. Hence, glass transition temperatures slightly 
decreased. The sample, which was stored at 60 °C was therefore stored at a temperature 
around its Tg, as shown in Figure II-111. However, specific surface areas for all samples were 
between ~1.5 m²/g and ~1.7 m²/g over storage time, and no visible collapse or browning was 
observed during storage, independent of storage temperature. Lyophilized cakes of HPβCD 
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seem to be quite brittle at a (very low) concentration of approximately 20 mg/ml solids and 
cakes showed some macroscopic damage with broken-off pieces, as shown in Figure II-112.  
 
Figure II-110: Residual moisture of lyophilized cakes of MabR1 stored at three different temperatures. 
 
Figure II-111: Glass transition temperatures of lyophilized cakes of MabR1 stored at three different temperatures. 
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Figure II-112: Macroscopic appearance of lyophilizate cakes based on 1 % HPβCD. 
 
II.3.13.6 STORAGE STABILITY OF HGH FORMULATED WITH 1% HPΒCD AND PS80 
Storage stability of 1 mg/ml hGH with 1.0 % HPβCD and 0.004 % PS80 was performed, and 
lyophilizates were stored at 60 °C, 40 °C and 25 °C. Turbidity and subvisible particles > 1 µm 
did not change significantly over observed storage time independent of storage temperature 
as shown in Figure II-113 and Figure II-114. However, hGH monomer content decreased when 
stored at 60 °C and dimer content increased while total protein AUC remained unchanged 
(Figure II-115, Figure II-116 and Figure II-117). The increase in dimer content for storage 
temperatures of 40 °C and 25 °C was only 0.1 %. These results were confirmed by AF4 with 
a temperature-dependent increase in dimer content of hGH after 118 days, as shown in Figure 
II-118.  
 
Figure II-113: Turbidity for hGH formulated with 1 % HPβCD and 0.004 % PS80. Storage stability was performed at 60 °C, 
40 °C and 25 °C. 
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Figure II-114: Subvisible particles > 1 µm for hGH formulated with 1 % HPβCD and 0.004 % PS80. Storage stability was 
performed at 60 °C, 40 °C and 25 °C. 
 
Figure II-115: Relative monomer content as determined by SE-HPLC of hGH stored at three different temperatures.  
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Figure II-116: Relative dimer content as determined by SE-HPLC of hGH stored at three different temperatures.  
 
Figure II-117: Total protein recovery as determined by SE-HPLC for hGH stored at three different temperatures. 
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Figure II-118: Relative monomer and dimer content as determined by AF4 of hGH + 1 % HPβCD + 0.004 % PS80 stored at 
three temperatures for 118 days. 
II.3.13.7 PHYSICO-CHEMICAL INVESTIGATION OF STORED HGH SAMPLES 
Residual moisture for stored samples increased over storage time, which was most 
pronounced for samples stored at 60 °C, as depictured in Figure II-119. Glass transition 
temperatures were quite high with temperatures of around 80 °C and did not change 
significantly over storage period (see Figure II-120). Reconstitution was very fast and complete 
dissolution was obtained within less than 10 seconds. 
 
Figure II-119: Residual moistures for stored samples of hGH over storage time. 
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Figure II-120: Glass transition temperatures for stored samples of hGH over storage time. 
 
II.3.13.8 SUMMARY AND DISCUSSION 
Different results for HPβCD as bulking agent in combination with 0.004 % PS80 were obtained. 
When HPβCD was used in a 1:1 mass ratio of excipient:MabR1, poor stability of the antibody 
was observed and HPβCD was inferior to sucrose. However, it is important to mention that 
formulations based on HPβCD did not collapse during the collapse freeze-drying conditions 
but an elegant cake structure was retained whereas sucrose based formulations collapsed 
during the freeze-drying process. It has been discussed that the high temperatures 
encountered during the aggressive freeze-drying process may anneal the amorphous glass 
and thus, increased long-term stability is possible (see discussion in section II.3.8.5). While 
this is true for both formulations, only the collapsed sucrose formulations can profit from the 
low SSA generated with a collapse freeze-drying process. Hence, comparison of both 
formulations is limited considering thermal history and SSA and the different residual moistures 
and Tgs. However, another hint that HPβCD is probably not a significant better lyoprotectant 
than sucrose can be found in the data from section II.3.5, where storage stability of MabR1 
was investigated formulated with sucrose and both excipients, HPβCD and PS80. HPβCD was 
added in substantial amounts (6 mg/ml) to sucrose, which was used in a concentration of only 
10 mg/ml. At these concentrations, increased storage stability of HPβCD-containing 
formulations should have been visible compared to the formulation with PS80, which only 
contains sucrose as lyoprotectant. This was not the case and degradation of the model 
antibody was equally fast with no clear advantage of the HPβCD formulation. For hGH 
however, at a excipient:protein ratio of 10:1, at least at storage temperatures of 40 °C and 
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25 °C, acceptable stabilization of the protein was observed. These findings indicate that there 
is a potential of HPβCD to act as bulking agent and stabilization of certain proteins can be 
obtained. From a toxicological aspect, higher concentrations of HPβCD can be employed and 
up to 3 g/day are tolerated in humans [79]. Economic advantages of HPβCD with its high glass 
transition temperatures, especially Tg’, enables more efficient freeze-drying cycles if product 
stability is comparable to commonly used excipients. Employment of HPβCD should therefore 
be considered, however, from our perspective, combination with polysorbates is necessary if 
subvisible particles are a major concern. 
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II.3.14 SUBVISIBLE PARTICLE FORMATION BY PLACEBO HPβCD 
II.3.14.1 INTRODUCTION 
Freeze-drying is the most important process for drying of temperature-sensitive active 
pharmaceutical ingredients, especially proteins. The process includes a freezing step followed 
by primary drying with removal of ice by sublimation. Unfrozen water is removed by diffusion 
and desorption in the secondary drying step and typical residual moisture levels of 1.0 % (m/m) 
are obtained. The freeze-drying process is considered gentle and activity-retaining, however, 
it comprises several stresses to proteins such as cold denaturation, presence of the ice-water 
interface, freeze-concentration with possible crystallization of excipients and removal of water 
and hydration shell [1]. Furthermore, upon reconstitution, a large liquid-air interface is formed 
which can also be detrimental for protein stability [80]. To counteract stresses from the freeze-
drying process, excipients are added to formulations of proteins. To protect proteins from 
interfacial denaturation and aggregation, surfactants like polysorbates currently are the gold 
standard. However, their tendency to create peroxides with potentially oxidation of proteins is 
receiving a lot of attention recently [76, 78, 81]. A possible alternative to polysorbates is 
HPβCD, which is also known to accumulate at the air-water interface [24]. However, we 
observed that after freeze-drying and rehydration of HPβCD-containing samples, subvisible 
particles were formed. Particles present in a formulation can originate from various sources, 
e.g. filters, packaging material or stoppers. However, in protein formulations, subvisible 
particles are often formed by aggregation of protein monomers and this is considered a serious 
product quality issue [82]. While quantification of subvisible particles in the range of > 1 µm is 
quite easy, the origin of those particles is difficult to determine. Furthermore, situation becomes 
increasingly difficult if subvisible particles can be formed not only by a protein present but also 
by excipients in this formulation.  The aim of this work was to study the formation of aggregates 
of HPβCD and to investigate in which process step these particles form. In addition, we wanted 
to find out, which formulation- and process parameters are influencing subvisible particle 
formation and how formation of those particles can be avoided. 
II.3.14.2 MATERIALS 
Sodium phosphate monobasic dihydrate and sodium phosphate dibasic dehydrate were 
obtained from Merck (Merck, Darmstadt, Germany). Potassium phosphate dibasic, 
polysorbate 80 and sucrose was obtained by Sigma Aldrich Chemicals (Sigma Aldrich, Munich, 
Germany). Hydroxypropyl-beta-cyclodextrin, (HPβCD) (Cavasol W7 HP Pharma, molar 
degree of substitution (mDS) 0.59 – 0.73) was obtained from Wacker (Wacker Chemie AG, 
Munich, Germany) and was the main employed cyclodextrin derivative in the study; HPβCD 
(Kleptose HP, Roquette, Frankfurt, Germany) with a different mDS of 0.87 was kindly provided 
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by Roquette. β-Cyclodextrin (β-CD) was used from Wacker (Cavamax W7 Pharma, Wacker 
Chemie AG, Munich, Germany). All chemicals were of analytical grade. 
II.3.14.3 PREPARATION OF FORMULATIONS (FOR PLACEBO FORMULATIONS ONLY) 
Formulations were prepared by mixing concentrated stock solutions of excipients and protein 
and final dilution with buffer. For Sucrose, Trehalose, Arginine phosphate and HPβCD, usually 
10 % (w/v) solutions were prepared. A 10 mM sodium/potassium phosphate buffer pH=7.2 was 
used to prepare 5.05 % Arginine phosphate, 5 % Sucrose and 5 % Trehalose in combination 
with 0.0 %, 0.1 % or 1.0 % HPβCD. In addition, a formulation with 1.0 % HPβCD was prepared. 
All solutions were filtered through 0.22 µm Celluloseacetate filters (VWR, Ismaning, Germany) 
which were pre-rinsed with at least 5 ml of water. Either 2.3 ml or 3 ml of each formulation was 
pipetted into DIN 6R or DIN 20R vials, respectively, semi-stoppered and transferred to the 
freeze-dryer.  
II.3.14.4 CONVENTIONAL FREEZE-DRYING PROCESS (FOR PLACEBO FORMULATIONS ONLY) 
For the placebo freeze-drying experiments only, the following freeze-drying process was used: 
Lyophilization of the samples in a conventional process was performed using a Martin Christ 
Epsilon 2-6D freeze-dryer (Martin Christ, Osterode am Harz, Germany) or an FTS Lyostar 2 
(SP Scientific, Stone Ridge, USA). The samples were cooled to -60 °C within with 0.3 °C 
minute (slow freezing, SF). In addition, a second set of samples was frozen with liquid nitrogen 
immersion on the lyophilizer tray (N2) and placed on the lyophilizer shelves at  
-60 °C. This temperature was held for 2 hours to ensure complete solidification of the samples. 
Subsequently, the pressure was reduced to 0.08 mbar and the temperature was raised to -
30 °C for primary drying with a heating rate of 0.5 °C per minute. These conditions were held 
for 45 hours. Secondary drying was performed at three temperatures, 0 °C for 5 hours, 30 °C 
for 3 h and 40 °C for 10 hours each at a pressure of 0.011 mbar. The heating rates were 
0.5 °C/min between the steps. After freeze-drying, re-pressurization of the dryer was 
performed using dry air to approximately 800 mbar and the vials were stoppered. Samples 
were analyzed directly after preparation (t0), after freeze-thawing (t1,FT), after primary drying 
(t2, PD) and secondary drying (t3, SD) 
II.3.14.5 SUBVISIBLE PARTICLE FORMATION DURING THE FREEZE-DRYING PROCESS 
After preparation of formulations and filtration as well as after freeze-thawing and the primary 
drying step, all samples remained clear with almost unchanged subvisible particle counts. 
However, in the samples with HPβCD, an increase in subvisible particles in the 1-digit 
micrometer range, as well as in turbidity was detected after the secondary drying step. This 
increase in subvisible particles and turbidity was observable independent on presence of 
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amorphous stabilizers sucrose, trehalose or arginine phosphate or when HPβCD was used as 
single excipient as shown in Figure II-121, Figure II-122, Figure II-123 and Figure II-124. The 
amount of subvisible particles detected after secondary drying as well as the turbidity value 
were influenced by the concentration of HPβCD used and the freezing protocol. As expected, 
the higher the concentration of HPβCD, the more particles are generated, which is true for the 
formulations based on Sucrose and Trehalose. Surprisingly, the opposite was observed with 
the formulations based on arginine phosphate and the lower concentration of HPβCD showed 
higher subvisible particles numbers than the formulation with 1.0 %. The impact of the freezing 
protocol was quite distinct and nitrogen immersion in general resulted in higher total particle 
counts than the slow ramp freezing protocol.  
 
Figure II-121: Subvisible particles and turbidity for sucrose-based formulations without HPβCD, or containing 0.1 % or 1.0 % 
HPβCD. Samples were analysed after preparation (t0), freeze-thawing, primary drying or secondary drying and were either 
ramp frozen (SF) or liquid nitrogen immersed (N2).  
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Figure II-122: Subvisible particles and turbidity for trehalose-based formulations without HPβCD, or containing 0.1 % or 1.0 % 
HPβCD. Samples were analysed after preparation (t0), freeze-thawing, primary drying or secondary drying and were either 
ramp frozen (SF) or liquid nitrogen immersed (N2). 
 
Figure II-123: Subvisible particles and turbidity for arginine phosphate-based formulations without HPβCD, or containing 0.1 % 
or 1.0 % HPβCD. Samples were analysed after preparation (t0), freeze-thawing, primary drying or secondary drying and were 
either ramp frozen (SF) or liquid nitrogen immersed (N2). 
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Figure II-124: Subvisible particles and turbidity for formulations with 1.0 % HPβCD. Samples were analysed after preparation 
(t0), freeze-thawing, primary drying or secondary drying and were either ramp frozen (SF) or liquid nitrogen immersed (N2). 
II.3.14.6 INFLUENCE OF RESIDUAL MOISTURE 
The formation of subvisible particles during the freeze-drying process was observed after 
secondary drying only, in which, among other product quality attributes, the residual moisture 
is decreased from 20 -5 % to a desired level of around 1 % (w/v) or below [83]. Consequently, 
one of the possible product quality attributes influencing particle formation is the residual 
moisture of the product. After secondary drying at 40 °C, residual moistures of all samples 
were well below 1.0 % and even below 0.5 % for the sucrose and trehalose based 
formulations. To see the influence of residual moisture on particle formation, a the trehalose-
based formulations with no HPβCD, 0.1 % or 1.0 % was freeze-dried and extracted from the 
freeze-drier after 3 hours of secondary drying at 3 different temperatures (10 °C, 25 °C and 
40 °C) to produce different residual moisture levels. Freezing and primary drying was carried 
out exactly as in the other experiments. Trehalose as bulking agent was chosen because glass 
transition temperatures of trehalose are higher at comparable residual moisture levels than 
sucrose and macroscopic collapse can be avoided. The formulations containing 5 % trehalose 
only, which served as a control, did not show a correlation between residual moisture and 
subvisible particles whereas an increase in subvisible particle concentrations was observed in 
the samples containing HPβCD starting at residual moistures of around 0.5 % as shown in 
Figure II-125 and Figure II-126. This was more pronounced with the formulation of 1.0 % 
HPβCD compared to the lower concentration of 0.1 %.  
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Figure II-125: Subvisible particle and formation and residual moisture of 0.1 % (w/v) HPβCD in combination with 5 % Trehalose. 
Samples were either ramp frozen with 0.3 °C/min (SF) or liquid nitrogen immersed (N2).  
 
Figure II-126: Subvisible particle formation and residual moisture of 1.0 % (w/v) HPβCD in combination with 5 % Trehalose. 
Samples were either ramp frozen with 0.3 °C/min (SF) or liquid nitrogen immersed (N2). 
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II.3.14.7 INFLUENCE OF SPECIFIC SURFACE AREA 
In addition to the influence of residual moisture, an influence of the freezing protocol was 
detected. Fast freezing with liquid nitrogen leads to super-cooling and nucleation of a small 
fraction of the liquid followed by directional solidification of the entire liquid. This leads to 
lamellar ice crystals and a comparable large specific surface area. Contrary, ramp freezing 
with a low speed leads to global super-cooling and nucleation with a lower specific surface 
area. A clear impact of those two different freezing protocols was observed with the samples 
containing HPβCD in both concentrations and HPβCD alone. Samples which contained 
HPβCD and were liquid nitrogen frozen showed a strong correlation between specific surface 
area and particle concentrations, as shown in Figure II-127.  
 
Figure II-127: Results obtained for light obscuration of all formulations and corresponding specific surface areas. Subvisible 
particle formation correlates with specific surface area. SF = ramp frozen, N2 = liquid nitrogen frozen. 
Microflow imaging analysis (MFI) of the samples freeze-dried at 40 °C from the residual 
moisture study (section II.3.14.6) was performed to confirm that the particles formed are in fact 
in the micrometer range because it is known that for the light obscuration method, a large 
amount of smaller particles can be detected as less but larger particles due to coincidences in 
the detector. The MFI is capable to detect subvisible particles already at a size of 0.75 µm with 
an improved sensitivity compared to the PAMAS SVSS and hence, particle numbers are 
actually much more but the trends, as observed with light obscuration are the same, as shown 
in Figure II-128. Similar to the results from light obscuration, essentially all particles were in 
the lower single digit micrometer range.  
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Figure II-128: Subvisible particles determined by microflow imaging and specific surface area for all formulations.  
SF = ramp frozen, N2 = liquid nitrogen frozen. 
If an increase in SSA correlates with an increase in subvisible particles, a decrease in SSA 
should decrease particle formation. To test this hypothesis, collapse freeze-drying was 
performed with both freezing protocols. Collapse freeze-drying is primary drying at a product 
temperature above the collapse temperature, Tc, above which viscous flow of the amorphous 
matrix is occurring. Freeze-drying with macrocollapse of the matrix results in products with low 
specific surface area and, compared to conventional freeze-drying, to relatively high residual 
moistures. Collapse freeze-drying, as performed in this study, lead to a product temperature 
of approximately -25 °C for the formulation of 5 % Sucrose + 1.0 % HPβCD while the Tg’, which 
is usually 1-3 °C lower than Tc, at least for this type of formulation, is -29.9 °C, as shown in 
Table II-24. Drying above Tc results in macroscopic collapse of all samples based on sucrose, 
however, the formulation with 1.0 % HPβCD showed no macroscopic collapse, as shown in 
Figure II-129. However, reconstitution times were less than 30 seconds for all formulations. 
Table II-24: Tg’ and delta Cp (dCp) of the formulations based on Sucrose with no, 0.1 % or 1.0 % HPβCD and the formulation 
with only 1.0 % HPβCD. 
Formulation Tg’ [°C] dCp [J*g/K] 
5 % Sucrose -33.93 ± 0.29 0.16 ± 0.01 
5 % Sucrose + 0.1 % HPβCD -33.43 ± 0.38 0.15 ± 0.01 
5 % Sucrose + 1.0 % HPβCD -29.87 ± 0.23 0.17 ± 0.02 
1 % HPβCD -14.07 ± 0.21 0.09 ± 0.01 
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A B 
Figure II-129: Macroscopic appearance of (A) 5 % Sucrose + 1.0 % HPβCD and (B) 1.0 % HPβCD alone. The pictures show the 
liquid nitrogen frozen samples.  
As expected, collapse of the samples lead to an immense reduction of SSA. Furthermore, no 
significant difference of subvisible particles concentrations could be observed after freeze-
drying and rehydration compared to the reference, 5 % sucrose, as shown in Table II-25. For 
the non-collapsed 1.0 % HPβCD formulation, subvisible particle formation was observed with 
a strong correlation with SSA.  
Table II-25: Subvisible particle formation as detected with light obscuration for formulations based on Sucrose with no, 0.1 % or 
1.0 % HPβCD as well the formulation with 1.0 % HPβCD alone. SF = ramp frozen, N2 = liquid nitrogen immersion. 
Formulation Freezing protocol Subv. Particles > 1 µm 
Specific surface area 
[m²/g] 
5 % Sucrose 
SF 854 ± 189 0.11 
N2 694 ± 177 0.08 
5 % Sucrose  
+ 0.1 % HPβCD 
SF 1310 ± 895 0.09 
N2 885 ± 493 0.12 
5 % Sucrose 
 + 1.0 % HPβCD 
SF 1743 ± 698 0.08 
N2 1451 ± 321 0.12 
1 % HPβCD 
SF 6053 ± 857 2.09 
N2 19646 ± 12768 7.97 
 
Residual moistures were, as expected, higher for the collapsed samples than the non-
collapsed samples. Surprisingly, the freezing protocol showed a significant influence in 
residual moisture levels and the nitrogen frozen samples showed higher residual moisture than 
the ramp frozen samples, as presented in Table II-26.  
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Table II-26: Residual moisture of collapse freeze-dried samples. SF = ramp frozen, N2 = liquid nitrogen immersion. 
Formulation Freezing protocol Residual moisture [%] 
5 % Sucrose 
SF 2.04 ± 0.05 
N2 2.82 ± 0.21 
5 % Sucrose + 0.1 % HPβCD 
SF 2.00 ± 0.04 
N2 2.70 ± 0.42 
5 % Sucrose + 1.0 % HPβCD 
SF 1.88 ± 0.14 
N2 3.06 ± 0.12 
1 % HPβCD 
SF 0.83 ± 0.14 
N2 1.01 ± 0.28 
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II.3.14.8 PRESENCE OF POLYSORBATE 80 
In the previous sections, a strong correlation of specific surface area and the subvisible 
particles formed could be observed. HPβCD is a surface active derivative of β-CD and is 
expected to be present at the ice/liquid interface during freezing as well as the solid/void 
interface of the dried product. In addition, it is known that surfactants like polysorbates can 
displace HPβCD from these interfaces [71]. If aggregation of HPβCD is interface-driven, the 
addition of polysorbate is expected to interfere with this process and differences should be 
observable. To test this hypothesis, a formulation with 1.0 % HPβCD was compared to a 
formulation consisting of 1.0 % HPβCD and 0.04 % polysorbate 80 after freeze-drying and 
rehydration. In addition, the formulation consisting of 1.0 % HPβCD was reconstituted with a 
solution of 0.04 % polysorbate 80 to test, if dissolution of HPβCD aggregates can happen in 
the presence of this surfactant. For both formulations, the ramp freezing and the liquid nitrogen 
immersion freezing protocols were applied.  
 
Figure II-130: Results from light obscuration and turbidity for 1.0 % HPβCD without and with 0.04 % polysorbate 80 and the 
formulation of 1.0 % HPβCD which was reconstituted with a solution of 0.04 % polysorbate 80. SF= ramp frozen, N2 = liquid 
nitrogen immersion.  
The addition of 0.04 % polysorbate 80 to 1.0 % HPβCD completely prevented subvisible 
particle formation while the reconstitution with 0.04 % polysorbate only slightly reduced 
subvisible particles concentrations. Turbidity was almost unaffected for all formulations.  
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II.3.14.9 INFLUENCE OF IMPURITIES OF β-CD AND THE DEGREE OF SUBSTITUTION 
Synthesis of HPβCD is commercially done by derivatization of the starting material β-
cyclodextrin (β-CD), which is much less water soluble than the resulting derivative. However, 
traces of β-CD are unavoidable and are specified less than 1 % for the Wacker derivative and 
less than 0.1 % for the Roquette product. To test whether the subvisible particles originate 
from impurities of β-CD, the parent CD was added to sucrose in two concentrations of 0.001 % 
and 0.01 % which equals the maximum amount of impurities that can be present in both 
HPβCD products. The results from light obscuration and turbidity are shown in Figure II-131. 
The formulations with β-CD showed no significant difference to the reference 5 % sucrose 
independent of freezing protocol employed whereas subvisible particle concentrations and 
turbidity were higher with the formulations containing HPβCD.  
 
Figure II-131: Results for sucrose-based formulation with the addition of two different concentrations of β-CD. As reference, two 
different concentrations of HPβCD were employed. SF = ramp frozen, N2 = liquid nitrogen immersion. 
HPβCD self-aggregation is most probably driven by intermolecular hydrogen bonds between 
hydroxyl-moieties of the glucose units and the moieties introduced by hydroyxpropylation. 
Hence, the (molar) degree of substitution ((m)DS) is expected to influence the amount of 
particles after rehydration. Two different HPβCD derivatives from Wacker and Roquette were 
employed to test this hypothesis. Figure II-132 shows the results from light obscuration and 
turbidity. The product from Roquette (mDS 0.87) shows slightly higher particle counts than the 
derivative from Wacker (mDS between 0.59-0.73). The differences in the degree of substitution 
may be too small to have a noticeable impact in subvisible particle formation.  
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Figure II-132: Results from light obscuration and turbidity for the sucrose-based formulations of two different HPβCD derivatives 
in two concentrations. SF = ramp frozen, N2 = liquid nitrogen immersion.  
 
II.3.14.10 IMPACT OF SUBVISIBLE PARTICLES OF HPβCD ON THE AGGREGATION OF A 
MODEL ANTIBODY 
One possible problem occurring from self-aggregation of HPβCD, besides general increase in 
particle levels, is the potential ability of those particles to serve as heterogeneous nucleation 
seeds for protein aggregates formed during rehydration. To test this, reconstitution of a model 
antibody was performed using a solution of either 1.0 % HPβCD or a lyophilized, rehydrated 
solution of 1.0 % of HPβCD which contains a certain amount of particles. The antibody was 
freeze-dried with and without the presence of 0.04 % PS80. As depicted in Figure II-133, 
reconstitution of the antibody samples with HPβCD particles present did not lead to 
disproportional large amounts of subvisible particles. Independent of antibody formulation, the 
values obtained were comparable with the sums of the reference formulations, at least after 
reconstitution. A similar picture was observable also with Microflow imgaging, where also no 
unproportional large number of subvisible particles could be observed. However, there are 
some differences when the antibody lyophilizates were reconstituted with the non-lyophilized 
HPβCD solutions.  The amount of subvisible particles in this case was lower compared to 
reconstitution with water, as shown in Figure II-134. This was more pronounced in the 
formulation containing no polysorbate. 
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Figure II-133: Results from light obscuration for the model antibody Mab R1 which was reconstituted with solutions of 1.0 % 
HPβCD which were freshly prepared or lyophilized and rehydrated. The light grey bars on top of the dark grey bars represent 
the mathematical sum of those two samples and the dark grey bar in each case the actual particle concentration after 
reconstitution. 
   
 
Figure II-134: Results from microflow imaging for the model antibody Mab R1 which was reconstituted with solutions of 1.0 % 
HPβCD which were freshly prepared or lyophilized and rehydrated. The light grey bars on top of the dark grey bars represent 
the mathematical sum of those two samples and the dark grey bar in each case the actual particle concentrations after 
reconstitution. 
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II.3.14.11 SUMMARY AND DISCUSSION 
Our results obtained from freeze-drying of various pharmaceutically relevant formulations of 
HPβCD show strong evidence that subvisible particles can be formed by HPβCD after freeze-
drying and rehydration. To our knowledge, this has not been reported yet in the literature. 
However, aggregation due to hydrogen bonds of parent CDs in the nm range has been 
observed by dynamic light scattering in aqueous solutions [84]. In addition, also an influence 
of derivatization of the glucose monomers has been observed, however, aggregation of those 
derivatives, including HPβCD was found to be negligible in literature [85]. Main factors 
influencing particle formation in our study are residual moisture and (specific) surface area. 
This is supported by the fact that a significant increase of subvisible particles are formed after 
the secondary drying step but not after the primary drying or the freeze-thawing step. The 
results from microflow imaging confirm that the particles detected by light obscuration are in 
fact subvisible particles. In addition, the freezing protocol and the freeze-drying process also 
greatly influence the formation of subvisible particles. It is known that, in contrast to the parent 
cyclodextrins α-, β-, and γ-CD, certain derivatives like methylated or hydroxypropylated 
decrease the surface tension of water by accumulating at the air-water interface [24], so it is 
no surprise that an increase in the ice-water and the solid-void interface has a certain effect 
on subvisible particle formation. A large specific surface area, obtained from liquid nitrogen 
immersion, leads to a larger amount of subvisible particles than a smaller specific surface area, 
obtained by ramp freezing with 0.3 °C/min or a drying process with a product temperature Tp 
> Tc with resulting collapse of the lyophilized cake. However, in this case, also the residual 
moisture could not be decreased to a very low level of less than 0.5 %. Furthermore, it is known 
that HPβCD can be displaced from the air-water interface by the addition of polysorbate 80 
[71]. Our data show that the addition of polysorbate 80 did almost completely inhibit subvisible 
particle formation by HPβCD. β-CD impurities seemed not to be responsible for subvisible 
particle formation. The concentration which could be present in our studies is at maximum 
0.01 % (w/v) and therefore much lower that the solubility of β-CD in water which is 
approximately 1.85 % (w/v) [86] and also much lower as the concentration which has been 
used in the aggregation studies of parent CDs [85] . Based on the results obtained in this study, 
the authors speculate that formation of subvisible particles by HPβCD takes place at the solid-
void interface due to close proximity of single molecules. While the residual water content is 
decreased, the formation of intermolecular hydrogen bonds may be the reason for aggregation 
of HPβCD, although this is speculative and there is no direct evidence in our data.  To mitigate 
formation of particles of HPβCD, one could increase residual moisture of the formulations; 
however, this is not always applicable, because an increase in residual moisture decreases 
glass transition temperatures of dried products. One should also keep the surface area of a 
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formulation as low as possible, which can be done by using controlled ice nucleation with low 
degrees of super-cooling or an additional annealing step after the freezing step. 
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II.3.15 FINAL DISCUSSION 
II.3.15.1 INFLUENCE OF SPECIFIC SURFACE AREA 
As shown in the sections in chapter II, the freeze- and spray-drying processes had a significant 
impact on MabR1 stability. The different drying processes differed in process conditions and 
in product quality attributes. Table II-27 shows a short overview on the different drying 
processes employed in this study. 
Table II-27: Overview of the different drying processes and their impact on product quality attributes. 
Process Specific surface area Residual moisture 
Conventional FD High (> 1 m²/g) Low (< 1 % w/w) 
Controlled-nucleation at high Tp  Low (0.5 m²/g) Intermediate (1 % - 2 %)a 
Collapse FD Very low (< 0.2 m²/g) High (2 % - 5 %, formulation dependent) 
Spray drying High (> 1-2 m²/g)b High (2 % - 5 %, formulation dependent) 
a: can be changed if process conditions in secondary drying are changed. 
b: Surface area is larger after atomization and is decreased during drying-induced shrinkage of droplets. 
Figure II-135 shows an overview on the correlation of SSA generated by different freeze-drying 
processes and the corresponding subvisible particles formed immediately after freeze-drying 
and rehydration. Results from spray-drying are not included because the impact of foreign 
subvisible particles, which were also present in the placebos, was difficult to estimate and 
specific surface area measured of the dried product differs from the surface area generated by 
atomization. A trend towards lower subvisible particles with lower SSA can be observed for the 
formulations which contain HPβCD as well as for sucrose-based formulations which did not 
contain any surfactant. A large difference between sucrose concentrations was also observed 
with significantly lower subvisible particles for the 5 % formulation compared to 1 % sucrose-
based formulations. The formulations which contain 0.04 % or 0.004 % polysorbate 80, both 
concentrations are larger than the CMC, which is 0.0014 % (w/v) (equals 0.010 mM [87]), did 
not show a correlation between SSA and subvisible particles. Comparing the results from 
freeze-thaw studies, in which HPβCD as well as polysorbate 80 were very effective stabilizers, 
with the results after freeze-drying and rehydration, the following conclusion can be drawn: 
HPβCD seems to be able to stabilize better at the ice-liquid interface formed during the freezing 
step as well as in the thawing step than at the liquid-air interface, which is encountered during 
rehydration of the dried products. HPβCD, in addition, is slowly covering the air-liquid interface 
and is not able to displace an antibody which has already accumulated at this interface. Hence, 
kinetics are also expected to influence the stabilization mechanism of HPβCD. The results 
from atomization experiments in the spray-drying experiment also point in this direction. When 
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HPβCD-containing samples were reconstituted with a solution of polysorbate 80, lower 
subvisible particle counts were observed, indicating that a positive effect of PS80 on subvisible 
particles is effective at the liquid-air interface during reconstitution which is not observed for 
HPβCD to this extent. With all this results in mind, HPβCD is an effective stabilizer, if the 
interface area is kept low. 
 
Figure II-135: Overview of specific surface area (SSA) vs. subvisible particles > 1 µm for all formulations except spray-dried 
formulations investigated in this study. For HPβCD and PS80, each point represents either the excipient in combination with 1 % 
or 5 % Sucrose. 
In general, a low SSA can be considered beneficial for protein formulations independent of 
employing HPβCD as an excipient if one assumes that degradation of protein is the sum of 
degradation in the bulk and at the interface [70]. The cumulative degradation rate k can then 
be described using 
 =		 + 	   Equation II-1 
with kobs being the observed degradation constant, kS is the rate constant of protein located at 
the surface of the dried product and FPS is the corresponding fraction of protein at the surface; 
kB is is the rate constant of bulk degradation and FPB is the fraction of protein in the bulk [70]. 
Consequently, the lower the fraction of protein at the surface is, the lower the overall 
degradation rate is. Furthermore, water uptake during storage may be lower for samples with 
lower SSA compared to samples with a higher SSA and chemical degradation, which is 
triggered at the surface, is expected to be slowed. There are some hints in literature that a low 
SSA is indeed increasing long-term storage stability of proteins, as shown for antibodies [70, 
88] and interferon-γ [80]. However, it is difficult to rule out other effects which contribute to 
long-term storage stability of lyophilizates besides SSA, e.g. residual moisture, molecular 
mobility, glass transition temperatures, etc. This is even harder to accomplish if the different 
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SSAs are produced by different drying methods. Controlled ice nucleation may be a valuable 
tool to study SSAs-dependent stability effects of lyophilizates. 
II.3.15.2 PLACEBO PARTICLES OF HPβCD 
As presented in chapter II.3.14, placebo particles of HPβCD can be formed during freeze-
drying and rehydration. These particles are formed after secondary drying and their numbers 
depends on residual moisture and specific surface area. With the studies performed for 
MabR1, one critical aspect was to control formation of those particles because their number 
may, in the best case and if those particles are “inert”, contribute to total number of subvisible 
particles or even act as heterogeneous seeds to trigger aggregation of proteins. That had been 
observed for an antibody in the presence of micro- and nanoparticles [89, 90]. Although we 
could not confirm that placebo particles of HPβCD lead to excessive aggregation of MabR1 
(see section II.3.14.10), it shall be noted that subvisible particles of protein formulations were 
acceptable only when subvisible particles of placebo controls were also minimized. 
Unfortunately, we were not able to distinguish between proteinaceous and non-protein 
particles in antibody formulations in this study. A useful tool for this scientific challenge would 
be raman spectroscopy of filtered particles as available with the RapID® device. In the 
literature available so far on cyclodextrin and protein stability, no subvisible particle counts 
have been published. Subvisible particle aggregates in the µm-range have attracted protein 
formulations scientists’ attention quite recently [54, 91], thus formation of HPβCD placebo-
particles may have been unnoticed in published literature of cyclodextrins in freeze-drying so 
far.  
II.3.15.3 POSSIBLE STABILIZATION MECHANISM OF HPβCD 
While it has been discussed that HPβCD is binding to hGH [79], we could not show an 
interaction of HPβCD (0.6 % and 1.0 %) with MabR1 at a concentration of 10 mg/ml at least 
by microcalorimetry, as shown in Figure II-136. In general, aggregates form through partially 
unfolded proteins (so called molten globules, which have a larger surface than the native state) 
and probably not by complete unfolded species [92]. The Lumry-Eyring framework [93] is a 
model, in which a native protein (N) reversibly transforms to a partially unfolded transition state 
(TS*), which is prone to aggregate to an aggregation intermediate (AI) see (1). AI is capable of 
interacting with Aggregates containing m aggregates (Am), forming a complex Am+I, see (2). 
N ⇆ TS* → AI         (1) 
AI + Am → Am+I         (2) 
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If HPβCD binds to the unfolded state of the protein TS*, this state is thermodynamically favored 
and a lower Tm should be observed. However, although not extensively studied, this was not 
the case in our studies with almost superimposing melting curves of MabR1 at 10 mg/ml, as 
shown in Figure II-136.  
 
Figure II-136: Results from microcalorimetry for MabR1 formulated at 10 mg/ml. 
In the case of non-interaction for MabR1, HPβCD still showed positive effects compared to 
sucrose alone. As shown with the results from ESCA, HPβCD is not able to displace the protein 
from the interface similar to polysorbate. However, HPβCD is present at the interface, and 
phase separation of protein and stabilizer is possibly reduced. HPβCD may then stabilize by a 
mechanism shown for various excipients. Sugars, like trehalose or sucrose, polyols like 
mannitol or sorbitol and some amino acids are assumed to stabilize proteins via the preferential 
hydration / exclusion mechanism in solutions [94]. These excipients are excluded from the 
surface of proteins; the protein is preferentially hydrated by water molecules, which is an 
energetically unfavorable state. Partially unfolded or dissociated proteins have a larger surface 
than the native state [94, 95]. According to the law of Le Chatelier, the equilibrium   
N ⇆ TS* → AI 
is shifted to the native state (N) in the presence of an excipient stabilizing via the preferential 
exclusion mechanism. Whether this stabilization mechanism is also applicable to an interface 
is questionable, since the protein may not be fully hydrated in this case. However, protein 
molecules, accumulating at an interface, may still be protected by the presence of foreign 
molecules that can also diffuse to interfaces and reach a sufficient concentration to stabilize 
via the preferential exclusion mechanism and further aggregation to the aggregation 
intermediate AI or  AM+I may be attenuated. Concluding, HPβCD might therefore exert different 
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stabilization mechanisms which are connected to its unique structural properties: complexation 
of amino acids residues by the hydrophobic cavity; accumulation at interfaces due to 
hydroxypropylation; carbohydrate-like stabilization due to glucose sub-units.  
 
II.3.16 SUMMARY 
In this chapter, the potential use of cyclodextrins, especially the derivative HPβCD, in freeze-
drying was investigated. HPβCD was used as a potential alternative to polysorbates, which 
can degrade and exert a negative influence on protein stability. Three different model proteins, 
which are sensitive to interfacial stress conditions, were investigated: a monoclonal antibody 
(MabR1), human growth hormone (hGH) and granulocyte-colony stimulating factor (GCSF). In 
addition, HPβCD was also employed in spray-drying of MabR1. It was found that HPβCD can 
be an alternative to polysorbates. In drying processes, in which intermediate to high specific 
surface areas are obtained (conventional freeze-drying and spray-drying), polysorbate was 
superior to HPβCD with the studied model antibody. However, when specific surface areas are 
kept small, for example by employing controlled ice nucleation or collapse freeze-drying, 
acceptable protein stability was obtained for both excipients. The collapse freeze-drying 
process could also be transferred to the other two model proteins, hGH and GCSF. While hGH 
was very well stabilized by HPβCD and this combination was superior to polysorbate, drying 
of GCSF resulted in a general instability of both formulations studied.  Storage stable 
lyophilizates of MabR1 were only obtained when sucrose concentration was increased from 1 
% to 5 % (w/v). Even under accelerated stress conditions, these products exceptionally 
retained protein stability, which was also true for hGH. While polysorbate was superior in the 
spray-drying study, the present data set suggests that oxidation of MabR1 damaged protein 
stability, resulting in increased dimer contents after drying and subsequent storage.  Thus, a 
reasonable formulation strategy employing HPβCD is to keep the absolute surface area low, 
which is based on ESCA data suggesting that HPβCD co-exists with the antibody at the solid-
void interface in a similar manner than in liquid formulations. A concentration of 6 mg/ml 
HPβCD was found to be optimal in the studies. A side aspect of the chapter was the potential 
use of HPβCD as lyoprotectant. While we could show that state-of-the-art pharmaceutical 
formulations can be obtained with HPβCD in combination with PS for hGH, however, there 
was no evidence that HPβCD may be a better cryoprotectant than the much more widely used 
sucrose or trehalose. 
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III. CONTROLLED ICE NUCLEATION IN PHARMACEUTICAL 
FREEZE-DRYING 
 
III.1 INTRODUCTION 
Controlled ice nucleation is a new upcoming technology in pharmaceutical freeze-drying. The 
term “controlled” refers to the ability to not accept the random nature of spontaneous water-to-
ice conversion but to actually influence ice nucleation during the freezing step in the freeze-
drying process.  In this chapter, a review on ice nucleation and crystallization is given and 
methods to achieve controlled ice nucleation as well as other modifications of the freezing step 
are presented. Further, we developed a method to achieve controlled ice nucleation and also 
investigated its applicability in a pilot-scale freeze-drier. Finally, the developed method was 
used to study ice nucleation effects on protein and placebo formulations. Finally, the Mpemba 
effect, a surprising phenomenon that hot water freezes faster than cold water, was investigated 
using lyophilization equipment. 
 
 
 
     
Chapter III: Controlled ice nucleation in pharmaceutical freeze-drying 
160 
III.2 CONTROLLED ICE NUCLEATION IN THE FIELD OF FREEZE-DRYING: 
FUNDAMENTALS AND TECHNOLOGY REVIEW2 
III.2.1 INTRODUCTION 
Lyophilization, the most important drying process for biologicals, usually consists of three 
process steps. An aqueous solution is frozen and subsequently, water is removed by 
sublimation during primary drying. Non-frozen water is removed by diffusion and desorption 
during secondary drying. Although the importance of the freezing step has long been known 
in literature, the transformation of water to ice could not be controlled directly. The need to 
control the temperature at which the super-cooled aqueous solution spontaneously forms ice 
(Tn) can improve primary drying times and product uniformity. These benefits, saving process 
time, energy and money have recently led to the development of several methods to actively 
control ice nucleation in pharmaceutical drug solutions. The goal of this review is to supply the 
reader with background information about ice nucleation, impact on product quality attributes 
and to present the different technical solutions to induce ice nucleation. 
III.2.2 FUNDAMENTALS OF ICE NUCLEATION AND IMPACT ON THE FREEZE-DRYING 
PROCESS 
III.2.2.1 THE ICE NUCLEATION PROCESS 
Freezing of water is a highly complex process which becomes even more complex with 
pharmaceutical formulations used in freeze-drying. In general, freezing of water includes the 
following steps: (1) cooling of the solution below its equilibrium freezing temperature with a 
defined cooling rate; (2) primary nucleation which is the formation of an ice nucleus; (3) 
secondary nucleation which instantly follows primary nucleation and describes the growth of 
the nucleus to ice crystals; (4) completion of the liquid-to-solid phase transition by further 
growth of ice crystals [1]. The nomenclature is adopted from to the work of Searles and co-
workers [1]; the term secondary nucleation refers to ice crystallization only; the authors want 
to point out that the term secondary nucleation or secondary crystallization is also used in the 
literature for crystallization of solutes [2]. While lowering the temperature below the equilibrium 
freezing temperature, ice nucleation is usually not observed in pharmaceutical formulations 
with low particle levels and samples are super-cooled up to -20 °C [1]. Pure water can even 
                                               
2
 The section in the thesis was part of the publication Geidobler, R. and G. Winter, Controlled ice 
nucleation in the field of freeze-drying: Fundamentals and technology review. European Journal of 
Pharmaceutics and Biopharmaceutics, 2013. The text was written by R. Geidobler and was corrected 
for publication by G. Winter. 
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be super-cooled to -48 °C in the absence of particulates or other impurities [3]. It is important 
to distinguish between global super-cooling (the whole solution is homogeneously super-
cooled) and local super-cooling (only a fraction of the liquid is super-cooled).  Slow cooling 
rates usually lead to global super-cooling whereas local super-cooling is observed above a 
critical cooling rate, e.g. with liquid nitrogen immersion [1, 4]. In the super-cooled, liquid state, 
many different possibilities to form networks of hydrogen bonds are possible. Only by the 
formation of a nucleus of water molecules with relatively long-lasting hydrogen bonds, growth 
of this initial nucleus, and rapid, homogeneous crystallization of ice is possible [5]. The 
appearance of the initial nucleus is called primary nucleation. The number of those nucleation 
sites is increased with a higher degree of super-cooling [6]. Secondary nucleation, which is the 
growth of the nuclei proceeds with a certain interface velocity in the range of cm/s [7]. During 
crystallization, the temperature of the ice-liquid mixture rises close the equilibrium freezing 
temperature and crystallization stops. Consequently, not the entire liquid freezes instantly 
during secondary nucleation. With continuous heat removal, crystallization proceeds until all 
crystallisable water is transformed from the liquid to the solid state [8]. The speed of ice crystal 
growth and complete solidification is determined by the removal of generated heat [8]. After 
complete solidification, the temperature of the sample drops. Figure III-1 shows typical 
thermocouple readings for standard, ramp frozen samples.  
 
Figure III-1: Typical thermocouple readings for shelf ramp freezing. 
In the field of pharmaceutical freeze-drying, heterogeneous nucleation of ice is reality [4]. In 
contrast to homogeneous nucleation in pure water, ice nucleation is triggered by impurities, 
which can act as foreign ice nucleation sites [1]. Such impurities hence increase the average 
ice nucleation temperature in a batch [1]. Still, super-cooling of pharmaceutical formulations 
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up to -20 °C or -30 °C could be observed. The amount of sub-micron particles is expected to 
be higher in lab-scale environment and may decrease dramatically in a manufacturing 
environment. It may be concluded that in production scale, ice nucleation temperatures are in 
average lower than in early development and therefore modifications of the freeze-drying 
process are necessary [9].  
III.2.2.2 THE IMPORTANCE OF THE DEGREE OF SUPER-COOLING 
Based on the aforementioned physics, there are some implications concerning the degree of 
super-cooling. First, the degree of super-cooling influences the fraction of ice formed after 
secondary nucleation and temperature rise since crystallization stops when the equilibrium 
freezing temperature is reached. The higher the degree of super-cooling, the more 
crystallization heat can be absorbed by the super-cooled solution and the more water instantly 
freezes. The fraction of ice initially frozen can be calculated according to Searles et al [1]: 
x=	mwnmwf =
Tf-TnCPw
1- CC'g∆Hm
 
Equation III-1: Fraction of water crystallized dependent on nucleation temperature.  
With the mass of water crystallized at nucleation mwn, and the mass of freezable water mwf. Tf 
is the equilibrium freezing temperature of water and Tn is the nucleation temperature. CPw is 
the heat capacity of water (around 4.2 J/g*K), and C is the mass fraction of solutes. C’g is the 
mass fraction of solutes in the maximally freeze-concentrated state.  ∆Hm is the crystallization 
heat of ice [1] (334 J/g [10]). The equation is simplified and does not take into account minor 
changes of equilibrium freezing temperature depression, crystallization heat and heat capacity 
of water.  To give an estimate, 7 % – 27 % of water crystallized at nucleation temperatures 
from -5 °C to -19 °C [1]. The amount of total crystallisable water and unfrozen water is mainly 
determined by the composition of the formulation and is not influenced by the ice nucleation 
temperature.  
Second, due to a colder environment, e.g. a cold freeze-dryer shelf, ice crystal growth is also 
faster with low ice nucleation temperatures since heat is removed relatively fast via the cold 
shelf. Contrary, with a lower degree of super-cooling, resulting in a higher nucleation 
temperature, a smaller fraction of ice is instantly frozen and also ice crystal growth is slower 
since the freeze-dryer shelf is warmer and thus the driving force of heat removal is lower. The 
difference between a low and a high nucleation temperature is illustrated in Figure III-2. 
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Figure III-2: Exemplary description of ice nucleation at different product temperatures. A: Ice nucleation at a high product 
temperature of around -5 °C. Fewer but larger ice crystals are generated which grow to larger ice crystals. Also, a smaller 
fraction of ice is instantly formed. B: Many small ice crystals are formed by large super-cooling and a larger fraction of total 
freezable water instantly freezes. These ice crystals also grow but their average size will be smaller than those from a higher Tn. 
The differences in number of nuclei, fraction of instantly frozen water and ice crystallization 
growth rate leads to a lot of different morphologies of ice [11]. For example, with a super-
cooling of around -1.5°C, dendritic ice crystals are formed whereas different needle-like 
crystals or platelets are formed with lower nucleation temperatures [11]. For a given ice 
nucleation temperature Tn, more than one ice crystal morphology max exist, indicating that Tn 
is probably the most important but not the only parameter influencing ice morphology [11]. 
Obviously, different solutes in various concentrations can affect ice crystal morphology [12] 
and also the presence of tertiary butyl alcohol (TBA)  can change ice morphology [13]. 
Directional solidification can lead to  chimney-like [14] or lamellar  ice crystals [8].   
III.2.2.3 THE INITIATION OF ICE NUCLEATION AND SIMILARITIES TO ANNEALING 
 Any method that allows for a control of the nucleation temperature Tn results in several 
degrees of freedom for the freeze-drying scientist. In principle, there are three parameters 
which can directly be controlled. First, the nucleation temperature Tn; second, the isothermal 
hold time post nucleation (which can be zero in the case of nucleation control during shelf 
ramping); third, the cooling rate of the shelf post nucleation. In the literature, different methods 
have been used for ice nucleation. In one approach, ice nucleation was induced at several 
product temperatures and subsequently, the shelf temperature was held for 15 additional 
minutes and cooled down after that time span [15]. In another approach, the shelf was 
immediately cooled down after ice nucleation in all vials to complete solidification [9]. Also, ice 
nucleation during shelf ramping has been performed. In this case, nucleation has been 
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triggered when a special vial, monitored using a thermocouple, was cooled below a specific 
temperature [16-19]. However, in larger freeze-dryers, cooling of all shelves may show some 
variations, and not all vials may show the same temperature during the shelf ramping [17]. 
Figure III-3 shows an example of controlled ice nucleation after equilibration of the vials on the 
freeze-dryer shelf.  
 
Figure III-3: Thermocouple readings for controlled nucleation at approximately -5 °C followed by 20 minutes of isothermal hold 
(unpublished data by the authors). 
While the link between Tn and primary drying time is already well established (see also 
following chapters), there are no systematic investigations on the relevance of the speed of 
final solidification which is controlled by the isothermal hold time and the cooling rate of the 
shelf ramp. There are some aspects which may favour a long isothermal post nucleation hold 
time. First, crystallization and complete solidification proceeds quite slow due to slow heat 
removal. It can be speculated that this may result in very large ice crystals yielding large pores 
with a low tortuosity. Furthermore, at an ice nucleation temperature far above Tg’, annealing or 
devitrification is simultaneously taking place and the extent is dependent on post nucleation 
isothermal hold time and the following shelf ramp. Annealing is usually performed after ramp 
freezing at elevated temperatures above Tg’ to allow crystallization of initially amorphous 
excipients [20] and Ostwald ripening of ice crystals to improve sample homogeneity and 
primary drying speed [21]. With annealing, the ice/water interface is initially large and is 
reduced due to Ostwald ripening process in which smaller ice crystals melt in favour of larger 
ice crystals while the interfacial free energy is decreased [21]. It can be considered as an 
advantage for interfacial-sensitive drugs that during controlled ice nucleation and isothermal 
hold, the ice/water interface area remains smaller compared to ramp freezing followed by 
annealing. Of course, also the downsides have to be considered. For active ingredients, which 
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are sensitive to freeze-concentration, a long isothermal hold time may be detrimental and a 
fast ramp cooling may result in better process stability of those drugs. Unwanted crystallization, 
for example of buffer components may also occur and result in pH shifts [22]. Furthermore, 
annealing may lead to phase separation of polymer-containing formulations [23, 24]. 
III.2.2.4 IMPACT OF ICE CRYSTAL SIZE ON PRIMARY AND SECONDARY DRYING 
A link between ice nucleation temperature and ice crystal size has been established quite early 
[25] and this correlation has been confirmed by several publications from the field of food 
science and freeze-drying. An early correlation between ice nucleation temperature and 
primary drying speed was established by Roy and Pikal [26]. They observed that the presence 
of a thermocouple probe in a vial increased Tn and those vials finished primary drying earlier 
than the other vials without thermocouples.  A strong correlation between Tn and sublimation 
rates was also observed by Searles et al [1]. Samples, which nucleated at high product 
temperatures also showed higher primary drying rates as determined by mass loss. Direct 
analysis of ice crystal size and distribution by optical microscopy in a cold chamber was 
correlated to sublimation rates by Hottot et al [27, 28]. They found that larger ice crystals, 
generated by annealing of ramp-frozen samples increased sublimation rates whereas small 
ice crystals, prepared by liquid nitrogen immersion, resulted in rather low sublimation rates. 
The link between ice nucleation, temperature and sublimation rates is therefore considered as 
well-understood.  
Large ice crystals provide less resistance to water vapour flow during sublimation because 
they leave behind larger pores [9, 15]. Freeze-dried cake pore size is interrelated to its specific 
surface area (SSA) by assuming a capillary tube model [9]. 
SSA	 m2g "=	 2ερs1-ε ∙ 1r 
Equation III-2: Specfic surface area and pore radius. 
With ( being the sample porosity, ) the sample density and r is pore radius [9]. The specific 
surface area is therefore inversely connected to the radius of pores.   
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Furthermore, dry layer resistance of freeze-dried cakes can be connected to pore size radius 
[9]:  
R+p=-πRT2M ∙ 34 ∙ τ²ε ∙ 1r 
Equation III-3: Product resistance and pore radius. 
With 456  equals product resistance, R is the gas constant, T is the absolute temperature, M is 
the molecular weight of water, ( is cake porosity and r is pore size radius. 7 is a parameter 
describing the tortuosity of the cake by taking into account the length of the channels and the 
thickness of the porous system [9]. Consequently, by increasing pore size, dry layer resistance 
is decreased which decreases primary drying time. Furthermore, product temperature during 
steady state heat and mass transfer during primary drying is slightly lower due to lower product 
resistance. This allows for further fine-tuning of shelf temperature, hence additional reduction 
of primary drying time.  
However, the specific surface area determines the speed of desorption of water in the 
secondary drying stage [29, 30]. A rate limiting step in secondary drying kinetics is the diffusion 
of water from the amorphous solid solution to the solid/void interface [29]. A lower specific 
surface area therefore decreases secondary drying kinetics for two reasons: first, the surface 
area for evaporation of water is reduced; second, the path of diffusion becomes longer due to 
thicker walls of the lyophilized cake. Of course, this is only valid if cake porosity and density 
are constant. A given freeze-drying process therefore leads to different residual moistures 
depending if ice nucleation occurs at higher or lower product temperatures. In fact, it has been 
shown that the higher the nucleation temperature, the higher the residual moisture of water 
develops [31]. This has also been experimentally confirmed by Konstantinidis et al [15]. Hence, 
modification of a freeze-drying cycle applying controlled nucleation may also involve extension 
of secondary primary drying time, or, more preferably, an increase in secondary drying 
temperature to achieve sufficiently low residual moisture. Another interrelated aspect is the 
shelf temperature ramp between primary and secondary drying. In this dynamic situation, the 
glass transition temperature Tg is increased while the water content is simultaneously 
decreased. For fully amorphous products, it is important that Tshelf  is at least lower than Tg to 
avoid structural collapse of the lyophilized cake by exceeding the actual glass transition 
temperature. Heating rates of approximately 0.15 °C/min are suggested in the literature [30]. 
This is also true for mixtures of crystalline bulking agents and amorphous co-stabilizers; 
however, structural collapse may not be macroscopically visible.  
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III.2.2.5 HOMOGENEITY ASPECTS 
Controlling the ice nucleation temperature not only allows selecting ice nucleation temperature, 
but it is claimed that also homogeneity of those samples may be improved because variations 
in random ice nucleation temperatures are reduced. Recent studies mainly focus on the 
benefits of ice nucleation at elevated temperatures, at which samples normally do not nucleate.  
Indeed, reduction in standard deviations for certain product characteristics have been 
observed, e.g. for specific surface area [32] as well as freeze-drying process parameters, e.g. 
the slope of the pirani gauge indicating the end of sublimation [33]. However, slightly increased 
standard deviations of controlled nucleated samples at -5 °C compared to random nucleated 
samples with respect to residual moisture and specific surface area were also observed [15]. 
Comparison of controlled-nucleated samples with uncontrolled, random nucleated samples is 
currently biased by the different product properties these two populations have, e.g. different 
residual moistures and specific surface areas. So far, no comparison of controlled nucleated 
samples with a Tn similar to that of random nucleation has been published. In addition, standard 
deviations usually observed in random-nucleated samples are not that high as one would 
expect looking at the distribution of ice nucleation temperatures [15]. Furthermore, controlled 
nucleated samples will certainly also show certain variability in product properties. These 
differences may not result from initial ice crystal distribution but from different freezing rates 
post nucleation due to variations in intra shelf temperature distribution, variations of vial heat 
transfer coefficients, various heat input during primary and secondary drying, pressure 
inhomogeneity during primary drying, the edge-vial effect and product temperature variations. 
Finally, currently marketed lyophilized products are produced without control of ice nucleation 
temperature and are accepted by the authorities and the scientific community. Homogeneity is 
not yet a striking argument for controlled ice nucleation. 
III.2.3 METHODS TO INDUCE AND CONTROL ICE NUCLEATION 
The main scope of this review is to present methods which allow free selection of the ice 
nucleation temperature Tn. Besides that, also other methods, which increase the average ice 
nucleation temperature, are presented. Additives like silver iodide or Pseudomonas syringae 
suspensions are beyond the scope of the review due to regulatory reasons; their effect on ice 
nucleation in the field of freeze-drying was reported by Searles et al [1].  An overview of all the 
methods is presented in Table III-1. 
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Table III-1: Overview of methods that allow to control the ice nucleation temperature or to increase average ice nucleation 
temperature. Please note that the column “Repeatability” somewhat conflicts with the requirement to induce ice nucleation very 
fast. During repetitions, heterogeneity of samples may originate. 
Method 
Ability 
to 
select 
Tn 
Scalability 
Positive / 
negative 
pressures 
used 
Usable 
in 
aseptic 
environ-
ments 
Efficiency Repeat-
ability 
Retro-fit 
needed Ref. 
Ice fog 
(original) Yes Difficult 
Negative, 
67 mbar Yes * 
Up to 
100 % 
(after 5 
minutes) 
Yes Yes [9, 32] 
Ice fog 
(commercial 
scale) 
Yes Yes No Yes Up to 100 % 
Yes 
(circulation) Yes 
[16, 
17] 
Ice fog  
(ice seed 
generator) 
Yes Yes Negative,  67 mbar Yes 
No data 
published 
Not proven, 
difficult * Yes 
[34, 
35] 
Ice fog 
(ventilation 
through cold 
condenser) 
Yes Not yet proven 
Negative,  
3.7 mbar 
Not yet 
proven ~99 % 
Not proven, 
difficult * No [36] 
Depres-
surization 
technique 
Yes Yes 
Positive, 
up to 
2 bar 
over-
pressure 
Yes Up to 100 % Yes Yes 
[15, 
37] 
Ultrasound 
ice crystal-
lization 
Yes Difficult * No Difficult 
* 
Up to 80 % Yes Yes [18, 33] 
Vacuum 
induced 
surface 
freezing 
No Difficult * Negative  (~1 mbar) Yes 
No data 
published No No 
[14, 
31] 
Gap freezing No Yes No Yes - No 
Yes 
(Ther-
mal in-
sulators) 
[38] 
Temperature 
quench 
freezing 
No Yes No Yes * Up to 100 % Yes Yes [39] 
Electro-
freezing Yes Difficult * No 
Difficult, 
invasive 
High, up to 
~96 % Yes Yes 
[40, 
41] 
Pre-cooled 
shelf method No Difficult * No Yes - No No 
[1, 
28] 
Mechanical 
agitation Yes* Difficult * No Yes - Yes * Yes [42] 
*: expectation by the author 
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III.2.3.1 REQUIREMENTS FOR A METHOD INDUCING ICE NUCLEATION 
For any method which is employed to induce ice nucleation in freeze-drying processes, there 
are several requirements which need to be fulfilled: 
Success of nucleation: Most important, of course, is the ability to induce ice nucleation in super-
cooled solutions. Furthermore, ice nucleation should be independent of freeze-drying 
equipment, vial type and size, fill volume, formulation and lyophilization stopper geometry.  
Robustness and controllability: Any method needs to be robust and should allow for ice 
nucleation in a reproducible and well controllable way and nucleation success should be 
100 %. Beyond that, ice nucleation should take place immediately to ensure homogeneity in 
product temperatures. The method should be scalable to allow its use both in early 
development and production units. Since many methods have increased technical needs, the 
software controlling the freeze-drying process should be as flexible as possible. An optimal 
method should control the product temperature prior to ice nucleation to actually control Tn and 
not just a specific time after process start.   
Product quality: Product quality is not allowed to be altered in any negative way by the method 
of choice, sterility and aseptic conditions must be maintained throughout the nucleation 
process. Operational qualification of the method must be possible and the method should not 
have a negative impact on media fill freeze-drying runs.  
III.2.3.2 MONITORING OF THE NUCLEATION EVENT 
One of the greatest challenges faced by any method employed in a freeze-drying process is 
the ability to achieve 100 % nucleation success and the monitoring of the nucleation event. Up 
to now, monitoring of ice nucleation is performed using thermocouples, preferably attached to 
the outside of the vial to not induce ice nucleation by the temperature sensors itself. For the 
ice fog method, vials were chosen for which ice nucleation was expected to be difficult [17]. 
However, only a limited amount of vials can be monitored this way. Monitoring was also done 
visually using a camera which was built into the freeze-dryer [15]. However, up to now, there 
is no technology available which is able to monitor ice nucleation of all vials simultaneously 
and can be retrofitted to freeze-dryers of all sizes. Samples nucleated at higher temperatures 
differ from samples with lower nucleation temperatures and show different residual moistures 
and specific surface areas. By that, identification of differently nucleated vials can be carried 
out after the drying process has been finished. While BET SSA measurements are time-
consuming and destructive, residual moisture of lyophilized samples can be determined non-
invasively by near-infrared spectroscopy [43].  
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III.2.3.3 THE ICE FOG TECHNIQUE 
As first proposed by Rowe [44], the obviously easiest way to induce ice nucleation of super-
cooled solutions is by using ice crystal as seeds. It was first applied in the field of freeze-drying 
by Rhambhatla and co-workers [9]. Nitrogen gas is transported at slightly increased pressure 
through copper coils which were immersed in liquid nitrogen, thus cooling the gas stream to 
temperatures less than -40°C. Subsequently, the gas enters the product chamber as shown in 
Figure III-4, method A. Water vapour, already present in the chamber, is cooled by the cold 
gas and forms ice crystals. The gas enters the chamber at minimum overpressure and the ice 
crystals pass into the pre-cooled vials inducing ice nucleation. Despite the striking concept, it 
is difficult to distribute ice crystals fast and homogeneously throughout the product chamber. 
The first approach was successful at various product temperatures ranging from -1 °C to -12°C 
and a partial freeze-dryer load of one shelf [9]. However, complete ice nucleation for all vials 
containing 5 % (w/v) sucrose took up to 30 minutes and during this relatively long time span, 
annealing for the earlier nucleated samples took place while remaining at a temperature far 
above Tg’, which impacted homogeneity in the samples [9]. By improving the technical setup, 
the temperature of the gas could be lowered to less than -50 °C. Further, distribution of the 
cold gas within the freeze-dryer could be optimized by employing a circular tube with holes. 
Ice nucleation of all samples was completed within five minutes [9]. To reduce the time needed 
for nucleation and improving product homogeneity, a follow-up study by Patel and co-workers 
[32] was conducted. The ice-fog was introduced in the product chamber after depressurizing 
the product chamber to approximately 66 mbar. Higher pressures (above 66 mbar) required 
several repetitions of the process. By this optimization, ice nucleation of all vials was achieved 
in around one minute for one shelf, but for a full loaded freeze-dryer, the process had to be 
repeated four times to achieve complete ice nucleation in all samples within five minutes.  
Inhomogeneous Ostwald ripening is likely to happen during this time span and may cause 
heterogeneity in the samples. To circumvent the problem, the authors proposed to use the 
CIP/SIP equipment in a manufacturing freeze-dryer to optimize distribution of ice crystals [32]. 
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Figure III-4: Overview of the various ice fog methods. A: Original ice fog method, B: improved ice fog method with circulation 
(adapted from [17]), C: ice fog generation in an external condenser, D: re-pressurization method through cold condenser. 
Currently, development of the ice fog method continues to ensure fast and uniform distribution 
of ice crystals. One approach taken by the companies Linde and IMA to address this problem 
is to mix sterile water vapour with liquid nitrogen cooled nitrogen gas in an ejector [16, 17, 19]. 
The hardware setup is illustrated in Figure III-4, method B. Water vapour will freeze upon 
contact with the cold gas and is brought into the product chamber, subsequently inducing ice 
nucleation. The ejector allows selecting the density of the ice fog and also serves as a pump 
for the ice fog without the need for mechanical parts, which is beneficial for steam sterilization. 
The ice fog mixture is removed from the product chamber through a second connection, is 
mixed with steam and enters the ejector again [17, 19]. This circulation of the ice fog allows 
for sufficient distribution and ice nucleation was achieved in 30 to 50 seconds by this method 
in lab- and pilot scale freeze-dryers of 1.1 m² and 2.5 m² shelf area [17, 19].  With the use of 
steam and sterile-filtered nitrogen gas, sterility of the process is maintained [17, 19]. 
Liquid nitrogen is necessary to successfully apply the ice fog technique in the methods above; 
however, handling of liquid nitrogen requires a certain effort and continuous supply. Hence, 
there are also approaches to create an ice fog without the need for liquid nitrogen. For 
example, an ice fog can be generated in an external product chamber or condenser, separated 
by an isolation valve by injection of moisturized gas with adjustable humidity [34, 35]. First, the 
whole system is depressurized to approximately 67 mbar similar to the approach of Patel et al 
[32]. Depending on the setup, either an external, second condenser as shown in Figure III-4, 
method C or the condenser of the freeze-drying unit is used to create an ice fog by injection of 
humidified gas. The ice crystals are then released into the product chamber by opening the 
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isolation valve, driven by the pressure difference between the product chamber and the ice fog 
compartment [35]. According to the manufacturer, the method could be scaled up to freeze-
dryers with a shelf area of 3 square meters [34]. Ice nucleation is fast in the time scale of 
seconds [35] and works with vials, syringes and microtiter well plates [34]. 
 In another method recently published, ice nucleation could be induced by first depressurizing 
the entire freeze-dryer, followed by immediately re-pressurization of the system via the cold 
condenser [36]. It was speculated that, by depressurizing the chamber to approximately 3.7 
mbar, a large enough batch will create enough water vapour which is transported onto the 
condenser. During re-pressurization through the condenser, as shown in Figure III-4, method 
D, these ice crystals could be blown back into the product chamber. The hypothesis is 
supported by the fact that small batches could only be nucleated when the condenser had 
certain ice pre-load. Re-pressurization via the product chamber did not lead to ice nucleation, 
so the sudden increase in pressure alone was not responsible for successful ice nucleation.  
Ice nucleation was achieved almost instantly [36]. An advantage of this method is that no 
hardware modifications of the freeze-dryer are required; however, the depressurization step 
needs to be well controlled to avoid boiling of solutions.  
III.2.3.4 HIGH PRESSURE SHIFT FREEZING / DEPRESSURIZATION TECHNIQUE 
High pressure shift freezing [45-47] and high pressure assisted freezing [45, 46] has been 
known for several years from food science. The thermodynamic freezing temperature of water 
can be lowered to approximately -20 °C by an increase of pressure to approximately 2000 bar, 
because the system evades the volume expansion of ice  [45].  The sample is then cooled to 
sub-zero temperatures, and pressure is released [45]. During pressure release to atmospheric 
pressure, the equilibrium freezing point of water is increased and ice nucleation takes place.  
With this technique, a high degree of super-cooling can be achieved because product 
temperature is above the melting curve and small ice crystals are obtained [45]. The concept 
of pressurizing and depressurizing the product chamber which contains the product vials was 
adopted by Gasteyer et al and transferred to the field of freeze-drying [37, 48]. However, 
product chambers of freeze-dryers are not able to withstand high pressure of 2000 bar, and 
pressurization was performed at approximately 2.9 bar with argon. The shelf-temperature is 
then lowered to the desired product temperature and ice nucleation is induced by de-
pressurizing the product chamber to 1 bar [15]. The pressure difference for successful 
application is at least 0.48 bar and de-pressurization needs to be sufficiently fast with a rate of 
at least 0.014 bar/sec [37]. Having a closer look at the phase diagram of water, the original 
concept of high pressure shift freezing is only partly applicable. With a comparably low 
pressure of around 2.9 bar, the product is constantly super-cooled and in metastable state 
during lowering of the shelf temperature and with pressure release, the melting curve is not 
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crossed. Consequently, the mode of action of the depressurization technique is not completely 
understood and the authors speculated that cooling of the liquid product surface by expansion 
of the gas would be inducing ice nucleation  [15]. This theory is supported by the fact that ice 
nucleation proceeds from the top to the bottom of the liquid. Local evaporation and self-cooling 
of the product or a pressure wave, mechanically disturbing the liquid surface, are also 
imaginable [15].  Furthermore, under pressurized conditions, gas is dissolved in the super-
cooled aqueous liquid. During depressurization, bubbles may be formed which could induce 
ice nucleation [15]. One or more of these mechanisms may contribute to successful nucleation.  
The depressurization technique has been shown to be effective from 1 m² shelf area up to 5 m² 
shelf area [49]. A freeze-dryer, capable of using the depressurization technique needs to be 
able to handle the high pressures involved, which most production scale, steam-sterilizable 
freeze-dryers do. Furthermore, the calibration status of manometers needs to be maintained 
in such systems. To quickly pressurize and depressurize the product chamber, the freeze-
dryer needs to be retrofitted with manifolds. Lab-scale freeze-dryers are usually not designed 
to withstand high positive pressures, so there are difficulties to use the depressurization 
technique in early development. 
III.2.3.5 VACUUM INDUCED SURFACE FREEZING 
As first presented by Kramer et al, formation of ice can also be achieved by evaporative self-
cooling of the sample [14]. The product is placed on the lyophilizer shelf and equilibrated at 
10 °C. For pure water, the chamber is then depressurized to approximately 1 mbar and the 
pressure is held for 5 minutes, until a thin layer of ice is formed due to local super-cooling 
which will serve as nucleation seeds. To avoid boiling and puff-off of the product, the pressure 
is then increased rapidly to 1 bar and simultaneously the shelf temperature is reduced to 
temperatures of 3-4 K below the onset of ice melting temperatures to avoid melting of the ice 
layer. Large chimney like ice crystals were obtained by directional solidification. The shelf 
temperature is held for 1 hour at this set-point to allow for Ostwald ripening and complete 
solidification. The samples are vitrified by lowering the shelf temperature to -40 °C with 2 
°C/min [14]. A modification of this method for highly concentrated, large fill volume formulations 
was published by Liu et al [31]. The shelf temperature was set to -10 °C and pressure was set 
to 0.8 mbar. After creation of the ice layer, pressure was increased and the shelves were 
cooled to -45 °C. Unfortunately, there are several drawbacks of this method. It is questionable 
if the technology can be scaled to large scale freeze-dryers, because massive evaporation of 
water may induce choked flow in the freeze-dryer and chamber pressures of 1 mbar or even 
0.8 mbar may not be controllable. Furthermore, it is important that, after formation of the ice 
layer, pressure is rapidly increased and shelf-temperature is lowered, as discussed above. 
This is only possible with a thorough monitoring of the nucleation process as discussed in 
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section III.2.3.1 and can only be executed if nucleation is induced in all vials in a short time 
period.  Furthermore, the pressure which is needed to form ice on the surface is formulation 
dependent [14] and needs to be experimentally determined for every batch. Although large ice 
crystals were obtained with this method [14], it was also observed by Liu et al that two-layer 
solidification occurred when the shelf temperature was lowered quickly, because a second ice 
nucleation front also started from the bottom [31]. In this case, a broken cake was observed 
after freeze-drying [31]. Macroscopic defects of the cake could lead to rejection of those 
samples.   
III.2.3.6 ULTRASOUND INDUCED FREEZING 
It has been known for many years that in super-cooled water, nucleation of ice can be achieved 
by ultrasonic vibration [50], which is also called sonocrystallization. The impact of ultrasonic 
waves on liquids leads to cavitation, the formation of gas-filled bubbles. Cavitation produces a 
locally complex situation of pressure and temperature and both influence vapour pressure and 
equilibrium freezing temperature [50, 51].  It is assumed that, by collapse of a cavitation bubble, 
ice starts to form if a correct cavitation intensity is used; however, this intensity is quite difficult 
to determine [52]. Nakagawa et al have shown that ultrasound-induced nucleation is also 
possible in glass vials by attaching an ultrasound generator and transducer to a temperature 
controllable aluminium plate on which the glass vials were placed. By triggering the ultrasonic 
wave at a defined temperature for 1 second, ice nucleation was observed. However, up-scaling 
of this technique is quite difficult. In order to efficiently propagate the ultrasonic waves, silicon 
oil had to be used to ensure good contact of the vial with the aluminium plate. With changing 
geometries of different vial types, a series of trial-and-error tests are necessary to find the 
correct ultrasonic frequency and the frequency is also dependent on the resonance frequency 
of the aluminium plate [18]. Furthermore, ice nucleation fails if vials are placed on so-called 
nodal points with minimum ultrasonic intensity [18].  In addition, also fragmentation of larger 
ice crystals in was observed after already nucleated sucrose samples were treated with 
ultrasound [53]. Nevertheless, a prototype freeze-dryer has been built to test ultrasound-
induced ice nucleation [33]. The efficiency of ice nucleation was somewhat dependent on the 
product temperature with favourable lower temperatures. Unfortunately, only around 80 % of 
the vials could be nucleated by the protocol used [33]. 
III.2.3.7 ELECTROFREEZING 
It has been reported early that super-cooled water can be nucleated by electric current. [54]. 
Development of appropriate electrodes in fact lead to successful ice nucleation in super-cooled 
solutions, however, these approaches are invasive and therefore not practical in 
pharmaceutical freeze-drying. In addition, care has to be taken to select the right electrode 
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material [55] and success of ice nucleation is also somewhat dependent on formulation 
composition, for example the presence of ionic substances [40, 41]. For difficult to nucleate 
formulations, indirect nucleation, that is separate nucleation of water and growing ice crystals 
proceeds into the super-cooled formulation. Phase transformation was induced by repeated 
pulses of 4 kV for 2.5 ms with a gold wire electrode [40]. Hydroxyethyl starch (HES) could be 
nucleated at temperatures as high as –1.5 °C using this method. However, the impact of 
electric current on sensitive drug molecules like proteins was not tested. Since every vial needs 
an electrode with accompanying cable connections, scale-up is considered impossible. 
III.2.3.8 PRE-COOLED SHELF METHOD 
A modification of the ice nucleation temperature was observed by placing the vials on a pre-
cooled shelf in the lyophilizer. The shelves are cooled to around -44 °C and the vials are placed 
on those cold shelves. While cooling from room temperature to the shelf set point, it was 
observed that the average nucleation temperature was increased compared to standard ramp 
freezing but also heterogeneity in Tn was still heterogeneous [1]. The initial set-point plays a 
role as the effect was less pronounced with a temperature of -40 °C [1]. In another study, only 
small differences between the pre-cooled shelf method and ramp freezing with 0.6 °C/min were 
observed with respect to ice crystal size and sublimation rates [28]. With the pre-cooled shelf 
method, also the filling volume and vial geometry plays an important role resulting in 
differences in cooling rates and subsequent freezing rates [28, 56]. In production scale, the 
use of pre-cooled shelves has already been established. Care has to be taken that the cold 
shelves do not mist over with ice due to contact with humid air. Slight positive inert gas pressure 
in the freeze-drier may prevent icing of the shelves and the use of a slot door with movable 
shelves is recommended.  
III.2.3.9 TEMPERATURE QUENCH FREEZING 
As recently introduced in a patent, ice nucleation can be induced and also to a certain extent 
controlled by temperature quench freezing [39]. Although described for a controlled rate 
freezer, this technique is applicable to freeze-drying. Temperature control is provided by mixing 
liquid nitrogen with gaseous nitrogen and the cryogen mixture is passed through a heater to 
control its temperature. The vials are placed on a porous metal plate, through which uniform 
and laminar distribution of the cryogen is ensured. The gas is collected and removed through 
an exhaust manifold above the vials. This system allows for very fast cooling and heating rates. 
Samples are first cooled and equilibrated at a temperature below the equilibrium freezing 
temperature, e.g. at -5 °C for several minutes. Subsequently, the temperature of the cryogenic 
liquid nitrogen is rapidly decreased to –80 °C within approximately 2 minutes, which results in 
a fast temperature drop in the vials to -10 °C followed by uniform ice nucleation. The gas 
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temperature may then be adjusted to a specific temperature to permit Ostwald ripening or fast 
solidification. Currently, there are no literature reports on temperature quench freezing used in 
lyophilization. However, implementation of this method is limited by high cooling and heating 
rates of the shelves which are usually not even achievable with liquid nitrogen boosters. To 
circumvent this problem, vials could be frozen in a controlled rate freezer and transported to 
the freeze-drying unit subsequently. The nucleation temperature cannot be controlled directly 
by this method and it is expected that nucleation temperatures are in general lower compared 
to other ice nucleation methods. 
III.2.3.10 GAP FREEZING 
Gap freezing was recently published in a patent, introducing a concept of thermally insulating 
the samples from the lyophilizer shelves by the use of a spacer with low thermal conductivity 
[38]. Cooling of the samples is then mainly provided by radiation. The goal of this setup is to 
ensure that the samples freeze from the bottom and the top simultaneously to avoid formation 
of a highly concentrated amorphous layer on top of the vial which may decrease primary drying 
time by its high resistance. By employing different spacers, the average nucleation 
temperature could be increased. However, since the spacers are difficult to remove, changes 
to the freeze-drying process have to be made, for example higher shelf temperatures 
throughout primary and secondary drying. Development and up-scaling of those processes is 
expected to be difficult. 
III.2.3.11 AGITATION INDUCED ICE NUCLEATION 
In an early patent, a special construction of a freeze-dryer is described [42]. The shelves are 
connected to the hydraulic unit of the freeze-dryer which is mounted on swing-metal 
connections on top of the product chamber. A vibrator is able to agitate the whole shelf 
package via the hydraulic piston and the vibrator can be adjusted in frequency [42]. This setup 
was originally designed to improve unloading of vials from the freeze-dryer if sticking of vials 
with the stopper to the corresponding upper shelf occurs [42]. However, this setup may be 
suitable to induce ice nucleation by mechanical agitation of the vials. Both lab-scale and 
production-scale freeze-dryers can be equipped with the vibrator. Up to now, there are no 
literature reports on this concept and the equipment, including vibrator, swing metal connectors 
and seals is probably quite expensive. 
III.2.4 SUMMARY AND OUTLOOK 
A lot progress has been made to control ice nucleation temperature in pharmaceutical 
formulations, resulting in various, well-engineered techniques which allows for further control 
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of the freeze-drying process. The ability to control and select Tn is another step towards a 
better understanding of the resulting product and perfectly fits in the quality by design approach 
of the authorities by eliminating another variable in the freeze-drying process. Control of Tn can 
lead to less out-of-specification samples and may reduce failures and trial-and-error 
approaches in up-scaling of freeze-drying processes. Primary drying times can be massively 
shortened when Tn is selected at lower super-cooling. However, new questions have to be 
answered. Although a variety of methods allow to freely select Tn, it is unknown if different 
methods, although inducing ice nucleation at the same product temperature, will result in a 
similar product with comparable ice crystal size and distribution. Ice crystal morphology, 
although documented in many studies, is very heterogeneous and description of ice crystals 
is not always uniform. More studies on the significance of ice crystal morphology (and not only 
size) may be useful. Furthermore, little is known about the impact of ice nucleation on 
relaxation times and long-term stability. In addition, the plurality of excipients may pose a 
challenge when Tn is comparably high and the state of freeze-concentration is prolonged. The 
freeze-drying process needs to be adapted regarding temperature/pressure conditions in 
primary and secondary drying to make best use of the controlled features of the frozen product. 
With potentially smaller specific surface area, increased secondary drying temperatures have 
to be considered. The near future will certainly bring up some interesting new experimental 
work with will further illuminate the freezing process of pharmaceuticals. 
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III.3 A NEW APPROACH TO ACHIEVE CONTROLLED ICE NUCLEATION OF SUPER-
COOLED SOLUTIONS DURING THE FREEZING STEP IN FREEZE-DRYING3 
III.3.1 INTRODUCTION 
Controlled ice nucleation of super-cooled solutions has recently attracted a lot of interest in the 
field of freeze-drying [1-4]. Ice nucleation is a stochastic event and the probability of 
spontaneous ice crystal formation is, among others, dependent on the presence of foreign 
particles [5]. Thus, ice nucleation becomes a major issue during scale-up from lab-scale to 
almost particle-free clean room production environment [6]. Controlling ice nucleation at a 
certain product temperature is expected to lead to a more uniform product since the degree of 
super-cooling and nucleation temperature is influencing product parameters, for example cake 
resistance [5], specific surface area and residual moisture [2]. Reduction of cake resistance is 
greatly reducing primary drying time [6] and therefore saves energy, time and money since 
primary drying usually is the longest step in a freeze-drying cycle. 
However, ice nucleation of super-cooled aqueous solutions is difficult to achieve. One method 
to achieve controlled nucleation is the “ice-fog” technology, introduced by Pikal et al [5]. A 
stream of cold nitrogen gas is released into the product chamber to freeze present water vapor.  
Ice crystals, passing into the super-cooled solution, induce ice nucleation. However, it takes 
up to five minutes until all vials are frozen. Currently, this technique is improved by 
depressurizing the product chamber before releasing the cold nitrogen into the chamber, 
resulting in a faster freezing of vials [3].  
Another recently published technique involves pressurizing the product chamber with an inert 
gas up to 2 bar over-pressure and quickly release the overpressure by evacuation, inducing 
instant ice nucleation [2]. However, the mechanism of ice nucleation is not fully understood. 
Moreover, this technique is rather expensive and is only applicable for freeze-driers which are 
capable to resist around 2 bars over-pressure and requires major technical changes to the 
freeze-drier.  
Besides those two methods there are further methods of minor commercial interest, for 
example electro-freezing [7], vacuum-induced surface freezing [8] and nucleation by 
ultrasound [9]. A review recently published summarizes all of the abovementioned techniques 
[4]. 
                                               
3
 This section was published as Geidobler, R., S. Mannschedel, and G. Winter, A new approach to 
achieve controlled ice nucleation of supercooled solutions during the freezing step in freeze-drying. 
Journal of Pharmaceutical Sciences, 2012. 101(12): p. 4409-4413. 
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In this article, we want to present a cheap and easy way to instantly induce ice nucleation that 
can be used in lab-scale and large-scale equipment without the use of liquid nitrogen and 
without any need for technical changes or hardware modifications. The procedure involves first 
a well-controlled depressurizing step and secondly, a re-pressurization through the venting 
valve of the condenser. With a condenser, having some water load, immediate nucleation in 
the vials takes place.  
III.3.2 MATERIALS AND METHODS 
III.3.2.1 MATERIALS 
Type 1 glass vials (DIN 2R and DIN 10R) were used throughout the study. Stoppers were 
provided by West Pharmaceuticals. High purified water (Purelab Plus, USF Elga, Celle, 
Germany) which is filtered through a 0.2 µm filter at the dispenser, was either used alone to 
be frozen or to prepare a 5 % (w/v) sucrose formulation (Boehringer Ingelheim, Germany). 
Experiments were carried out using a FTS Lyostar II (SP Scientific, Stone Ridge, USA) lab-
scale freeze-drier. To show transferability to other freeze-driers, an Epsilon 2-6D (Martin 
Christ, Osterode am Harz, Germany) lab-scale freeze-drier was also employed. Various 
amounts of vials were loaded into the freeze-driers to test scalability. The amounts of vials 
ranged from 9 to around 600 vials. 
III.3.2.2 INDUCTION OF ICE NUCLEATION 
The vials are loaded on to the freeze-dryer and are equipped with thermocouples (Type T, 
Newport Electronics, Deckenpfronn, Germany for the Lyostar II and PT100 temperature 
sensors, provided by Martin Christ for the Epsilon 2-6D) to monitor product temperature 
invasively. The shelves of the lyophilizer are cooled and the product is equilibrated to the 
desired product temperature. The freeze-dryer is then depressurized to a specified vacuum 
set point and immediately brought to atmospheric pressure using either the release valve of 
the Lyostar II or the drain valve of the Epsilon 2-6D which ventilates both systems via the cold 
condenser. During the re-pressurization, almost instant nucleation of the product takes place. 
The re-pressurization took place with an over-pressure of 0.8 bar of gaseous nitrogen which 
passed through a sterile 0.2 µm gas filter (Merck Millipore GmbH, Schwalbach, Germany) 
before entering the freeze-drier and takes around 5 minutes. The success of nucleation was 
determined by drawing the vials onto a Plexiglas pane and visual inspection. No additional 
nucleation could be induced by this method, as tests with super-cooled and agitated samples 
showed. 
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III.3.3 RESULTS 
III.3.3.1 INFLUENCE OF VACUUM SET-POINT 
During the experiments, a vacuum set-point of around 3.7 mbar (appr. 2.8 Torr) turned out to 
be the optimal vacuum set point to induce ice nucleation because on the one hand side it lead 
to successful nucleation of the super-cooled solutions and on the other hand did not 
significantly decrease product temperature, as lower vacuum set-points did, e.g. 1.87 mbar.  
It is also worth noting that, with this vacuum setting, we never accidently performed vacuum-
induced surface freezing, for which chamber pressure needs to be much lower (1 mbar [8]). 
Furthermore, we found that product temperature massively dropped by applying such low 
pressures as 1 mbar, which would result in non-controlled nucleation due to random 
evaporative cooling and warming due to nucleation, as shown in Figure III-5. 
 
Figure III-5: Temperature profile of 7 thermocouples during vacuum pull-down, placed inside 3 ml of water in DIN 10R vials.  
(a) Set-point of our method (3.7 mbar), (b) random ice-nucleation due to evaporative self-cooling.  
III.3.3.2 INFLUENCE OF CONDENSER ICE PRE-LOAD AND BATCH SIZE 
Loosely attached ice from the condenser, which is then blown into the product chamber during 
re-pressurization, is most likely the predominant mechanism by which ice nucleation is induced 
in our method. Ice loaded on the condenser is therefore an important parameter.  
Freezing of larger batches (more than ~ 300 ml, DIN 10R vials) could be performed starting 
with a defrosted, empty condenser. It is obvious that a large batch of vials and volume creates 
a large amount of water vapor in the product chamber which is transported to the condenser 
due to temperature and pressure gradients. During re-pressurization, in-situ generated ice 
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crystals from the condenser may be transferred back into the product chamber, inducing ice 
nucleation.  
Successful and reproducible nucleation even of very small batches (~10 vials 2R filled with 
1 ml solution) could be obtained by opening the condenser to the outside via a venting valve 
and a sterile filter and collecting ice from humid air. It is worth noting that without a cold 
condenser, nucleation of the vials was not possible. A rapid change in pressure alone hence 
is not responsible for ice nucleation. Furthermore, placement of a tray filled with 100 ml water 
into the drying chamber during vacuum pull down resulted also in successful, reproducible 
freezing of a small amount of vials (9 2R vials filled with 1 ml water).  
III.3.3.3 SUCCESS OF NUCLEATION 
While nucleation of very small batches was 100 % successful using the aforementioned 
methods, we could also scale up the method to 115 DIN 10R vials filled with 3 ml of water and 
594 DIN 2R vials filled with 1 ml of water or sucrose solution and achieved almost 100 % 
nucleation (see Table III-2).  
Figure III-7 shows a batch of 111 vials DIN 10R filled with 3 ml water which is nucleated at a 
product temperature of around -4.5 °C with a vacuum set-point of 3.7 mbar. Ice nucleation is 
fast and is finished within 4-5 seconds. Figure III-6 shows the pressure gauge readings and 
temperature profiles of 8 thermocouples placed in 5% Sucrose solution which was nucleated 
at around -5 °C.  
Table III-2: Nucleation rates for different loadings of the freeze-drier.  All experiments were carried out with the aforementioned 
settings: vacuum set-point 3.7 mbar, re-pressurize through condenser chamber. Product temperature varied between -4 °C and 
-6 °C. 
# Freeze-dryer loading Fill volume per 
vial [ml] 
Nucleation success [%] 
(n=3) 
1 9 Vials (2R) of water, pre-loaded condenser 1 100.00 ± 0.00 
2 115 Vials (10R) of water 3 99.43 ± 1.00 
3 594 Vials (2R) of 5 % sucrose 1 99.04 ± 1.67 
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Figure III-6: Temperature profile of 8 thermocouples placed inside a 5 % sucrose solution in the Lyostar II. Nucleation was 
induced at around -5 °C to - 6 °C 
A: 
0s 
 
B: 
2s 
 
C: 
4s 
 
Figure III-7: Ice nucleation in 111 vials 10R filled with 3 ml water, placed in the Lyostar II. Ice nucleation took place at around  
-4.5 °C and is finished after 4-5 seconds. 
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III.3.4 DISCUSSION 
The presented method allows to achieve successful and reproducible ice nucleation, 
independent of freeze-drier, vial size or fill volume. However, the mechanism is not yet fully 
understood. One theory is that the water vapor stream, generated during evacuation of the 
system, is frozen by cold nitrogen gas and blown back into the product chamber. However, our 
results point towards the assumption that loosely attached ice crystals, blown from the 
condenser during re-pressurizing the system via the condenser, are transported into the 
product chamber and lead to instant nucleation in all vials. Ice crystals can either be provided 
by allowing water to freeze on the condenser or by in-situ generation during vacuum pull down. 
At first glance, the transferal of ice crystals into all vials containing the product is expected to 
be quite difficult, however, due to the quick expansion of the gas and the resulting fast gas flow 
entering the chamber, it was no problem to nucleate 2R vials with a very small opening of the 
stopper. Another important variable during vacuum release is product chamber temperature. 
In theory, ice crystals cannot exist at a temperature warmer than 0.01 °C, according to the 
phase diagram of water. The product chamber in our freeze-drier, as measured with 
thermocouples, was approximately 8 °C even when shelves were equilibrated at -7 °C. 
However, since the gas entering the system has to pass the cold condenser of around -80 °C, 
it is significantly cooled down. Tests with a thermometer, placed at the opening of the drain 
valve with closed isolation valve showed that the condenser-exiting gas stream had a 
temperature of around -8 °C at atmospheric pressure. It is expected that the situation during 
re-pressurizing the system is far more complex, involving expansion of the gas, warming of 
gas due to emissivity of drier components and temperature changes due to possible melting 
of ice crystals. Furthermore, it is expected that also the condenser temperature is an important 
parameter; however, we could not test the method yet with a condenser temperature of around 
-50 °C. 
Another important factor is the vacuum set-point when using in-situ ice crystal generation. We 
found that 3.7 mbar (appr. 2.8 Torr) was successful for a product temperature of around  
-3 to -5 °C at the moment of nucleation, but it is expected that this needs to be re-adjusted if 
lower product temperatures (e.g., -10 °C) are desired. It is important to keep the balance 
between generating enough water vapour in the chamber and accompanying product 
temperature drop by evaporative self-cooling during vacuum pull down to avoid vacuum 
induced surface freezing. In addition, no boiling or bubbling of the solutions was observed with 
our method; however, as by pulling vacuum, a certain de-gassing of the samples is likely to 
happen. Re-pressurization of the samples did not blow up the solution in the vials. 
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III.3.5 OUTLOOK 
For successful application of this very simple method in large-scale production, it is necessary 
to validate and fix batch size and total volume to ensure that enough water vapor is generated, 
frozen and reproducible nucleation of all vials is achieved. It is easily possible to allow sterile, 
water vapor saturated air from the outside to freeze on the condenser. Of course, it is 
necessary to ensure that no contaminants are transferred into the product chamber when the 
gas stream is reversed during re-pressurization via the condenser compared to the regular use 
of the unit. Mass spectroscopy could be a valuable tool to check for contaminants like silicon 
oil droplets in the gas stream. At least for development purpose, we provide a very elegant and 
simple tool for everyone who wants to assure immediate and homogeneous nucleation in the 
entire batch during development or in the context of basic research on nucleation effects. 
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III.4 TRANSFERABILITY TO A PILOT-SCALE FREEZE-DRYER 
III.4.1 INTRODUCTION 
After development of the method to induce ice nucleation (see section III.3) in a laboratory 
scale freeze-dryer, we wanted to find out if the method is also scalable to larger freeze-dryers. 
We got access to use a pilot scale freeze-dryer with 2.5 m² shelf area. 
III.4.2 MATERIALS AND METHODS 
III.4.2.1 PREPARATION AND FILLING OF 5 % SUCROSE  
Sucrose (Suedzucker, AG, Mannheim, Germany) was dissolved in highly-purified water and 
filtered using a 0.2 µm PVDF sterile filter (Steritop, Merck Millipore, Darmstadt, Germany). An 
Inova VFVM 3031S (Optima Pharma, Schwaebisch Hall, Germany) was used to fill either 3 ml 
of the sucrose solution in 10R Vials or 1 ml in DIN 2R vials (Schott, Mainz, Germany). 1540 
vials (10R) and 3540 vials (2R) were prepared, resulting in a load of approximately 10 l. 
Approximately one third of each vial type was used without stopper, the rest was semi-
stoppered with lyophilization stoppers (West Pharmaceuticals, Lionville, PA, USA). 
III.4.2.2 LOADING OF THE FREEZE-DRIER AND INDUCTION OF ICE NUCLEATION 
The vials were loaded into a pilot-scale freeze-drier (Hof Sonderanlagen, Lohra, Germany) 
with a shelf area of 2.5 m² and a condenser capacity of 30 kg and were equilibrated at 1 °C 
overnight. Before nucleation, the shelf temperature was reduced to -5 °C to obtain 
approximately the same product temperature. The product temperature was monitored using 
built-in PT100 temperature probes. On each of the 4 shelves, one thermocouple was placed 
into a vial without stopper. Table III-3 shows the loading of the freeze-dryer shelves with the 
different types of vials as well as the placement of the temperature probes. 
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Table III-3: Schematics of loading of the freeze-dryer with two different vial types and use of stopper. TP=temperature probe 
was used in one vial of this tray. The cell values indicate tray number / vial type (2R, 10R) / use of stopper (yes, no). 
Shelf Pos. left middle right 
1 
back 1 / 2R / yes 12 / 2R / no / TP 1 4 / 2R / yes 
front 2 / 2R / yes 3 / 2R / yes 11 / 2R / yes 
2 
back 5 / 2R / yes 7 / 2R / yes 6 / 2R / yes 
front 8 / 2R / yes 13 / 2R / no / TP 2 10 / 2R / yes (3 rows no) 
3 
back 2 / 10R / yes 3 / 10R / yes 5 / 10R / yes 
front 1 / 10R / yes 11 / 10R / no / TP3 6 / 10R / yes 
4 
back 7 / 10R / yes 4 / 10R / yes 9 / 10R / no / TP4 
front 8 / 10R / yes/no (50:50) 14 / 2R / no, not full 10 / 10R / no 
 
Ice nucleation was induced by evacuation of the product and condenser chamber to 6.44 mbar 
which took approximately 10 minutes followed by re-pressurization via the cold condenser, 
which had a temperature of -58.4 °C and -50.6 °C, measured at two different positions. The 
product chamber was monitored using a Samsung NX100 digital camera and the condenser 
chamber was monitored using a Logitech Quickcam Pro 9000. After induction of nucleation, 
the vials were allowed to stand for additional 15 minutes on the lyophilizer shelves before 
unloading. After unloading, each tray was analysed visually and a picture was taken of the vial 
bottom by placing each tray on a transparent acrylic glass pane.  
III.4.3 RESULTS 
III.4.3.1 INDUCTION OF NUCLEATION 
After incubation of the samples over night at 1 °C, water condensed in the chamber which 
froze on the shelves when those were cooled to -5 °C. It was also observed that the vials 
without stoppers froze whereas only few samples with stoppers froze when they were 
equilibrated at -5 °C. In previous experiments, when only a partial load of the freeze-drier was 
employed, we found that a vacuum set-point of 3.7 mbar was a good compromise between 
product temperature drop and high success rates of the method. However, with a full load in 
the pilot scale freeze-drier, this set-point could not be reached within a short period of time, 
indicating massive generation of water vapour in the product chamber. Thus, re-pressurization 
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was performed at 6.44 mbar. The videos showed a dense ice fog with many small ice crystals 
for a period of approximately 4 seconds. Snapshots of the videos from condenser and product 
chamber are shown in Figure III-8 and Figure III-10. 
    
    
    
 
   
Figure III-8: Snapshots of the video taken from the product chamber. A very fine, dense ice fog is observable immediately after 
re-pressurization. The images represent a total time of approximately 4 seconds.  
The thermocouples employed to monitor product temperature showed that ice nucleation was 
successful, as shown in Figure III-9. However, thermocouple 3 showed earlier freezing during 
equilibration and is therefore not shown in the figure. The other sensors 1, 2 and 4 showed 
nucleation during the ice nucleation procedure. Usually, no nucleation takes place during 
equilibration at -5 °C, this may be due to different particle loads of the non-washed vials 
employed or the presence of frozen water on the shelves. 
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Figure III-9: Thermocouple and pressure traces of the nucleation induction in the pilot-scale freeze-dryer. The increase in 
product temperature simultaneous with pressure drop indicates ice nucleation.  
    
    
    
Figure III-10: Snapshots of the video taken from the condenser. At the time of re-pressurization, a fine and dense ice fog is 
visible which is blown upwards into the product chamber. The ice fog is visible for approximately 2 seconds.  
III.4.3.2 SUCCESS OF NUCLEATION 
All vials except 19 vials of the 2R type with stoppers from shelf 3 and 2 were frozen when they 
were unloaded from the freeze-drier. Vials, which are nucleated with the method employed, 
usually show turbidity due to ice crystals formed but the appearance of the surface of the 
ice/water mixture is almost the same as in solution. It could be observed that, especially with 
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the larger 10R vials without stoppers which froze earlier, a defective ice structure was formed 
due the vacuum pull down, as shown in Figure III-11. Some of the 10R vials with stoppers also 
froze earlier, and a defective ice structure could be observed. In tray 4, only 5 of 170 vials 
(appr. 3 %) and in tray, 14 of 172 vials (appr. 8 %) showed this defective ice structure. For the 
2R vials, almost all vials looked the same with no defective ice structures, indicating that 
probably all of the vials were nucleated with the method and did not freeze before or during 
the vacuum pull down. A representative picture of those vials is shown in Figure III-12. 
 
Figure III-11: Normal ice structure in 10R vials (left) and defective ice structure of the vials which were frozen before vacuum pull 
down (right). 
 
Figure III-12: Ice structure of DIN 2R vials with and without stoppers after ice nucleation. 
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III.4.4 DISCUSSION AND OUTLOOK 
We experienced some problems with earlier freezing of the vials during equilibration which 
was unexpected because usually, no ice nucleation is observable during equilibration at this 
rather high temperature. However, ice nucleation temperature can be increased by higher 
amount of particles present in the solution. Possible reason for earlier nucleation of the vials 
may be the use of non-washed vials, particles present in sucrose solution after filling in a non-
classified environment and transferral to the freeze-dryer. However, these sources of 
contamination can easily be excluded in class A clean rooms and no pre-nucleation is expected 
to be observable in those environments. These already nucleated vials showed a defective ice 
structure when the pressure was reduced to induce nucleation. Nevertheless, we could 
determine visually that only a small fraction of vials were frozen earlier and also most of the 
vials containing temperature probes did not nucleate during equilibration.  Our results show 
that the method developed with lab-scale freeze-dryers (Martin Christ Epsilon 2-6D, 0.21 m² 
shelf area and SP Scientifc Lyostar 3, 0.43 m² shelf area) is also transferrable to a larger pilot-
scale freeze-dryer with a shelf area of 2.5 m². We observed that, for a fully-loaded freeze-dryer, 
the vacuum set-point to generate enough water vapour in the chamber can be set higher than 
for partial loads. On the one hand, a higher vacuum set-point is beneficial to avoid boiling or 
puff-off of the liquid, on the other hand, for partial loads, the vacuum set-point needs to be 
determined depending on load of the freeze-dryer. With the fully-loaded freeze-dryer and the 
vacuum set-point of 6.44, we were able to create a very dense ice fog, which is important 
because in every vial at least one ice crystal has to be blown to induce ice nucleation. 
Furthermore, we also confirmed that, also with a slightly higher condenser temperature of 
approximately -54 °C, our method can be used. We therefore propose that, if not only shelf 
area is scaled but also other dimensions of the freeze-dryer, especially vacuum pull down rate, 
re-pressurization gas flow, ventilation cross-sections and valve sizes, our method may be used 
also in those larger freeze-dryers. Since the condenser chamber of those freeze-dryers is also 
cleaned and steam sterilized using the same CIP/SIP system as the product chamber and the 
ventilation gas is the same as used for backfill of the chamber after freeze-drying, we do not 
expect difficulties regarding sterility of the nucleated samples.  
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III.5 FREEZE-THAW STUDIES OF A MONOCLONAL ANTIBODY 
III.5.1 INTRODUCTION 
One of the stresses involved in freeze-drying is the generation of an ice-liquid interface which 
is transferred to an ice-glass interface. It is long known that proteins can denature at this 
interface during freezing and it is also known that, by increasing this interface, more protein 
can degrade (e.g. [1]). Controlled ice nucleation is known to change SSA and pore sizes, 
therefore also ice-liquid interfaces are expected to be changed. Hence, controlled nucleation 
can be a valuable tool to check protein degradation at these interfaces, since controlled ice 
nucleation allows not only selection of the nucleation temperature but also the post-nucleation 
hold time. In this study, the impact of different nucleation temperatures and post-nucleation 
temperatures on the stability of the model protein MabR1 was investigated. MabR1 was 
formulated at 1 mg/ml and 1.0 % Sucrose was added as a cryoprotectant. As controls, also 
formulations containing 0.6 % HPβCD and 0.004 % PS80 were added, because they already 
showed to protect MabR1 from interfacial degradation. 
III.5.2 MATERIALS AND METHODS 
III.5.2.1 MATERIALS 
A monoclonal antibody MabR1 was used as a model protein because it is sensitive to freezing-
associated stresses. The antibody was formulated in a 10.5 mM sodium-phosphate buffer at 
pH=6.4. Sodium phosphate monobasic and dibasic were bought from Merck, Darmstadt, 
Germany or Applichem, Darmstadt, Germany; Sodium chloride was purchased from BDH 
Problao (VWR, Ismaning, Germany) and sucrose was kindly provided from Suedzucker, 
Plattling, Germany. Polysorbate 80 was obtained from Sigma Aldrich Chemicals. 
Hydroxypropyl-beta-cyclodextrin (Cavasol HP Pharma) was kindly provided by Wacker 
Chemie AG, München. Germany. All chemicals were of analytical grade.  
III.5.2.2 PREPARATION OF FORMULATIONS 
Formulations were prepared by mixing concentrated stock solutions of excipients and protein 
and final dilution with buffer. For Sucrose, HPβCD, 10 % solutions were prepared and for 
polysorbate 80, a 1 % (w/v) solution was used. The final solutions were filtered through 0.22 µm 
PVDF filters (Pall Acrodisc) which were pre-rinsed with at least 5 ml of buffer to remove 
extractables, particularly surfactant residuals. 2.3 ml of filtered solutions were pipetted into DIN 
6R vials which were semi-stoppered and transferred to the freeze-dryer.  
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III.5.2.3 INDUCTION OF ICE NUCLEATION AND THAWING EXPERIMENT 
The experiments were performed in an FTS Lyostar 2 (SP Scientific, Stone Ridge, NY, USA). 
The vials were loaded into the freeze-drier and equilibrated to the desired product temperature 
and ice nucleation was induced with our published method [2]. Due to only a small amount of 
samples which were subjected to the nucleation procedure, the condenser had to be pre-
loaded with 10 ml of high-purified water. Subsequently, the freeze-dried was depressurized to 
3.7 mbar and re-pressurized via the cold condenser. The samples were held for the desired 
amount of time at the shelf temperature and after that time span, the shelf temperature was 
reduced to -50 °C with a ramp speed of 2 °C/min. Samples were equilibrated for at least 1 h at 
-50 °C and then thawed in a water bath of 25 °C. 
III.5.2.4 TURBIDITY 
The turbidity of samples was measured using a Hach Lange Nephla nephelometer (Hach 
Lange GmbH, Düsseldorf, Germany). Scattered light of λ = 860 nm laser is detected at an 
angle of 90 ° and the result is given in FNU (Formazine nephelometric units). 1.9 ml were 
pipetted in pre-rinsed turbidity glass cuvettes with a flat bottom and placed into the device. 
Measurement was performed twice with a 90 ° turn between measurements.  
III.5.2.5 LIGHT OBSCURATION 
Subvisible particles were determined using a PAMAS SVSS-35 particle counter (PAMAS - 
Partikelmess- und Analysesysteme GmbH, Rutesheim, Germany) equipped with an HCB-LD-
25/25 sensor which has a detection limit of approximately 120,000 particles > 1 µm per ml. 
The rinsing volume was 0.5 ml and was followed by three measurements of 0.3 ml. Before 
each measurement, the system was rinsed with highly purified water until the total particle 
concentration was less than 100 per ml and no particles larger than 10 µm were present in the 
measurement cell. The samples were analyzed in the turbidity cuvettes. Data collection was 
done using PAMAS PMA software and particle diameters in the range of >1 µm to 200 µm 
were determined. All results are given in cumulative particles per milliliter.  
III.5.2.6 ASYMMETRICAL FLOW-FIELD-FLOW FRACTIONATION (AF4) 
An orthogonal method to size exclusion chromatography is asymmetrical flow-field-flow 
fractionation. Protein fragments, monomer as well as higher molecular aggregates are 
separated by a liquid cross flow combined with a parabolic channel flow. A Postnova AF2000 
system (Postnova GmbH, Landsberg am Lech, Germany) was used for separation equipped 
with a PN 1122 pump, a PN 5300 autosampler. A Shimadzu SPD 10 UV detector was used to 
monitor protein absorption at λ = 280 nm. Furthermore, the system is equipped with a PN 3150 
refractive index detector and a PN 3620 or a Wyatt miniDawn MALLS detector. A spacer of 
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500 µm was used. For MabR1, A buffer with 10 mM sodium phosphate and 150 mM sodium 
chloride was used. Approximately 30 µg were injected into the separation channel equipped 
with a regenerated cellulose membrane (RC) with a cut off of 10 kDa and focused for 4 min 
with an injection flow of 0.2 ml/min and a cross flow of 2.0 ml/min. Subsequently, protein 
species were separated with a constant cross-flow of 2.0 ml/min and a detector flow of 1.0 
ml/min for 25 minutes. The cross flow is reduced to 0 ml/min within 5 minutes and elution is 
continued for additional 20 minutes at a detector flow of 1.0 ml/min. 
III.5.3 RESULTS 
III.5.3.1 SUBVISIBLE PARTICLES AND TURBIDITY 
The nucleation temperature Tn and also the isothermal hold time post-nucleation had an impact 
on subvisible particle formation and turbidity of MabR1. Subvisible particles and turbidity 
increased with decreasing nucleation temperature from -4 °C and -6 °C to -10 °C and 
decreased with prolonged isothermal hold from 5 minutes to 2h. When polysorbate 80 or 
HPβCD was added, no increase in subvisible particles and turbidity was observed. The ramp 
frozen MabR1 showed the highest amount of subvisible particles and turbidity, as shown in 
Figure III-13. 
 
Figure III-13: Results from light obscuration and turbidity for nucleation experiments of MabR1 formulated with sucrose. The °C 
value indicates the nucleation temperature and the time span indicates post-nucleation isothermal hold.  
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III.5.3.2 ASYMMETRICAL FLOW-FIELD-FLOW FRACTIONATION 
It was further checked if the various freezing protocols had an impact on the relative amount 
of protein species, which were detected with AF4. As shown in Figure III-14, only minor 
changes were detectable for protein species as detected with AF4 for MabR1.  
 
Figure III-14: Results from AF4 for nucleation experiments of MabR1 formulated with sucrose.  
III.5.4 DISCUSSION 
Since both, nucleation temperature and isothermal hold time, had a small influence on 
subvisible particle concentrations, controlled nucleation may be a valuable tool to study protein 
aggregation at the ice-liquid interface. While the nucleation temperature influences ice crystal 
size and distribution, the rate of ice crystal growth, influenced by the shelf temperature and 
hold time, seems also to affect protein degradation. Furthermore, the long isothermal hold 
post-nucleation also allows Ostwald ripening of ice crystals. Interestingly, the slower the ice 
crystal growth, the lower the subvisible particles were. These findings suggest that protein 
unfolding takes place at the end, when crystal growth is complete and the amount is 
determined by final interface area. However, it has to be further investigated if a freezing 
procedure, at which the protein is held for a long period of time at a high temperature above 
Tg’ is negatively influencing protein stability with respect to physical and chemical degradation.  
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III.6 INFLUENCE OF THE FREEZING STEP ON THE PROPERTIES OF TWO PLACEBO 
MODEL FORMULATIONS 
III.6.1 INTRODUCTION 
As stated in the literature, the ice nucleation temperature is the most important parameter 
influencing ice crystal size, primary drying time and product quality attributes like residual 
moisture or specific surface area [1]. However, as observed in the previous chapter, also the 
isothermal hold time post-nucleation has an impact on protein stability. This study was 
conducted to elucidate the influence of nucleation temperature and isothermal hold time on the 
specific surface area, residual moisture, solid state properties (amorphous vs. crystalline) and 
reconstitution time of two model formulations, 5 % Sucrose and 3.75 % Mannitol + 1.25 % 
Sucrose. 
III.6.2 MATERIALS AND METHODS 
III.6.2.1 MATERIALS 
Sucrose was kindly provided by Suedzucker (Suedzucker, Plattling, Germany) and Mannitol  
was purchased from Boehringer Ingelheim (Ingelheim am Rhein, Germany).  
III.6.2.2 PREPARATION OF FORMULATIONS 
5 % Sucrose or 3.75 % Mannitol and 1.25 % Sucrose were dissolved in highly-purified water 
(USF Elga) and filtered through 0.22 µm celluloseacetate syringe filters (VWR, Ismaning, 
Germany). 2.3 ml of each formulation was transferred into DIN 6R vials (MGlas AG, 
Muennerstadt, Germany) and subjected to the different freezing variations.  
III.6.2.3 INDUCTION OF ICE NUCLEATION AND FREEZE-DRYING PROCESS 
The vials were equilibrated at the desired nucleation temperature and ice nucleation was 
induced using our previously published method [2]. Due to the small batch size of 
approximately 24 vials for each freezing procedure, the condenser was pre-loaded with water 
by spraying 10 ml of highly-purified water on the condenser coils before pulling of vacuum. The 
product temperature was monitored using Type T thermocouples (Newport electronics, 
Deckenpfronn, Germany) throughout the whole process. After induction of nucleation, the shelf 
temperature was held for various time spans and then cooled to -50 °C with 1 °C/min. Samples 
were unloaded from the freeze-drier using a pre-cooled shelf and transferred to a deep-freezer 
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with -80 °C on dry ice. Table III-4 shows the freezing procedures for both investigated 
formulations.  
Table III-4: Freezing procedures for both formulations of 5 % Sucrose and 3.75 % Mannitol + 1.25 % Sucrose.  
Nucleation temperature Isothermal hold post-nucleation 
-4 5 minutes / 30 minutes / 90 minutes 
-7 5 minutes / 30 minutes / 90 minutes 
-10 5 minutes / 30 minutes / 90 minutes 
Ramp 1 °C/min 
Ramp + Annealing Increase of temperature to -19 °C; hold for 6 h; cool temperature to -50 °C 
 
After all vials had been treated with the respective freezing procedure, they were transferred 
to the freeze-drier, a FTS Lyostar 3. Primary drying was carried out at a pressure of 0.067 mbar 
and a shelf temperature of -27 °C. These rather conservative drying conditions were chosen 
to avoid any changes in ice crystals or pore volume due to microcollapse in the samples during 
drying. After primary drying was finished, the shelf temperature was increased to 30 °C with a 
ramp of 0.1 °C/min and this temperature was held for 6 h. 
III.6.2.4 RESIDUAL MOISTURE 
To determine residual moisture of collapsed freeze-dried and spray-dried samples, the Karl-
Fischer direct injection method with methanol was used. Between 10 and 50 mg of sample 
aliquots were prepared in a glove box with a relative humidity of less than 10 %, filled into DIN 
2R Vials and crimped. Approximately 2.5 ml of methanol with very low water content was 
added to the sample for extraction of water. Subsequently, the sample was placed in an 
ultrasonic bath for 10 minutes. An aliquot of 1 ml was injected into a coulometric Karl Fischer 
titrator (737 KF Coulometer, Metrohm, Filderstadt, Germany). The results are calculated in 
relative water content (m/m). 
III.6.2.5 SPECIFIC SURFACE AREA 
Specific surface area of lyophilizates was determined using Brunauer-Emmet-Teller krypton 
gas adsorption in a liquid nitrogen bath at 77.3 K (Autosorb 1, Quantachrome, Odelzhausen, 
Germany). Samples were gently crushed with a spatula and weighed into glass tubes. 
Outgassing was performed at least for 2 h at room temperature and an outgassing test was 
performed before every measurement. An eleven point gas adsorption curve was measured, 
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covering a p/p0 ratio of appr. 0.05 to 0.30. Data evaluation was performed according to the 
multipoint BET method fit of the Autosorb 1 software. 
III.6.2.6 X-RAY POWDER DIFFRACTION 
X-Ray diffraction (XRD ) measurements of lyophilized powders were performed on a STOE 
powder diffractometer in transmission geometry (Cu Kα1, λ = 1.5406 Å) equipped with a bent 
image plate detector. Samples were placed on a multi-sample holder on cellulose filter paper. 
A blank run was subtracted from every sample. 
III.6.2.7 SCANNING ELECTRON MICROSCOPY 
The lyophilized powder was gently crushed and placed on Leit-Tabs (Plano GmbH, Wetzlar, 
Germany), carbon sputtered under vacuum and visualized by a Joel JSM-6500F field emission 
scanning electron microscope (Joel Inc.,Peabody, USA). 
III.6.2.8 RECONSTITUTION TIME 
Water was added to the lyophilized product and the time needed to obtain a clear solution was 
noted. 
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III.6.3 RESULTS 
III.6.3.1  LYOPHILIZATION PROCESS 
For the different formulations and freezing protocols, the product temperature (Tp) during 
steady-state sublimation was determined by thermocouples. The product temperature allows 
to qualitatively estimate the product resistance. A lower product resistance leads to higher 
sublimation rates and lower product temperatures. As shown in Table III-5, controlled 
nucleation at any temperature lead to slightly lower product temperatures compared to ramp-
frozen samples and ramp-frozen samples but annealed samples. This tendency is more 
pronounced for the sucrose formulations whereas with the mannitol-sucrose combinations, the 
differences were smaller. Furthermore, it can be observed, that an increase in post-nucleation 
hold time could further lower Tp. This is also more pronounced for the formulation of 5 % 
sucrose. 
Table III-5: Product temperature (Tp) during steady state primary drying of both formulations for various freezing protocols.  
Nucleation temperature 
[°C] 
Isothermal hold post 
nucleation Tp 5 % Sucrose 
Tp 3.75 % Mannitol + 
1.25 % Sucrose 
-4 5 -40.8 -40.3 
 30 - - 
 90 -42.0 -39.6 
-7 5 - - 
 30 -39.8 -40.1 
 90 - - 
-10 5 -40.5 -40.3 
 30 -40.5 -40.5 
 90 -42.5 -41.3 
Ramp -37.5 -39.1 
Ramp + Annealing -38.0 -39.7 
 
III.6.3.2 X-RAY POWDER DIFFRACTION 
As shown in Figure III-15, 5 % sucrose remained fully amorphous with no peaks in x-ray 
diffractogram, independent of freezing protocol. In contrast, the mannitol-sucrose 
combinations showed distinct peaks in the diffractograms, independent on freezing procedure, 
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which indicates crystallization of mannitol (see Figure III-16). The sample which was nucleated 
at a product temperature of -10 °C and held for 5 minutes (orange line) showed peaks at 9.6 
and 17.9 ° 2-theta which both can be attributed to mannitol hydrate [3]. The other formulations 
showed distinct peaks at 9.7 and 20.4 but no peaks at 9.6 and only a very small peak at 17.9 ° 
2-theta. These results suggest that in most cases, δ-mannitol is the predominant form, but 
small amounts of mannitol-hydrate are still present.  
 
Figure III-15: Xray-powder diffraction patterns for 5 % Sucrose formulations. 
 
Figure III-16: Xray-powder diffraction patterns for Mannitol-Sucrose formulations. 
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III.6.3.3 SPECIFIC SURFACE AREA AND RESIDUAL MOISTURE 
Figure III-17 shows the specific surface area (SSA) and residual moisture of the 5 % Sucrose 
formulation with the different freezing protocols. Different SSAs and residual moistures were 
obtained for the freezing protocols; however, some combinations of nucleation temperature 
and isothermal hold post-nucleation lead to similar residual moisture values and SSAs. In 
general, SSAs were lower for all controlled-nucleation samples compared to ramp-frozen 
samples and ramp-frozen and annealed samples. A trend to lower SSAs and higher residual 
moistures could be observed for one nucleation temperature and increasing hold time. This is 
true for all nucleation temperatures; however, with decreasing nucleation temperatures, higher 
SSAs and lower residual moistures were obtained. Consequently, the lowest SSA obtainable 
was with the highest nucleation temperature of -4 °C and the longest hold time of 90 min. Ramp 
frozen samples, with or without annealing, showed the highest SSAs, however, the annealed 
samples showed slightly higher residual moistures. 
 
Figure III-17: Specific surface area and residual moisture for 5 % Sucrose formulations and the performed freezing protocols. 
A different picture was obtained for the combination of Mannitol and Sucrose. While SSAs 
were in general higher than with the sucrose formulation, standard deviations for SSA and 
residual moisture were quite high for those formulations and trends were not easily visible. 
Controlled nucleation lead to slightly smaller SSAs than ramp or ramp followed by annealing.  
The results imply that by crystallization of mannitol, some of the effects of controlled nucleation 
can be mitigated. At least, homogeneity of those samples as indicated by standard deviations 
is not as good as with the fully amorphous sucrose formulation. 
Chapter III: Controlled ice nucleation in pharmaceutical freeze-drying 
205 
 
Figure III-18: Specific surface area and residual moisture for 3.75 % Mannitol + 1.25 % Sucrose formulations and various 
freezing protocols. 
III.6.3.4 SCANNING ELECTRON MICROSCOPY 
Differences in scanning electron microscopy were observed for both samples and freezing 
protocols. Whereas with both formulations, small pores and a quite dense structure was 
observed for ramp frozen as well as ramp frozen and annealed samples, the samples which 
were nucleated at higher temperatures showed bigger pores. This was most pronounced for 
the amorphous samples of sucrose, as shown in Figure III-19. Figure III-20 shows SEM-
pictures of Mannitol/Sucrose mixtures. Differences in pore sizes of ramp frozen and controlled 
nucleated samples are also visible, however, these differences were less pronounced than 
with sucrose based formulations, further indicating that, by mannitol crystallization, the impact 
of freezing protocol is slightly mitigated.  
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Figure III-19: SEM pictures of various sucrose samples. All pictures were taken with a magnification of 50 x.  
-4 °C, 5min (A); -4 °C, 90 min (B); -10 °C, 5 min (C); -10 °C, 30 min (D); Ramp-frozen (E); Ramp + Annealing (F). 
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Figure III-20: SEM pictures of various mannitol/sucrose samples. All pictures were taken with a magnification of 50 x.  
-4 °C, 5 min (A); -4 °C, 90 min (B); -10 °C, 5 min (C); -10 °C, 90 min (D); Ramp-frozen (E); Ramp + Annealing (F). 
III.6.3.5 RECONSTITUTION TIME 
All samples were fully reconstituted within 10 seconds and no differences between the samples 
were observable. The changes in SSA generated by controlled nucleation did not, at least not 
in this scale, influence reconstitution time. 
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III.6.4  DISCUSSION 
As observed, both, the ice nucleation temperature and the isothermal hold time had an 
influence on SSA and residual moisture as well as on crystallinity of the solid. The 
Mannitol/Sucrose mixture, with crystalline mannitol and amorphous sucrose showed bigger 
standard deviations than the fully amorphous formulation of sucrose. Furthermore, during the 
freezing process as conducted in our study, mannitol hydrate was obtained, which is usually 
avoided in freeze-drying [3].  Neither Tn nor isothermal hold time had an influence on 
reconstitution times. No evidence of increased homogeneity of controlled nucleated samples 
was observed compared to ramp frozen samples. 
III.6.5 CONCLUSION 
By making use of controlled ice nucleation, not only the ice nucleation temperature can be 
selected but also the post-nucleation hold time, if desired, can be controlled as well as the 
ramp post nucleation. In this study, the impact of the post-nucleation hold time was investigated 
for two model formulations, 5% Sucrose and a mixture of mannitol and sucrose 3:1 with 5 % 
solids in total. It was found that for sucrose a long post nucleation hold time further decreased 
SSA compared to a short period, possibly by fostering Ostwald ripening of ice crystals. 
Basically, this trend was observed for all nucleation temperatures studied. For the mannitol 
mixtures, no distinct correlations were observed, indicating that mannitol crystallization 
somehow interferes with ice crystallisation. To our knowledge, this is the first study which 
shows that also the post-nucleation hold time can influence the final product quality attributes 
and not only the ice nucleation temperature itself, which is often stated in literature. However, 
as stated in section III.5, freeze-concentration takes place after nucleation and an API must 
withstand this stress if a long post-nucleation isothermal hold is desired.  
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III.7.1 INTRODUCTION 
Controlled ice nucleation in the field of freeze-drying has become of major interest in the 
scientific and industrial community because of the recent advancements of methods [2, 4-6] 
and the ability to control the ice nucleation temperature, Tn. The ice nucleation temperature 
affects the average ice crystal size and distribution; higher nucleation temperatures lead to 
larger ice crystals [7]. During sublimation, these large ice crystals generate large pores which 
reduce the water vapour resistance of the cake, also called product resistance, Rp [8]. Hence, 
primary drying times are greatly reduced with high nucleation temperatures [1]. Furthermore, 
the ice nucleation temperature interrelated ice crystal size not only influences primary drying 
times but affects also other product quality attributes, for example residual moisture and 
specific surface area [9]. 
Some freeze-dried protein pharmaceuticals, especially monoclonal antibodies, require 
administration of high doses > 100 mg [10]. These APIs are usually formulated at high 
concentrations and will be freeze-dried if an acceptable shelf-life time cannot be achieved with 
a liquid formulation. Freeze-drying has also been used as a simple method to create even 
higher concentrated antibody solution by reconstituting the lyophilized cake in e.g. the half of 
the volume. Upon administration, a diluent is added and the lyophilized cake dissolves. One 
of the challenges of those highly-concentrated freeze-dried products is their comparable long 
reconstitution time [10] which can last for up to 1 hour, whereas lower concentrated 
formulations yield an injectable solution within less than 1 minute [11], even for collapsed 
lyophilizates [12] .  
Rehydration of a lyophilized cake includes the following steps: (1) wetting of the lyophilized 
cake with displacement of gas in pores, (2) hydration of the solid. These steps are expected 
to be influenced by product attributes, e.g. pore sizes and specific surface area [10].  
The aim of our study was to use our previously developed method to induce ice nucleation in 
highly concentrated protein solutions. Furthermore, we want to study if controlled nucleation 
of highly concentrated protein formulations of bovine serum albumin and a monoclonal 
antibody also shows positive effects on primary drying time and on reconstitution time of these 
lyophilizates.  
III.7.2 MATERIALS AND METHODS 
III.7.2.1 MATERIALS AND PREPARATION OF FORMULATIONS 
Bovine serum albumin (BSA) was purchased from Fluka chemicals (Sigma-Aldrich, Munich, 
Germany) as a lyophilized powder.  A monoclonal antibody (mAb) was kindly provided by 
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Roche Diagnostics (Penzberg, Germany). Sucrose was kindly provided from Suedzucker 
(Suedzucker, Plattling, Germany). BSA was formulated at 10 mg/ml, 100 mg/ml and 
193.9 mg/ml with 5% sucrose (w/v) in a 10 mM sodium-phosphate buffer, pH=7.4. The 
antibody was formulated in 20 mM histidine buffer with 5 % trehalose at a concentration of 
10 mg/ml and 40 mM histidine buffer and 10 % trehalose at a concentration of 161.2 mg/ml, 
both at pH=5.4. The concentration of all formulations was checked after filtration through 0.22 
µm PVDF membrane filters (Millipore, Schwalbach, Germany) using a Nanodrop 2000 UV 
photometer (Thermo Scientific, Wilmington, USA). 1.0 ml of all BSA formulations, 0.8 ml of the 
low-concentrated mAb and 0.370 ml of the high-concentrated mAb were filled in DIN 2R tubing 
vials (MGlas AG, Muennerstadt, Germany) and semi-stoppered with lyophilization stoppers 
(kindly provided by West Pharmaceuticals, Eschweiler, Germany). The vials were arranged on 
a lyophilization tray and surrounded with two rows of 5% (w/v) sucrose shielding vials. 
III.7.2.2 FREEZING PROTOCOL AND FREEZE-DRYING PROCESS 
The samples were subjected to one of the following freezing protocols in a FTS Lyostar 3 (SP 
Scientific, Stone Ridge, USA):  
Controlled nucleation (CN): Controlled ice nucleation was performed as previously published 
by our group [2]. To increase water vapour amount in the chamber and condenser coils, a tray 
of 100 ml high-purified water was placed into the lyophilizer and in addition, 10 ml of water was 
sprayed on the condenser coils before triggering nucleation at a product temperature of -5 °C. 
After nucleation, the samples were thermally treated at -5 °C for 120 minutes. Complete 
solidification was achieved by ramping down to -60 °C with a ramp of 1°C/min. The product 
temperatures were monitored with type T thermocouples (Newport Electronics, Deckenpfronn, 
Germany).  
Ramp-freezing (Ramp): The samples were equilibrated at 5 °C for 30 minutes followed by 
ramping down the shelf with 1°C/min to -60 °C. 
Pre-cooled-shelf method (PCS): The freeze-dryer shelves were pre-cooled to -60 °C and the 
samples were placed on the cool shelves. The enormous temperature difference between 
liquid and shelf leads to nucleation of a small fraction of liquid at the bottom of each vial and 
crystallization proceeds from bottom up (directional solidification). Due to lack of material, this 
freezing method was not performed with the mAb formulation.  
T-type thermocouples were used to determine primary drying times during the freeze-drying 
process which was carried out at a pressure of 0,066 mbar and a shelf temperature of  
-22 °C. These rather conservative process conditions with low product temperatures were 
chosen to avoid changing the ice crystal size and distribution by an aggressive drying process 
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with possible microcollapse of the amorphous samples. Secondary drying was carried out at 
30 °C for 6h with a 0.1 °C/min ramp. After completion of secondary drying, samples were 
stoppered at approximately 700 mbar nitrogen atmosphere. 
III.7.2.3 DETERMINATION OF RECONSTITUTION TIMES 
For determination of reconstitution times, no generally accepted protocol is available. 
Therefore, we subjected the samples to one of the two protocols: 
Setup 1: Add the desired amount of water with a pipette to the lyophilized cake and let the 
sample sit without agitation.  
Setup 2: Add the desired amount of water to the lyophilized cake and put the vial on an orbital 
shaker (VWR, Ismaning, Germany) at a speed of 400 rpm. 
The time until a clear solution was obtained was recorded as the reconstitution time. 
III.7.2.4 RESIDUAL MOISTURE 
To determine residual moisture of the high concentration samples, the Karl-Fischer direct 
injection method with methanol was used. Approximately 2.5 ml of anhydrous methanol was 
added to the sample for extraction of water. Subsequently, the sample was placed in an 
ultrasonic bath for 10 minutes. An aliquot of 1 ml was injected into a coulometric Karl Fischer 
titrator (737 KF Coulometer, Metrohm, Filderstadt, Germany). The results are calculated in 
relative water content (m/m). 
III.7.2.5 SPECIFIC SURFACE AREA 
Specific surface area of high-concentrated lyophilizates was determined using Brunauer-
Emmet-Teller krypton gas adsorption in an liquid nitrogen bath at 77.3 K (Autosorb 1, 
Quantachrome, Odelzhausen, Germany). Approximately 100 mg to 200 mg of each sample 
was gently crushed with a spatula and weighed into glass tubes. Outgassing was performed 
at least for 2 h at room temperature and an outgassing test was performed before every 
measurement. An eleven point gas adsorption curve was measured, covering a p/p0 ratio of 
appr. 0.05 to 0.30. Data evaluation was performed according to the multipoint BET method fit 
of the Autosorb 1 software. 
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III.7.3 RESULTS 
III.7.3.1 LYOPHILIZATION PROCESS 
Controlled ice nucleation at high product temperatures followed by a long isothermal hold post-
nucleation has shown to yield the lowest achievable specific surface area (unpublished data 
by the authors). With a constant porosity of the freeze-dried cake, this freezing procedure 
results in large ice crystals and pores. Due to the resulting low product resistance, Rp, the 
product temperature during primary drying is slightly lower for the controlled nucleation 
samples compared to the other two sets of samples as shown in Figure III-21 and Table III-6. 
The differences in product temperatures become larger when higher concentrations of protein 
and excipient are employed. Furthermore, primary drying is finished earlier for the controlled-
nucleated samples, as shown in Table III-6.  
 
Figure III-21: Thermocouple and pressure readings from the freeze-drying run of samples with 100 mg/ml of BSA. The arrows 
indicate the product temperature at 7 h of primary drying. CN = controlled nucleation, PCS = pre-cooled shelf. 
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Table III-6: Product temperatures (Tp) and primary drying duration (d) of the three different freezing protocols for all protein 
concentrations. 
 Controlled nucleation Ramp freezing Pre-cooled shelf 
 
Product 
temperature 
(Tp) 
Primary drying 
duration  
(d)* 
Tp d Tp d 
BSA 10 mg/ml -39.8 °C 23.4 h -37.57 °C 27.6 h - - 
BSA 100 mg/ml -37.63 °C 25.0 h -34.53 °C 34.5 h -35.30 °C 34.5 h 
BSA 193.9 mg/ml -38.65 °C 24.2 h -35.15 °C 32.6 h -33.73 °C 32.6 h 
mAb 10 mg/ml -37.63 °C 22.9 h -35,03 °C 27,6 h - - 
mAb 161.2 mg/ml -33.21 °C 20.0 h -30.50 °C 25.0 h - - 
*: Primary drying time was determined from thermocouple readings. Tp was determined after 7 h of 
primary drying.  
 
III.7.3.2 SPECIFIC SURFACE AREA AND RESIDUAL MOISTURE 
It was found that residual moisture depends mainly on specific surface area and drying 
temperature in the secondary drying step [13]. As expected, the controlled nucleated samples 
showed a significant lower specific surface area than the ramp frozen samples, which also 
translates into higher residual moistures after secondary drying. The pre-cooled shelf method 
leads to similar specific surface areas and residual moistures than the ramp freezing protocol, 
as shown in Figure III-22. This is true for both concentrations of BSA. All samples had residual 
moistures of less than 1 %. As expected, the controlled nucleated samples with the lower SSA 
have higher residual moistures (0.5-0.8 %) compared to the samples processed differently 
(0.2-0.4 %). Those small differences on an overall very low level are not considered to as 
relevant for stability and reconstitution time.  
Chapter III: Controlled ice nucleation in pharmaceutical freeze-drying 
214 
 
Figure III-22: Specific surface area and residual moisture for BSA at both concentration and the monoclonal antibody. All 
experiments were performed in triplicates except for the mAb formulation where SSA was n=1 and residual moisture was 
determined n=2. 
III.7.3.3  RECONSTITUTION TIME AND BEHAVIOUR 
For both proteins, no measurable difference was observed when they were formulated at 
10 mg/ml and reconstitution was finished within 10 seconds. When BSA was formulated at 100 
mg/ml, the reconstitution times were all below 10 minutes with a reconstitution volume of 0.91 
ml and a clear impact of the freezing protocol was detectable, as shown in Figure III-23. 
Throughout all experiments, the samples which were nucleated at -5 °C showed faster cake 
dissolution than the ramp frozen samples. Also, the pre-cooled shelf samples in average 
showed faster reconstitution times independent of the reconstitution protocol. It is also 
important to note that the controlled nucleated samples showed much less foaming during 
rehydration than the samples with the other two freezing protocols, which simplifies 
identification of complete dissolution. It can be speculated that larger pores are beneficial for 
gas displacement from the cake.  Slightly different results were obtained with BSA at 
193.9 mg/ml. When those samples were rehydrated with 0.80 ml of water and were subjected 
to reconstitution setup 2 with constant agitation, it was observed that the controlled nucleation 
cakes seemed to have a head start, indicated by a faster yellowing of the liquid, however, in 
the end, reconstitution were only slightly shorter with controlled nucleation and pre-cooled shelf 
than with ramp freezing. When the double amount of water was added to the lyophilized cakes, 
a distinct difference was observable between the different freezing protocols. Dissolution of 
controlled nucleated samples was almost two-fold faster than ramp frozen samples, and also 
pre-cooled shelf samples showed slightly shortened reconstitution times. Finally for the 
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monoclonal antibody, the controlled nucleation method lead to a remarkable and drastic 
reduction in reconstitution times compared to the ramp frozen samples.  
 
Figure III-23: Reconstitution times determined for the different freezing protocols and reconstitution setups for all formulations. 
III.7.4 DISCUSSION AND OUTLOOK 
With this study, we could show that controlled ice nucleation with our previously published 
simple method is also applicable to highly concentrated protein formulations. Our results show 
that controlled ice nucleation can speed up primary drying of high-concentrated protein 
formulations and can have a positive impact on reconstitution times of such lyophilizates.  
While the reduction of reconstitution times was observable already at 100 mg/ml of the model 
protein BSA, the absolute reduction in reconstitution times was approximately 2 minutes. At 
the high concentration of 193.9 mg/ml, the effect was only visible when 1.6 ml instead of 0.8 
amount of water was added which results in a final concentration of approximately 120 mg/ml. 
For the antibody formulation, the reduction in reconstitution time was significant and a total 
reconstitution time of less than 5 minutes instead of 15 minutes was observed.  As a 
consequence, it is proposed that controlled nucleation may improve wetting of the cake and 
displacement of gas due to the larger pores and therefore speeds up dissolution of the solid 
cake. However, if protein concentrations approach the solubility limit, hydration of protein 
molecules is the velocity-determining step and wetting of the cake becomes less important for 
complete dissolution. In this case, reconstitution times may not be affected much by the 
freezing protocol. The pre-cooled shelf method also showed a positive influence on 
reconstitution times for BSA but was inferior to controlled nucleation.  
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Controlled ice nucleation has the potential to become an even more important method in 
freeze-drying because of the applicability on highly-concentrated protein formulations. 
Furthermore, for these formulations, not only economic benefits are possible but also product 
quality with respect to reconstitution times can be improved. In a next step, controlled 
nucleation can be combined with aggressive short primary drying for highly-concentrated mAb 
solutions, leading most likely to drastic economic savings that go along not with compromised 
but even improved product features. 
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III.8 THE MPEMBA EFFECT IS NOT APPLICABLE TO VIAL FREEZE-DRYING 
III.8.1 INTRODUCTION 
While making ice cream out of sugared milk in a refrigerator, Erasto Mpemba noticed that the 
milk, that had been boiled before in a container froze faster than when cooled from ambient 
temperature [1]. Later, he and Dr. Osbourne experimented with water and obtained similar 
results, which were published in 1969, thus establishing the term “Mpemba effect” [1]. Today, 
many possible explanations for this phenomenon are discussed. First, due to initial preheating, 
evaporation of water is increased, causing both mass loss and surface cooling [2]. Although 
the extent of evaporation is not sufficient for a full explanation, the exclusion of evaporation by 
covering the water surface led to elimination of the Mpemba effect [1]. Theoretical approaches 
[3], different behavior of either gaseous [4] or solid impurities [5] inside the cold and hot tap 
water are also discussed as possible explanations. For D. Auerbach [6] and J. Brownridge [7] 
however, the Mpemba effect occurred because of a lower degree of super-cooling for initially 
preheated water. Super-cooling in aqueous solutions describes the temperature difference 
between the thermodynamic freezing point and the actual ice nucleation temperature [8]. For 
pure water, super-cooling of 20 K is often observed [8]. Although the effect has long been 
known, it was never resolved completely and thus, a price of 1000 pounds was offered  by the 
royal society of chemistry in England last year.  
Controlled nucleation and the possibility to induce ice nucleation with a low degree of super-
cooling has recently become a focus of investigations in the field of freeze-drying [9]. A 
lyophilization cycle consists of three steps: freezing, primary drying and secondary drying, 
whereas primary drying is the most time-consuming step [9]. Investigations have shown the 
importance of ice nucleation temperature during the freezing step and its influence on the 
primary drying time and product characteristics [10-12]. A low degree of super-cooling leads 
to the formation of large ice crystals. Large ice crystals decrease product resistance during 
primary drying and thus reduce primary drying time. Another parameter, which influences the 
resulting ice morphology, is the nature of freezing. One can distinguish between global super-
cooling and directional solidification [8], whereas with global super-cooling, the entire volume 
reaches the same stadium of super-cooling, and with directional solidification, a smaller 
fraction is super-cooled whereas other parts have already nucleated. Nucleation and 
solidification then slowly proceeds through the whole solution during further cooling.  
Different modifications of the freezing step can be applied in order to obtain a lower degree of 
super-cooling and an optimized ice morphology. The ice fog technique [10, 11, 13], the 
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depressurization technique [12], vacuum induced surface freezing [14], annealing [15] and 
different ice nucleating agents [8] are described in literature to achieve “controlled nucleation”.  
In our study we want to find out whether the Mpemba effect might be considered when super-
cooling and nucleation shall be controlled for freeze-drying processes to modify ice crystal 
structure and, finally, product properties.   
III.8.2 MATERIALS AND METHODS 
Throughout the study, highly purified water (Purelab Plus, ELGA LabWater, Celle, Germany) 
was used which was filtered on the outlet port. Water was filled in pre-rinsed 10 R glass vials 
Type I (MGlas AG, Muennerstadt, Germany).  Type T thermocouples (SP Scientific, Stone 
Ridge, NY USA) were used to determine product temperature non-invasively on the outside. 
To ensure good contact with the vial, the thermocouples were dipped into Keratherm® Type 
KP97 thermal grease (KERAFOL, Eschenbach, Germany) and fixed on the vial outside about 
a millimeter over the bottom with a piece of adhesive tape. Filling volumes were 2.5 ml, 5.0 ml 
and 7.5 ml for different experiments. Each experiment was performed with three replicates.                                                                                                                             
For preheating, vials were first filled and closed with lyophilization stoppers. Then, the 
thermocouples were attached. Reference samples, were prepared similarly at room 
temperature and closed until transfer into the freeze-dryer (FTS LyoStar III, SP Scientific, 
Stone Ridge, NY USA). For the analysis of the evaporation mass loss, all the vials and 
corresponding stoppers were weighed before and after the experiment. The preheating 
process was controlled with a data logger thermometer (Omega Engineering, INC, 
Connecticut, USA). The closed vials were heated outside of the LyoStar III, completely opened 
by removal of the stopper and subsequently placed onto the pre-cooled freeze-dryer shelf. The 
non-heated reference vials were also opened and simultaneously positioned onto the pre-
cooled freeze-dryer shelves. The temperature measurement was performed by the software 
of the LyoStar III.  
The temperature difference between the initial product temperature and the shelf temperature 
was varied.  Samples remained at ambient room temperature (20 °C) or were preheated to 45 
°C, 65 °C and 85 °C. The freeze-dryer shelf was pre-cooled to -20 °C,  
-40 °C and -60 °C.   
For certain experiments, the chamber pressure in the freeze-dryer was reduced and adjusted 
manually by switching the vacuum pump on and off during the cooling/freezing process. The 
pressure was determined with a pirani gauge.  
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To mimic lyophilization conditions, one of the experiments was performed with semi-stoppered 
vials. The experiment was carried out at ambient pressure and the vials were preheated to 85 
°C. The shelf temperature was set to -20 °C and the filling volume was 7.5 ml.  
III.8.3 RESULTS 
III.8.3.1 IMPACT OF THE INITIAL PREHEATING AND THE SHELF TEMPERATURE 
A main objective of this study was to examine whether the preheated samples freeze differently 
compared to the samples loaded at room temperature. Hence, the preheating temperature and 
the shelf-temperature were varied.  
The samples with a fill volume of 7.5 ml, starting at 20 °C and placed on a -20 °C shelf, showed 
the same behavior throughout all experiments. Ice nucleation took place at temperatures 
between -11 °C and -19 °C. However, the preheated samples with same water volumes 
behaved differently with increasing initial temperatures. With a starting temperature of 65 °C, 
one sample out of three super-cooled only to -4.6 °C. With a preheating temperature of 85 °C, 
the ice nucleation started at approximately -5 °C for all samples. Consequently, a lower degree 
of super-cooling was observed with increasing preheating temperatures (Figure III-24).  
Figure III-25 shows the nucleation temperatures for samples with different pre-heating 
temperatures and pre-cooled shelf temperature setpoints. The difference between pre-heating 
temperature and shelf was kept constant at 105 K. A significant increase in nucleation 
temperature was observed compared to samples which were not pre-heated, independent of 
fill volume.  However, with decreasing shelf-temperature but 105 K temperature difference, the 
measured ice nucleation temperatures were also shifted to lower values. The temperature 
measurement on the outside of the vial is measuring the glass temperature. Although a good 
agreement between invasive and non-invasive temperature measurement was obtained for 
warmer shelf temperatures, a very low shelf temperature of  
-60 °C is quickly cooling the glass and this influences the nucleation temperature measured. 
However, measured ice nucleation temperatures were still significantly higher than for 
reference samples with a higher degree of super-cooling.  
Interestingly, the effect was not observable when a lyophilization stopper was put on top of the 
vial at 85 °C/ -20 °C. It is therefore obvious, that evaporation from the vials must have an effect. 
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Figure III-24: With an initial preheating of 80 °C, an effect of elevated ice nucleation temperature was observed on a pre-cooled 
shelf of -20 °C. The arrows mark the ice nucleation event. 
 
Figure III-25: The volume given indicates fill volume of the vials and the first temperature is the pre-heating temperature and the 
negative temperature is the pre-cooled shelf temperature. The phenomenon of a lower degree of super-cooling occurred in open 
samples with sufficient initial preheating or shelf cooling (three columns on the left) but was not observed after the performed 
covering method. Please note that ice nucleation temperatures are becoming slightly lower with lower pre-cooling of the shelves 
because the non-invasive temperature measurement on the outside of the vial is influenced by the lower shelf temperatures. 
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III.8.3.2 VISUAL OBSERVATION OF THE FREEZING PROCESS 
During the processes, unexpected freezing behavior was observed. Usually, globally super-
cooled liquid turns opaque as it freezes. With pre-heated samples of 105 K temperature 
difference between pre-heating and shelf temperature however, an ice front inside of the 
sample could be observed, which moved from the bottom to the upper layers. Air bubbles 
assembled on the water surface, thus forming ice structures shown in Figure III-26. Throughout 
the freezing process, the main ice structure remained translucent. The ice/water phase 
conversion hence is driven by directional solidification. 
 
Figure III-26: Instead of the expected freezing behavior, when samples instantly appear turbid (global super-cooling), an ice 
front moving from the bottom up was observed (directional solidification). 
III.8.3.3 REDUCED PRESSURE EXPERIMENTS 
If enhanced evaporative self-cooling or the mass loss due to evaporation were the critical 
factors influencing the ice nucleation temperature, depressurizing the product chamber to 
60 mbar should increase the probability of nucleation at elevated temperatures. The measured 
mass loss due to evaporation rose after depressurizing the product chamber from 0.1 % to 
1.3 % of the fill volume. Surprisingly, the experiments showed no differences to atmospheric 
pressure conditions. 
III.8.4 DISCUSSION 
III.8.4.1 FREEZING AT ELEVATED TEMPERATURES 
Experiments, inspired by the Mpemba effect, showed that the phenomenon of nucleation at 
elevated temperatures occurred in preheated vials. The temperature difference between 
product and shelf of approximately 105 °C constantly provoked a lower super-cooling effect, 
independently of the filling volume. This included the measurements for preheating/shelf 
temperature settings of 85 °C/-20 °C, 65 °C/-40 °C and 45 °C/-60 °C, respectively. The initial 
temperature value of the water therefore is less important for the lower degree of super-cooling 
than the temperature difference between the solution and the shelf temperature. 
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By reducing the chamber pressure, the influence of evaporation increases but neither the 
cooling rates nor the ice nucleation temperatures changed from the results at ambient air 
pressure experiments. The evaporative self-cooling and enhanced mass loss through plain 
evaporation at ambient conditions therefore seem to not to be critical for the ice nucleation at 
higher temperatures.  
Although reduced chamber pressure did not affect the evaporation effect, restrictions of the 
opening for the gas phase on top of the vials by freeze-dry stoppers set to the drying position 
changed the situation dramatically. Semi-stoppered vials are not affected anymore and 
showed same super-cooling as “regular” ones. 
III.8.4.2 APPLICABILITY TO LYOPHILIZATION 
This study could show that the initial preheating of the samples actually results in lower 
degrees of super-cooling in full accordance with the Mpemba effect. As lyophilization is, among 
others, a stabilization technique for temperature-sensitive protein formulations [16], preheating 
temperatures much above 40 °C cannot be applied. However, a 105 K difference between the 
initial sample and  shelf temperature can be achieved with 45 °C samples and  
-60 °C shelf and results in a lower degree of super-cooling comparable to controlled ice 
nucleation at rel. high temperatures. Different from the pre-cooled shelf method [8], which is 
already described in literature, samples were not only placed onto pre-cooled shelves but also 
preheated. The standard deviations for nucleation temperatures we found were relatively low 
compared to the temperature distribution described in literature [8].  
The ice structure was not explicitly analyzed, but the solidification process was observed 
visually. Ice nucleation and solidification started from the bottom and the nucleation front 
moved slowly up to the water surface. The ice remained translucent throughout the freezing 
process. It is concluded that ice nucleation and freezing proceeds by directional solidification 
[8]. The relevance of this observation for product characteristics is subject to future 
investigations. 
In order to preserve the purity and sterility of the formulations, the vials are usually put into the 
freeze–dryer, covered with stoppers in the drying position with an opening for removal of water 
vapor. However, by placement of a lyophilization stopper, the effect of increased nucleation 
temperatures was eliminated. 
Consequently, the application of the Mpemba effect for controlled nucleation of state of the art 
freeze-drying processes for sterile dosage forms in vials or cartridges is not possible. But bulk 
freeze-drying processes on shelf trays or e.g. in Goretex Lyo Guard® and similar containers 
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might very well take advantage of the concept. The “Mpemba process” could be considered 
as an improvement on the pre-cooled shelf method. 
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III.9 SUMMARY OF CHAPTER III 
Controlled nucleation in freeze-drying is a new technology which has a high potential to 
improve freeze-drying processes with regard to economic benefits. The methods available 
require hardware modifications and/or retrofits and some of them are quite expensive. We 
developed a method that works in lab-scale and we could transfer this method also to a pilot-
scale freeze-drier. This allows everyone to study effects on controlled ice nucleation already 
in lab-scale. However, benefits of controlled ice nucleation besides more economic processes 
have not yet been shown, although this benefit is already quite important thinking on other 
ideas scientists had to improve primary drying. In addition, we found that not only nucleation 
temperature influenced final product quality attributes but also the post nucleation hold time, 
as shown for two placebo model formulations. Further, a longer post-nucleation hold time was 
also beneficial for subvisible particle formation of the model antibody MabR1 in freeze-thawing 
experiments. In this chapter, a first answer to the question “do we obtain a better product” was 
given. For highly-concentrated protein formulations, we obtained faster reconstitution times for 
the dried product compared to a conventional drying process. These formulations also profited 
from controlled nucleation regarding drying kinetics. 
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IV. FINAL SUMMARY 
 
The present thesis is divided into two parts. The first part, as described in chapter II, is about 
the potential use of cyclodextrins in drying of proteins and the second part (chapter III) 
evaluates controlled ice nucleation in freeze-drying. 
I. The objective of the first part was to assess the potential use of cyclodextrins in freeze-drying 
and its ability to provide an alternative to polysorbates. In section II.1, the literature on 
cyclodextrins in protein drying was reviewed as well as the potential protein stabilization 
mechanisms of cyclodextrins. The most important derivative of β-cyclodextrin is 
Hydroxypropyl-beta-cyclodextrin, which is a surface active molecule and has shown its ability 
to stabilize proteins in liquid protein formulations. In addition, HPβCD is approved by authorities 
and is considered safe from a toxicological perspective. Hence, this thesis clearly focused on 
HPβCD as excipient in freeze-drying. The freeze-drying process, although considered as 
gentle and activity-retaining, poses several stresses to proteins. To study protein degradation 
during the freeze-drying process, a model protein, MabR1 was used in the first screening study 
in section II.3.1. To further create challenging conditions, the amount of sucrose added was 
kept low and a mass ratio of sucrose to protein of 1:1 was chosen. It was found that MabR1 is 
sensitive to the formation of an ice-water interface as well as dehydration and the air-liquid 
interface present during reconstitution, rendering the model protein a good candidate to study 
excipient effects in the freeze-drying process. However, the gold standard to protect proteins 
at interfaces, surfactants of the polysorbate group combined with sucrose, showed better 
results and could more effectively suppress formation of subvisible particles than HPβCD, 
when employed as single excipient or in combination with sucrose. This was confirmed by 
using different concentrations of HPβCD and two different lots of the model antibody MabR1 
in section II.3.2 for conventional freeze-drying. However, it was shown that HPβCD is a very 
effective stabilizer in freeze-thaw studies even at very low concentrations of 1 mg/ml and the 
addition of HPβCD decreased subvisible particles compared to a formulation with sucrose only 
(no surfactant). With conventional freeze-drying, at least in our studies, we could observe 
stabilizing effects of HPβCD, but our goal, to provide an alternative to polysorbates, could not 
be reached. It could be shown that, especially during reconstitution of the freeze-dried cakes 
polysorbate was superior to HPβCD.  
Freeze-dried products can differ in their characteristics depending on the freeze-drying 
process. With the data in mind from the first studies, collapse freeze-drying was performed to 
intentionally decrease the specific surface area (SSA) of the dried product. Although 
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considered to be inelegant, it has been shown that collapse freeze-drying does not necessarily 
harm protein activity but can even improve stability of the dried product. In our case, the 
reduction of specific surface area at which proteins can possibly degrade and form aggregates 
during rehydration, lead to acceptable and comparable protein stability with HPβCD and 
polysorbate, as was shown in section II.3.3.  
Furthermore, by creating lyophilizates with intermediate specific surface area by employing the 
new technology of controlled ice nucleation at low super-cooling of the aqueous liquid in 
section II.3.4, a SSA between conventional freeze-drying and collapse freeze-drying could be 
obtained and also the number of subvisible particles formed for the formulation containing the 
model antibody and HPβCD were intermediate. Hence, a correlation between specific surface 
area and particulate matter could be established. This correlation was also true for the negative 
control of MabR1 when freeze-dried without surfactant. However, when both formulations of 
MabR1 formulated with sucrose + HPβCD or sucrose + polysorbate 80 were subjected to 
storage stability in section II.3.5, both formulations showed temperature-dependent 
degradation with formation of soluble and insoluble aggregates. Thus, sucrose concentration 
was increased to a mass ratio of 5:1 sucrose:protein. In preliminary experiments, this 
formulation was freeze-dried with controlled nucleation (section II.3.6) and with a collapse 
freeze-drying process (section II.3.7). Collapse of the freeze-dried cake reduced SSA to a 
minimum and showed lowest subvisible particle numbers for the formulations of sucrose with 
HPβCD or PS80, as already observed in the study with 1 % sucrose, while MabR1 stability 
was preserved. Controlled ice nucleation again showed higher subvisible particle 
concentrations and SSAs than collapse freeze-drying.  
A storage stability study of MabR1 was performed with the formulations based on 5 % sucrose 
in section II.3.8 and excellent storage stability of MabR1 was observed at 40 °C as well as 25 
°C and 2-8 °C for approximately 150 days.  
The formulation and process concept was then transferred to two other, structurally different 
model proteins which are sensitive to interfacial degradation, GCSF and hGH. Both proteins 
are also stable in liquid formulations and do not necessarily need to be dried; however, they 
are very suitable model proteins to study excipient effects on process stability. For hGH, 
collapse freeze-drying with HPβCD and polysorbate lead to acceptable formulations with an 
advantage for HPβCD with respect to subvisible particles and dimer formation, as shown in 
section II.3.10. In addition, storage stable lyophilizates of hGH were obtained for 3 months at 
2-8, 25 and 40 °C. Polysorbate 80 was superior to HPβCD for the model protein GCSF as 
detected with subvisible particle formation and monomer content, however, with both 
formulations, visible particles appeared in the subsequent storage stability study of GCSF, as 
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described in section II.3.11. The appearance of visible particles points into the direction of a 
general instability of GCSF in the dried state, thus, the storage stability study was cancelled. 
With the positive effects of a low SSA observed in the collapse freeze-drying studies in mind, 
we performed a control experiment with higher SSAs and spray-dried MabR1. While the 
stability immediately after spray-drying was better for polysorbate than for HPβCD, the dimer 
content of MabR1 was increased immediately after drying and further increased during storage 
of the spray-dried powder. These results suggest that the antibody was damaged and oxidation 
may have occurred during the spray-drying process and the following storage study. 
While most of the work focused on the ability of HPβCD to protect proteins at interfaces, 
another possibility of the cyclodextrin derivative is the ability to act as bulking agent in a 
carbohydrate-like manner. Due to its high glass transition temperatures, very economic, fast 
processes can be designed. However, we could not show an advantage in storage stability of 
MabR1 when using HPβCD compared to sucrose, as presented in section II.3.13.  
By using electron spectroscopy for chemical analysis (ESCA), we could gain insight into the 
situation at the interface of the freeze-dried products (see section II.3.9). It could be shown that 
for conventional freeze-drying a co-existence of the model antibody with HPβCD at the 
interface is supposedly the case and HPβCD is exerting a different stabilization mechanism on 
proteins compared to classical surfactants, which displace proteins from the interface. This 
finding was in good agreement with studies conducted at the liquid-air interface by other 
members of our research group.  
Another side aspect of the thesis was the surprising finding that HPβCD is forming subvisible 
placebo particles in the lower one-digit micrometer range when freeze-dried and rehydrated. 
The amount of particles formed was dependent on SSA and residual moisture and could also 
be reduced by employing controlled nucleation or collapse freeze-drying with the latter 
completely eliminating the formation of placebo particles. For the protein formulations, it 
remains unclear if, and to which extent, placebo particles contribute to total particle amounts.  
Finally, the goal of providing an alternative for polysorbates could be achieved for 
certain formulations; if the specific surface area is kept low, cyclodextrins may be a 
valuable alternative to the degradation-prone polysorbates.  
II. The second part of the thesis was focused on a new technology in freeze-drying, which is 
called controlled ice nucleation. Besides the parameters time, temperature and pressure, a 
new option to tune the freeze-drying process is possible with this technology: control of super-
cooling and the ice nucleation temperature as well as the post-nucleation thermal treatment. 
With commercial methods for all scales emerging for industrial freeze-drying, there is also a 
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need for a laboratory method to study effects of controlled ice nucleation on products in early 
development. In section III.2, we gave a general introduction into the topic of controlled ice 
nucleation and presented available methods as well as other modifications of the freezing step. 
In section III.3, we developed a method to induce ice nucleation in laboratory-scale freeze-
driers. So far, it is the only method without the need for hardware modifications and can be 
used in any freeze-dryer with external condenser. Water vapour is generated from the product 
vials in a controlled way by depressurization of the freeze-drier and is frozen on the cold 
condenser coils. Upon re-pressurization of the condenser compartment, the ice crystals are 
blown into the super-cooled solutions and induce ice nucleation. In lab-scale, success rates 
were larger than 99 %, and we were curious if this method can also work in larger freeze-
driers. Thus, in section III.4, we tested the method in a pilot-scale freeze-drier with 2.5 m² shelf 
area. Similar to the lab-scale equipment, we obtained a success rate of more than 99 %. We 
conclude that, if all components of a freeze-drier are scaled, the method is potentially also 
applicable to production-scale freeze-driers.  
In the following section III.5, the impact of nucleation temperature and post-nucleation hold 
time is evaluated for the model protein MabR1 in freeze-thaw studies. These investigations 
were performed to support the controlled ice nucleation sections in chapter II. It was found, 
that besides the ice nucleation temperature, also the post-nucleation hold time, which 
influences the velocity of ice crystallization had an impact on protein stability observed after 
freeze-thawing.  
The impact of the ice nucleation temperature as well as the post-nucleation hold time was 
further elucidated for two placebo model formulations in section III.6, confirming the importance 
of both variables for the final product quality attributes, e.g. the residual moisture and the 
specific surface area.  
In section III.7, we could show that controlled ice nucleation not only improves primary drying 
duration but can also improve reconstitution times of highly-concentration freeze-dried 
formulations by increasing wetting of the freeze-dried cake. If wetting of the solid is the velocity-
determining step, controlled ice nucleation can greatly improve rehydration and hence product 
quality of these pharmaceuticals.  
The Mpemba effect, an interesting observation that warm water freezes faster than cold, was 
investigated in section III.8 using freeze-drying equipment. Interestingly, it was found that pre-
heating of water influenced super-cooling of the liquid and, compared to cold water, nucleation 
and freezing occurred faster. The Mpemba effect was under investigation for several years 
and many possible explanations for this effect were proposed. Our observation with super-
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cooling differences of hot and cold water is in agreement with a study of the winner of the 
2012’s science competition advertised by the Royal Chemistry Society in London. 
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